Factors affecting post-exercise glycaemia in individuals with type 1 diabetes. by Daniel J, West
  Swansea University E-Theses                                     
_________________________________________________________________________
   
Factors affecting post-exercise glycaemia in individuals with type 1
diabetes.
   
West, Daniel J
   
 
 
 
 How to cite:                                     
_________________________________________________________________________
  
West, Daniel J (2011)  Factors affecting post-exercise glycaemia in individuals with type 1 diabetes..  thesis, Swansea
University.
http://cronfa.swan.ac.uk/Record/cronfa43143
 
 
 
 Use policy:                                     
_________________________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence: copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder. Permission for multiple reproductions should be obtained from
the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
Please link to the metadata record in the Swansea University repository, Cronfa (link given in the citation reference
above.)
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/
 FACTORS AFFECTING POST-EXERCISE 
GLYCAEMIA IN INDIVIDUALS WITH TYPE 1
DIABETES
DANIEL J. WEST
Submitted to Swansea University in fulfilment of 
the requirements for the Degree of Doctor of
Philosophy
2 0 1 1
ProQuest Number: 10821535
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10821535
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
LIBRARY
Nothing can stop the man with the right mental attitude
from achieving his goal
THOMAS JEFFERSON 
(1743- 1826)
TABLE OF CONTENT
Chapter Section Title Page
Declaration i
Contents ii
Acknowledgements xi
Summary xii
List of abbreviations xiv
List of figures xvi
List of tables xxii
Publications xxvi
1.0 Review of literature 1
1.1 Introduction 2
1.2 Blood glucose regulation in T1DM 3
1.3 Hypoglycaemia: variations in its form and time 5 
of onset
1.3.1 Iatrogenic hypoglycaemia 5
1.3.2 Exercise-induced hypoglycaemia 6
TABLE OF CONTENT (cont.)
1.3.3 Variation in the severity of hypoglycaemia 8
1.3.4 Defining hypoglycaemia 9
1.4 Treating T 1 DM: exogenous insulin therapy 10
1.4.1 The development of the insulin analogues 12
1.4.2 Calculating insulin dose: carbohydrate 15 
counting and rapid-acting insulin dose
1.4.3 Calculating basal insulin dose 16
1.5 The benefits of exercise for T 1 DM individuals 17
1.6 Exercise modality, intensity and duration 20
1.7 Strategies for preventing and/or minimising 23
post-exercise hypoglycaemia
1.7.1 The importance of insulin dose on 23 
post-exercise glycaemia
1.7.2 The safety of using pre-exercise insulin 30 
reductions
1.8 Current recommendations for carbohydrate 33
intake and exercise for T1DM
1.8.1 Carbohydrate type: the glycaemic index 37
TABLE OF CONTENT (cont.)
1.8.2 Exogenous carbohydrate oxidation 41
and glycaemia
1.9 Pre-exercise timing of carbohydrate consumption 43 
and insulin administration
1.10 Hormonal factors contributing to inter-individual 47 
difference in blood glucose responses to exercise
1.10.1 Glucagon responsiveness 47
1.10.2 The sympathoadrenal influence on 48 
blood glucose
1.11 Summary of thesis and experimental chapter 49
aims
2.0 Methodology 50
2.1 Ethics 51
2.2 Type 1 Diabetes Participants 51
2.2.1 Recruitment of participants 51
2.2.2 Insulin regimen of participants 52
2.3 Experimental design chapters 3 to 5 54
2.3.1 Health screening 55
iv
TABLE OF CONTENT (cont.)
2.3.2 General study protocol 55
2.3.3 Preliminary testing 57
2.3.4 Experimental procedures 61
2.3.5 Quantification of blood, serum and plasma 66 
analytes
2.4 Hypoglycaemia 76
2.5 Pre-exercise meal 77
2.6 Data collection following the laboratory testing 78
2.6.1 Self-recorded blood glucose 78
2.6.2 Post-laboratory activity 80
2.6.3 Self-recorded dietary intake and insulin 81 
administration
2.7 Data analysis 82
2.7.1 Calculation of blood glucose area under 82 
the curve
2.7.2 Calculation of substrate oxidation 83 
and energy expenditure
2.7.3 Sample size calculation 85
v
TABLE OF CONTENT (cont.)
2.7.4 Fasting blood glucose variability 85
2.7.5 Statistical analysis 86
3.0 The metabolic andglycaemic effects o f  87
reductions to pre-exercise insulin dose
3.1 Introduction 88
3.2 Methods 90
3.2.1 Statistical analysis 91
3.3 Results 92
3.3.1 Physiological responses to exercise 92
3.3.2 Blood glucose responses 94
3.3.3 Serum insulin responses 95
3.3.4 Counter-regulatory hormonal responses 98
3.3.5 S erum p-hydroxybutyrate responses 100
3.3.6 Blood pH and lactate responses 102
3.3.7 Patterns of carbohydrate and lipid 105 
oxidation
vi
TABLE OF CONTENT (cont.)
3.3.8 Post-laboratory activity and self-recorded 106
glycaemia and dietary intake
3.4 Discussion 107
4.0 The metabolic and glycaemic effects o f  113
alterations in the glycaemic index o f the carbo­
hydrate ingested before exercise
4.1 Introduction 114
4.2 Methods 116
4.2.1 Statistical analysis 117
4.3 Results 118
4.3.1 Physiological responses to exercise 118
4.3.2 Blood glucose responses 119
4.3.3 Counter-regulatory hormonal responses 121
4.3.4 Serum P-hydroxybutyrate responses 124
4.3.5 Blood lactate and pH responses 126
4.3.6 Serum triglyceride and NEFA responses 130
4.3.7 Serum glycerol responses 132
TABLE OF CONTENT (cont.)
4.3.8 Patterns of carbohydrate and lipid oxidation 134
4.3.9 Post-laboratory activity and self-recorded 136 
glycaemia and dietary intake
4.4 Discussion 137
5.0 The metabolic and glycaemic effects o f  alterations 142
in the pre-exercise timing o f carbohydrate and 
insulin administration
5.1 Introduction 143
5.2 Methods 146
4.2.1 Statistical analysis 147
5.3 Results 148
5.3.1 Physiological responses to exercise 148
5.3.2 Blood glucose responses 150
5.3.3 Serum insulin responses 153
5.3.4 Counter-regulatory hormonal responses 156
5.3.5 Serum p-hydroxybutyrate responses 159
5.3.6 Blood lactate and pH responses 161
viii
TABLE OF CONTENT (cont.)
5.3.7 Serum triglyceride and NEFA responses 165
5.3.8 Patterns of carbohydrate and lipid oxidation 168
5.3.9 Post-laboratory activity and self-recorded 170 
glycaemia and dietary intake
5.4 Discussion 172
6.0 General discussion 178
6.1 Summary of aims and findings 179
6.2 Impact of insulin reductions, carbohydrate 181
administration and timing on glycaemia before
and after running
6.2.1 Post-laboratory glycaemia 192
6.3 Changes in the pattern of substrate oxidation 193
6.4 The effects of insulin reductions and carbo- 200
hydrate consumption on ketogenesis
6.5 General conclusions 203
6.6 Limitations 204
6.7 Directions for future research 207
7.0 References 208
ix
Appendices
ACKNOWLEDGEMENTS
I wish to sincerely thank all of the following people:
The participants: Thanks for giving up so much of your time, without your commitment and 
dedication none of these investigations would have been possible.
Professor Steve Bain and Dr. Jeffrey Stephens: Thanks for your support with recruiting the 
participants and all the advice you provided during the publishing of the experimental 
chapters. Moreover, thanks for making the Diabetes UK APC such an enjoyable experience.
Dr. Liam Kilduff: Many thanks for all of the advice and support you have provided for me 
over the past 6 years. I really appreciate everything you have done for me.
Dr. Richard Bracken: Firstly, I wish to thank you for giving me the opportunity to study at 
doctorate level within such a good research team. However, most of all I would like to thank 
you for being a great supervisor; your enthusiasm, encouragement, support and 
meticulousness has not only been key in my learning and development, but also in the 
enjoyment I have had completing this body of work, and I am forever grateful.
SUMMARY
The overarching aim of this thesis was to examine factors that affect post-exercise glycaemia 
and contribute to minimising the risk of hypoglycaemia after exercise. An inability to 
regulate circulating insulin concentrations is considered the primary gluco-regulatory defect 
within T1DM. Therefore, the aim of chapter 3 was to examine the effects of pre-exercise 
rapid-acting insulin reductions on blood glucose responses before and after running in T1DM 
individuals, to test the hypothesis that reducing pre-exercise insulin dose may help preserve 
post-exercise glycaemia. The results demonstrate that a 75% reduction to pre-exercise rapid- 
acing insulin dose best preserved blood glucose before and after exercise, without increasing 
the risk of ketoacidosis, and reduced the risk of hypoglycaemia in free living conditions for 
24 hours following running.
An important factor determining blood glucose concentrations and subsequent patterns of 
fuel oxidation is the rate of appearance of carbohydrate into the circulation. Potentially, low 
GI carbohydrates may raise blood glucose less and increase the percentage contribution of 
lipids as a fuel because of a slower digestion. Therefore, the aim of chapter 4 was to examine 
the metabolic and blood glucose responses to ingestion of a high or low GI carbohydrate, 
combined with a 75% reduced insulin dose, before, during and for 24 hours after running. 
The results demonstrate that compared to a high GI carbohydrate, the low GI carbohydrate 
increased blood glucose concentrations less before exercise and maintained blood glucose 
better for 24 hours after running, via lower carbohydrate and higher lipid oxidation rates 
during the latter stages of running.
After manipulating both the insulin dose and the pre-exercise carbohydrate GI, to improve 
post-exercise blood glucose concentrations, the timing of the ingestion of carbohydrate
(alongside a reduced insulin dose) before exercise is an important factor which may further 
refine these strategies. Therefore, chapter 5 examined the metabolic and blood glucose 
responses to alterations in the timing of carbohydrate feeding and insulin administration prior 
to running. Our results demonstrated that administration of both a reduced rapid-acting 
insulin dose and low GI carbohydrate 30 minutes before exercise improved glycaemia for 24 
hours after running, by reductions in carbohydrate oxidation, leading to increased 
carbohydrate availability post-exercise.
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Chapter One 
Review of literature
1
1.1 Introduction
Type 1 diabetes (T1DM) is characterised by an absolute or relative lack of insulin, due to 
autoimmune destruction of the insulin secreting (3-cells within the pancreas. Ultimately, the 
loss of function of these cells results in the individual with T1DM being dependent upon 
exogenous insulin therapy. Within the UK, roughly 10% of all diabetes patients have T1DM, 
equalling roughly 230,000 people, at a cost to the National Health Service of approximately 
£lbn a year (Diabetes in the UK, 2008).
At present, the American College of Sports Medicine (ACSM; 2006) advocate T1DM 
individuals perform aerobic type exercise for various health benefits such as reduced 
glycosylated haemoglobin (HbAic; Mosher et al., 1998; Ramahlo et al., 2006; Salvatoni et al., 
2005; Sideraviciute et al., 2006), delayed micro- (The Diabetes Control and Complications 
Trial Research Group, 1993) and macro-vascular (UKPD Study Research Group, 1998) 
complications, increased insulin sensitivity (Lehmann et al., 1997), improved glucose 
clearance (Borghouts and Keizer, 2000) and ultimately, decreased mortality (Moy et al.,
1993).
However, despite these benefits of exercise, inadequate glucose regulation means that 
engaging in exercise results in a heightened risk of developing hypoglycaemia, i.e. blood 
glucose concentrations falling below the normal physiological range of 3.5 -  7 mmol.l'1, 
during and as long as 24 hours after exercise (MacDonald, 1987; Steppel and Horton, 2003; 
Tsalikian et al., 2005). Therefore, comprehensive strategies to help combat the increased risk 
of hypoglycaemia associated with exercise are required.
2
1.2 Blood glucose regulation in T1DM
At rest, exogenous insulin treatment reduces blood glucose concentrations, preventing 
hyperglycaemia and risk of ketosis (Cryer, 2001). However, circulating insulin 
concentrations are unregulated, and are the result of the passive absorption from the injection 
site of the previously administered insulin dose, and the particular insulin species’ 
pharmacokinetics (Cryer, 2001). Therefore, during exercise, contracting skeletal tissue 
(Hayashi et al., 1997), increased insulin sensitivity (Rose et al., 2001) and an inability to 
regulate circulating insulin concentrations, (Grimm, 2005) results in an augmented rate of 
glucose uptake from circulation and reductions to blood glucose concentrations. Moreover, 
exercise may exacerbate the increase in appearance of exogenous insulin (Dandona et al., 
1980), due to increased temperature (Koivisto et al., 1981) and blood flow (Lauritzen et al., 
1980). Thus, unaltered and/or increasing insulin concentrations means that hepatic glucose 
output remains inhibited (Zinrnan et al., 1977), as does adipocyte lipolysis. Therefore, the 
primary mechanism involved in maintaining blood glucose concentrations during exercise is 
lost within T1DM (Figure 1.1, part A).
Glucagon, the secondary counter-regulatory response is also effected within T1DM (Figure 
1.1, part A). Beta-cell death results in a progressive loss of a-cell function over time, 
potentially due to the loss of P-a cell signalling (Banarer et al., 2002), which results in the 
glucagon response to falling blood glucose becoming impaired or completely absent (Bolli et 
al., 1985; Gerich et al., 1973; Mokan et al., 1994). Consequently, the first (decreased insulin 
secretion) and second (increased glucagon secretion) defences against developing 
hypoglycaemia during exercise are defective in T1DM individuals. Failure of these defences 
results in individuals becoming reliant on the third counter-regulatory mechanism, adrenaline 
(Figure 1.1, part B). However, the adrenaline response to falling blood glucose concentrations
is typically attenuated (Amiel et al., 1988; Dagogo-Jack et al., 1993). Due to antecedent 
hypoglycaemia, and a decreased sympathetic neural system response (Steppel and Horton, 
2003; Figure 1.1, part C), the adrenaline response to falling blood glucose concentrations is 
predominantly shifted to a lower threshold (Dagogo-Jack et al., 1993). A loss o f  the primary 
and secondary mechanisms and a defective tertiary mechanism (Figure 1.1, part A, B and C) 
means that blood glucose concentrations will fall and hypoglycaemia becomes a frequent and 
dangerous occurrence during exercise. The increased risk o f developing hypoglycaemia 
during exercise is a major concern for T1DM individuals (Brazeau et al., 2008); as a result, 
the fear o f experiencing a hypoglycaemic incident is a major barrier for T1DM individuals 
wishing to exercise (Brazeau et al., 2008).
Decreased
glucose
<PNS> Increased sympathoadrenal outflow
(SNS)
'  increased NE 
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tremor arousal)
Increased ACh
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Muscle Kidney
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glucose clearance
IncreasedIncreased -« 
glucose production
I Increased
glucose
J
Figure 1.1: Blood glucose regulation in non-T lD M  and T1DM individuals (adapted from Cryer, 
2006).
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1.3 Hypoglycaemia: variations in its form and time of onse t
1.3.1 Iatrogenic hypoglycaemia
Unfortunately, due to intensive exogenous insulin therapy, hypoglycaemia is a fact of life for 
people with T1DM (Cryer, 2002). The primary aim of treating T1DM is to maintain blood 
glucose concentrations at or as close to euglycaemia as possible, however, with achieving this 
goal comes iatrogenic hypoglycaemia (Cryer et al., 2003), or treatment-induced 
hypoglycaemia. If too much insulin is administered in relation to dietary intake, the insulin 
mediated uptake of glucose, in addition to an inhibition of hepatic glucose production and 
compromised glucose-regulation (Cryer, 1994; 1997; 2001; Figure 1.1), causes falls in blood 
glucose below the normal physiological concentrations. These falls in blood glucose induce 
two forms of symptoms, neuroglycopaenic and neurogenic symptoms (Chiarelli et al., 1999). 
Neuroglycopaenic symptoms (e.g. confusion, unconsciousness, brain damage, death) are the 
result of a minimal glucose requirement by the brain (Becker and Ryan, 2000; Cryer et al., 
2003). Neurogenic symptoms include physiological changes such as pallor, sweating, 
tachycardia and hunger (Chiarelli et al., 1999; Cryer et al., 2003). Type 1 diabetes individuals 
may experience 2 episodes of symptomatic hypoglycaemia per week, with thousands of 
incidences over a lifetime, and at least 1 severe or temporarily disabling hypoglycaemic 
incident per year (Macleod et al., 1993; Reichard et al., 1991; The Diabetes Control and 
Complications Research Group, 1993).
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1.3.2 Exercise-induced hypoglycaem ia
During Exercise
Insulin facilitates muscle glycogen synthesis through its action on both glucose transport and 
glycogen synthase activity (Wojtaszewski et al., 2002). Specifically, insulin stimulates 
translocation of glucose transporter proteins (GLUT-4) to the plasma membrane, thereby 
enhancing the glucose transport capacity (Simpson et al., 2001) of the cell. Moreover, insulin 
enhances the activity of glycogen synthase by decreasing phosphorylation of the enzyme 
(Cohen, 1993), contributing to the increased uptake of glucose and subsequent storage within 
the myocyte.
Keeping these mechanisms in mind, it has been demonstrated that muscle glucose uptake 
during exercise is increased and occurs by an insulin-independent mechanism (Nesher et al., 
2001; Plough et al., 1984) and that insulin and contracting skeletal tissue have additive effects 
on glucose transport (Nesher et al., 1985; Plough et al., 1984). Moreover, during exercise the 
perfusion of the muscle is increased compared with rest, this increases the delivery of insulin 
to the active tissue (Wojtaszewski et al., 2002). Therefore, within the T1DM individual, 
contracting muscle and an inability to regulate circulating insulin concentrations, as these are 
the result of the passive absorption of the previously administered insulin dose, results in a 
synergistic uptake of blood glucose (DeFronzo et al., 1981). These factors, in combination 
with the suppressive effect of insulin on hepatic glucose output, and defective glucagon and 
adrenaline responses, results in a mismatch between glucose uptake and production and blood 
glucose concentrations will fall.
6
Post-exercise
The threat of developing hypoglycaemia is not only isolated to during exercise, it can also 
occur up to 24 hours after the cessation of exercise (MacDonald, 1987; Steppel and Horton, 
2003; Tsalikian et al., 2005). In a study by MacDonald (1987), 300 regularly exercising 
individuals with T1DM were followed prospectively over 2 years. Sixteen percent of those 
participants regularly developed late-onset (6-15 hours after vigorous exercise) 
hypoglycaemia, with over 50% of the hypoglycaemic incidences resulting in a loss of 
consciousness (severe hypoglycaemia). Additionally, Tsalikian et al. (2005) found that 
hypoglycaemia developed overnight more frequently in T1DM children after performance of 
continuous exercise that day (four 15 min periods of walking at a heart rate of 140 bpm) 
compared to nights when daily exercise was not performed. Plasma glucose concentrations 
fell in almost all of the 50 subjects and 11 developed clinical hypoglycaemia.
During exercise, human skeletal muscle relies heavily on intra-muscular glycogen stores as a 
source of energy for contractile activity (Wojtaszewski et al., 2002) and in the post-exercise 
period resynthesis of glycogen is important and has a high metabolic priority (Wojtaszewski 
et al., 2002). To compensate for the glycogen depleted state, the activity of glycogen synthase 
has been demonstrated to increase after exercise (Nielsen et al., 2001), independent from 
activation by insulin (Bogardus et al., 1983; Munger et al., 1993; Zachwieja et al., 1991). In 
addition, cellular changes in the prior exercised muscle primes glucose transport and 
glycogen synthase activation when subsequently stimulated by insulin (Wojtaszewski et al., 
2002). Therefore, enhanced insulin-stimulated recruitment of GLUT-4 transporters (Hansen 
et al., 1998), depleted muscle glycogen stores (Bogardus et al., 1983; Munger et al., 1993; 
Zachwieja et al., 1991), and an increased activity of glycogen synthase are mechanisms
contributing to the increase insulin sensitivity after exercise (Wojtaszewski et al., 2002).
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When considering these changes in insulin sensitivity, T1DM individuals are unable to 
compensate for the heightened sensitivity with a decrease in insulin concentrations, this 
results in and an augmented uptake of blood glucose from circulation (Bogardus et al., 1983). 
In addition, unaltered insulin concentrations means insulins suppressive effect at the 
hepatocyte and adipocyte remains. Moreover, glucagon is defective or absent (Mokan et al.,
1994) and does not rise after exercise (Gallen, 2003); combining this with an attenuated 
adrenaline response means hepatic glucose production is unable to match the peripheral 
uptake of glucose by muscle, which is elevated to replenish glycogen stores, and 
concentrations will fall and individuals will develop hypoglycaemia.
1.3.3 Variation in the severity of hypoglycaemia
The severity of the hypoglycaemic incident can vary within an individual (Cryer, 2006). For 
example, a drop in blood glucose below the normal physiological range of ~3.5 - 4 mmol.f1 
may induce symptomatic hypoglycaemia where the patient may become fatigued, develop 
parasthesia, pallor and have difficulty focusing (Cryer, 1997). However, defects in glucose 
sensing, primarily due to sympathoadrenal failure (Cryer, 2006), can result in typical 
symptoms of hypoglycaemia not materialising, and the individual becomes unaware of falling 
blood glucose (termed hypoglycaemia unawareness; Cryer 1999). Blood glucose 
concentrations may fall below 2.5 mmol.f1 and the individual is at risk of experiencing a 
severe hypoglycaemic incident that may result in a loss of consciousness, convulsions or even 
death (The Diabetes Control and Complications Research Group, 1993).
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1.3.4 Defining hypoglycaem ia
Based on a prior study examining exercise within T1DM individuals, a blood glucose 
concentration of <3.5 mmol.f1 will be defined as ‘hypoglycaemia’ (Rabasa-Lhoret et al., 
2001). Furthermore, as a drop in blood glucose below the normal physiological threshold of 4 
-  7 mmol.f1 (Saltiel and Kahn, 2001) can trigger symptoms of hypoglycaemia (Cryer, 1997), 
T1DM individuals are likely to correct their blood glucose concentrations before 
concentrations reach those that can be defined ‘hypoglycaemic’, therefore a blood glucose 
concentration of <4.0 mmol.f1 will be defined as ‘low blood glucose’.
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1.4 Treating T1DM: exogenous insulin therapy
Under normal physiological conditions, insulin is stored in the p-cell in its hexamer form (6 
monomers) due to a high tendency to self-associate, this is important as it facilitates 
proinsulin transportation as well as the conversion and intracellular storage o f  insulin 
microcrystals (Emdin et al., 1980). However, insulin is most readily absorbed through the 
capillary wall, and elicits its actions (binding to insulin receptors), in the monomeric form 
(Figure 1.2). This becomes a major obstacle for the administration o f regular human insulin 
(e.g. Actrapid, Table 1.1) and animal preparations, such as bovine or porcine insulins, as 
these insulins self-associate (Bolli et al., 1999).
Hexamers
‘A
^^apillary
Dimers and 
Monomers
DISSOCIATION DIFFUSION
Figure 1.2: The dissociation o f insulin hexam ers (from injection site or pancreas) into dimers and 
monomers for diffusion across the capillary wall (adapted from Gin and Hanaire-Broutin, 2005).
The dissociation rate o f these insulins into monomeric molecules is slow at the subcutaneous 
site o f injection and consequently its absorption is slow (Figure 1.2). Therefore, the pre- 
prandial treatment with short-acting (Table 1.1) insulin preparations results in a less than 
optimal increase in insulin concentrations in the early phase o f glucose absorption from the 
intestine. Consequently, blood glucose increases excessively 1-2 hours after meal ingestion 
(Dimitriadis and Gerich, 1983). Nonetheless, 4-5 hours after the subcutaneous insulin
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injection, the continuing absorption from the injection site results in inappropriate 
hyperinsulinemia which increases the risk of hypoglycaemia as by that time meal absorption 
is nearly complete (Dimitriadis and Gerich, 1983). Using insulins with these absorption 
kinetics means tight glycaemic control is a difficult task for T1DM individuals. These reasons 
are the basis for the development of the modem insulin analogues.
According to Bolli et al. (1999) the combination of a prandial insulin peak with a flat, square- 
wave interprandial plasma insulin profile (Figure 1.3), would closely mimic the 24 hour 
plasma insulin pattern of non-TlDM individuals who exhibit very small blood glucose 
variations regardless of being in a fasted or fed state.
50
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Figure 1.3: Twenty-four hour plasma insulin and glucose concentrations within a non-TlDM 
individual (adapted from Kruszynska, 2003).
Note: Descending arrows indicate feeding.
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1.4.1 The development of the insulin analogues
Biotechnology research has shown that one amino acid modification can lead to changes in 
the tridimensional structure o f the insulin molecule and to major alterations in its biological 
properties (Drejer et al., 1991). Dimarchi et al. (1994) studied the synthesis o f Insulin-like 
growth factor-I (IGF-1), and identified that this horm one is highly homologous with insulin, 
particularly at the C-terminal o f the B chain; however, this honnone does not self-associate 
into dimmers and hexamers. The normally occurring Pro-Lys sequence o f insulin at positions 
B28 and B29 is reversed in IGF-1 (Brems et al., 1992). This gave premise for the hypothesis 
that the Lys-Pro sequence renders IGF-1 incapable o f  self-association and the reversal o f this 
sequence in insulin (Figure 1.4) would lead to an insulin analogue incapable o f self­
association (Di Marchi et al., 1994), this theory was the basis for the development o f  the fast 
acting insulin analogue, lispro (Figure 1.4).
A-Ctttin
B-Chain
tarol
IB
Figure 1.4: The amino acid structure o f insulin lispro (Lys-Pro).
The reversal o f the amino acids Pro B28 and Lys B29 resulted in the development o f the 
widely used insulin lispro (Humalog®; Table 1.1); this modified analogue elicits an 
extremely fast rate o f absorption from the site o f  injection as well as a rapid onset time (5-20 
minutes) and a highly intense effect, this m aking insulin lispro very effective for prandial use 
(Howey et al., 1994). M anipulating amino acid sequences within the A and B chains o f
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insulin has led to the development o f multiple forms o f insulin, all o f  varying action times 
(Figure 1.5 and Table 1.1) e.g. insulin aspart and glargine.
a-chan
C14-FA
Long-acting analogues
Insulin glargine Detemir nsulm
Fast-acting analogues
Insukr' lispro Insu&n aspart
Figure 1.5: Alterations in the amino acid configuration o f  the A and B chain o f  insulin and the 
developm ent o f insulin analogues with varying action-tim e profiles (adapated from Owens, 2002).
0-ctiam
The modification o f the insulin structure allowed for T1DM individuals to be treated with a 
combination o f slow and fasting acting insulins, providing a 24 hour insulin profile, similar to 
a non-T lD M  individual, described by Bolli et al. (1999; Figure 1.3). This form o f therapy is 
termed ‘basal-bolus’, where individuals administer once/bi-daily doses o f  a slow-acting 
insulin (e.g. insulin detemir or glargine) which provides a peak less low level o f insulin for 24 
hours, restraining hepatic glucose output and ketogenesis and maintains low rates o f  glucose 
uptake into insulin sensitive tissues. The fast/rapid acting insulins are administered at meal 
times and provide rapid-increases in insulin concentrations, which coincide with the digestion 
o f the meal. Moreover, individuals may administer additional bolus insulin units in between 
meals to correct for high blood glucose concentrations.
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Table 1.1: The types of insulin currently available to T1DM individuals.
Action Insulin Insulin Manufacturer
Action Time (hours)
ReferenceType Name O nset Peak Duration
Humalog
(Lispro) Lilly 5 - 20 Min
4 5 - 6 0
mins
3 - 5
hours
Howey e t al. 
(1994)
R
A
PID
Insulin
Analogue
Apidra
(Glulisine)
Sanofi
Aventis 10 mins
4 5 - 6 0
mins
3-5
hours
Danne et al. 
(2005)
NovoRapid
(Aspart) Novo Nordisk 10 mins
4 5 - 6 0
mins
3-5
hours Plank et al. (2002)
SH
O
R
T
Regular
Humulin R Lilly 0 .5 -1hour
2 - 4
hours
6 - 8
hours Woodworth et al.
Actrapid Novo Nordisk 0.5 hours 2 .5 - 5hours 8 hours
(1994)
NPH
Humulin N Lilly 1-2 hours 6-12hours 18-24 Leopore e t al.
z
—\m
73
s
Novolin
NPH Novo Nordisk 1.5
04-12
hours 24
(2000)
m
o
5
m Lente
Humulin L Lilly 1-3 hours 6-12hours
18-24
hours
Novolin
Lente Novo Nordisk 2.5 hours
7-15
hours 22
S
Xm
o
*0
Humalog 
Mix (25% 
lispro and 
75% 
protamine 
suspension
Lilly 3 0 - 4 5mins 0.75-2.5 18-24
D iabetes C are 
Program m e of 
Nova Scotia 
(2002)
AJm
Humulin
20/80
Humulin
30/70
Lilly 30 mins 2-12hours 18-24
Ultralente
Humulin U Lilly 4-6 hours 8-20hours
24-28
hours Leopore e t al.
r~
Novolin
Ultralente Novo Nordisk 4 hours
8-24
hours
28
hours
(2000)
O
z
o Insulin
Analogue
Lantus
(Glargine) Lantus 1.5 hours none
20-24
hours
Leopore e t al. 
(2000)
Insulin
Analogue
Levemir
(Detemir) Novo Nordisk 2.5 hours none
20-24
hours
Porcellati e t al. 
(2007)
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1.4.2 Calculating insulin dose: carbohydrate counting and rapid-acting insulin 
dose
Carbohydrate counting allows T1DM individuals to adjust their rapid-acting insulin units to 
meals with varying carbohydrate content (Kulkami, 2005) allowing greater flexibility in their 
diets (Dias et al., 2010). Moreover, it has been shown to be important for glycaemic control, 
with reductions in HbAic of ~0.9% after just 3 months of carbohydrate counting (Dias et al., 
2010). Within those individuals treated with the basal-bolus regimen it is important that they 
understand what their target blood glucose is, i.e. euglycaemia, how the different insulins 
they are treated with act (i.e. onset of action and duration), and it is vital that individuals 
record their blood glucose responses to different meals. Through trial and error the patient is 
able to calculate their insulin : carbohydrate ratio through blood glucose concentrations being 
higher or lower than the target concentration, post-meal (Kulkami, 2003).
Individuals new to the basal-bolus regimen may start with a ratio of 0.5 - 1 insulin unit per 10 
or 15 g of carbohydrates, and through carefully recording their blood glucose responses they 
are able to self-adjust this ratio until optimal. For example, a T1DM individual elicited 
euglycaemic blood glucose concentrations after administering 5 insulin units with a meal 
containing 75 g of carbohydrates. For this individual, the insulin : carbohydrate ratio would 
be 1 IU per 15 g, or 1:15 (Kulkami, 2005). This ratio may change over the course of the day 
and individuals may need to alter this ratio to account for physical activity and/or planned or 
unplanned exercise (Kulkami, 2005).
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1.4.3 Calculating basal insulin dose
In contrast to rapid-acting insulin, there is no method to calculate basal dose other than trial 
and error. The clinician or diabetes specialist nurse may choose to increase or decrease the 
basal dose depending on HbAic, daily mean blood glucose concentrations, fasted blood 
glucose concentrations, between meal glucose excursions and the incidence of 
hypoglycaemia. Due to the importance of identifying an optimal basal dose for glycaemic 
control and restraining both hepatic glucose output and ketogenesis, it is doubtful that the 
individual will alter this dose in anticipation of exercise. Moreover, altering basal insulin 
units will have an influence on metabolism for as long as 24 hours after administration. 
Conversely, rapid-acting insulin alterations have a far more short-term effect, and it is for this 
reason that rapid-acting insulin is adjusted to changes in diet and exercise.
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1.5 The benefits of exercise  for T1DM individuals
Regular exercise can reduce the risk of chronic disease and premature death within both 
T1DM (Moy et al., 1993) and non-TlDM individuals (Warburton et al., 2006). Regular 
exercise within T1DM and non-TlDM has been shown to improve body composition, i.e. 
reduce abdominal adipocity and improved weight control (Lehmann et al., 1997; Seidell et 
al., 1991; Slattery et al., 1992; Warburton et al., 2001), enhance lipid lipoprotein profiles, i.e. 
increase high density lipoproteins and reduce low density lipoproteins (Berg et al., 1997; 
Durant et al., 1993; Lehmann et al., 1997; Tell and Vellar, 1988), improve glucose 
homeostasis and insulin sensitivity (Kelley and Goodpaster, 1999; Lehmann et al., 1997; 
Wallberg-Henriksson et al., 1998; Warburton et al., 2001; Young, 1995), reduce blood 
pressure (Lehmann et al., 1997; Whelton et al., 2002), improve autonomic tone (Tiukinhoy et 
al., 2003), reduce systemic inflammation (Adamopoulos et al., 2001), decrease blood 
coagulation (Physical Activity and Cardiovascular Health, 1996), improve coronary blood 
flow (Hambrecht et al., 2000), augment cardiac function (Gokce et al., 2002; Warburton et 
al., 1999) and enhance endothelial function (Fuchsjager-Mayrl et al., 2002; Gokce et al., 
2002; Kobayashi et al., 2003). There are additional benefits of exercise which are specific to 
T1DM individuals, exercise training has been demonstrated to reduce daily insulin dose 
(Ramalho et al., 2006) and improve long-term glycaemic control, through reductions in 
HbAic (Campaigne et al., 1984; Mosher et al., 1998; Salvatoni et al., 2005; Sideraviciute et 
al., 2006), and reduce the incidences of hypoglycaemia (Lehmann et al., 1997). However, the 
improvements in glycaemic control demonstrated within the existing literature have been 
induced by different exercise regimens (e.g. Mosher et al., 1998; Ramalho et al., 2006; 
Sideraviciute et al., 2006; Table 1.2). Moreover, research has demonstrated beneficial 
changes in the T1DM individual’s condition independent of changes in HbAic (Fuchsjager-
Lehmann et al., 1997; Mayrl et al., 2002; Table 1.3).
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1.6 Exercise modality, intensity  and  duration
At present the American College of Sports Medicine (2006) suggest T1DM individuals 
perform aerobic type exercise, for 20 -  60 minutes, 3 - 4  times per week at an intensity of 50 
-  80% of HR reserve or VO2 reserve. However, in terms of avoiding hypoglycaemia during 
and after the exercise bout, the most appropriate exercise modality, i.e. intermittent or 
continuous exercise, remains questionable. According to Guelfi et al. (2005b) continuous 
exercise is associated with a greater risk of hypoglycaemia than intermittent type exercise.
Research has demonstrated that the performance of intermittent high-intensity sprints ( 1 1 x 4  
s cycle sprints, every 2 mins for 20 minutes) does not increase the risk of developing 
hypoglycaemia during and for 60 minutes post-exercise, when compared to a resting control 
trial (Guelfi et al., 2005a). Moreover, intermittent (INT) exercise has been shown to preserve 
blood glucose concentrations more so than continuous (CON) exercise, and reduce the risk of 
hypoglycaemia during and after exercise (Guelfi et al., 2005b; Maran et al., 2010). In a study 
by Guelfi et al. (2005b), blood glucose responses to both continuous and intermittent exercise 
were compared. Participants performed 30 minutes of cycling at 40% V02peak (CON) or 30 
minutes of cycling at 40% V02peak, interspersed with 4 s maximal sprints every 2 minutes 
(INT). Blood glucose responses revealed a lesser decline during exercise under INT, despite 
performing more work. Moreover, concentrations remained stable for 60 minutes post­
exercise, whereas they continued to decline under CON. The preserved blood glucose 
concentrations were suggested to be related to large increases in catecholamines and growth 
hormone. According to Bussau et al. (2006) the drop in blood glucose that occurs post­
exercise after continuous exercise, as within the research of Guelfi et al. (2005b), can be 
prevented by the addition of a 10 s maximal sprint at the end o f the exercise bout (20 minutes
of cycling at 40% V02peak)- However, it is important to note that none of the aforementioned
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research employed pre-exercise insulin reductions. If pre-exercise insulin reductions were 
employed, such large differences in blood glucose between continuous and intermittent 
exercise may not occur.
Research has demonstrated no difference in blood glucose responses to continuous or 
intermittent exercise within 9 T1DM individuals (Bracken et al., 2008). Participants 
performed 45 minutes of continuous running and 45 minutes of intermittent running 
(designed to simulate intermittent team game play). Participants reduced their rapid-acting 
insulin dose by 50% with the meal prior to exercise and blood glucose responses were 
monitored during and for 24 hours after exercise using a continuous glucose monitoring 
system. Blood glucose responses revealed both conditions to induce a decline in blood 
glucose, however there were no between condition-differences in blood glucose responses. 
Comparing the research of Bracken and colleagues with Guelfi et al. (2005b), the heavy 
reduction to pre-exercise insulin may be a contributing factor to the lack of difference 
between conditions. Moreover, there is potential that if insulin reductions were employed 
before high-intensity interval exercise, the exercise induced increases in counter-regulatory 
hormones could create a milieu that promotes post-exercise hyperglycaemia.
From a practical application point of view, the work of Guelfi et al. (2005b) was designed to
simulate team game demands, however, only lasted 30 minutes and was performed on a cycle
ergometer. Potentially, performing maximal sprints on a cycle ergometer may be more simple
than during other types of exercise, e.g. treadmill running. Moreover, within the research of
Guelfi et al. (2005b) and Bussau et al. (2006) participant mean age was just 22 and 21 years
old, respectively. Potentially, it is unlikely that more elderly T1DM individuals will be
inclined to perform high-intensity intermittent exercise as a method to preserve blood glucose
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during after exercise, as the risk of injury may be higher (Wenger and Bell, 1986). 
Additionally, although high-intensity (90-100% V02max) exercise will increase cardiovascular 
fitness more so than lower intensity exercise (Tabata et al., 1996; Wenger and Bell, 1986), 
research suggests that when lower intensity exercise exceeds 35 minutes, there are similar 
gains in cardiovascular fitness, when compared with short-duration high-intensity training 
(Wenger and Bell, 1986). In light of this, methods to help preserve blood glucose 
concentrations during sub-maximal continuous exercise should be investigated.
At present, current literature examining different factors (e.g. exercise mode, insulin and 
carbohydrate administration before exercise) affecting blood glucose responses within T1DM 
individuals has been predominantly during and after cycling (Bussau et al., 2006; Campaigne 
et al., 1987; Chokkalingham et al., 2007; Dandona et al., 1980; Dube et al., 2005; Guelfi et 
al., 2005a; 2005b; Hernandez et al., 2000; Jenni et al., 2008; Mauvais-Jarvis et al., 2003 
Perrone et al., 2005; Peter et al., 2005; Rabasa-Lhoret et al., 2001; Touminen et al., 1995), 
with little research examining blood glucose responses to running (Bracken et al., 2008). 
Cycling is a primarily concentric form of exercise i.e. the muscle shortens as it contracts. 
However, in many daily activity patterns including body weight supporting exercises, such as 
jogging or running, there is a significant proportion of eccentric muscle action, where the 
muscle lengthens in the performance of the movement. Moreover, eccentric muscle actions 
have been demonstrated to hinder insulin action and glucose uptake for many hours following 
exercise (Asp et al., 1995; Asp et al., 1996). Additionally, running which supports body mass, 
would also act as a greater metabolic stress than cycling, which could have the potential to 
influence blood glucose responses not just during exercise, but also potentially in the hours 
after.
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1.7 S trategies for preventing and/or minimising post-exercise hypoglycaem ia
In light of the aforementioned defects in glucose regulation and the high risk of 
hypoglycaemia associated with exercise, strategies that help combat hypoglycaemia have 
received considerable attention within the literature (Campaigne et al., 1987; De Feo et al., 
2006; Dube et al., 2005; Grimm, 2005; Guelfi et al., 2005b; Hernandez et al., 2000; Iafusco et 
a;., 2006; Muvais-Jarvis et al., 2003; Rabasa-Lhoret et al., 2001). An important aspect of the 
research focuses on reducing the pre-exercise insulin dose (Campaigne et al., 1987; Muvais- 
Jarvis et al., 2003; Rabasa-Lhoret et al., 2001).
1.7.1 The importance of insulin dose on post-exercise glycaemia
Reducing the dose of insulin administered with a carbohydrate meal would result in a
reduction in the insulin to carbohydrate ratio, resulting in a reduced clearance of blood
glucose after digestion of the carbohydrate meal. This would result in a preservation of blood
glucose above normal concentrations before exercise (Rabasa-Lhoret et al., 2001). During
exercise the reduced insulin concentrations would aid in promoting a pattern of substrate
oxidation and glucose regulation similar to a non-TlDM individual (Chokkalingam et al.,
2007), i.e. reduced uptake of glucose and a subsequent reduction in carbohydrate oxidation
with a concomitant increased contribution to energy turnover from NEFA’s (Chokkalingam
et al., 2007; Figure 1.6). The lower circulating insulin concentrations would have a lesser
restraining influence over hepatic glucose production, and the provision of NEFA, from the
adipose tissue, for the active musculature (Figure 1.6). Moreover, a reduction in insulin
mediated glucose uptake, in combination with elevations in the catecholamines would reduce
the uptake and subsequent combustion of blood glucose and preserve blood glucose
concentrations (Cryer, 2003). In the post-exercise period, the greater blood glucose
concentrations would help compensate for the heightened uptake of glucose by the exercised
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tissue (Steppel and Horton, 2003), which is increased to replenish muscle glycogen stores. 
Moreover, the lower insulin concentrations would provide a milieu where the actions o f the 
gluco-regulatory hormones are not inhibited and insulin’s suppressive effect at the hepatocyte 
and adipocyte is lessened, such that substrates can be provided for both hepatic glucose 
production and replenishment o f muscle glycogen stores (Steppel and Horton, 2003). 
Therefore, the greater pre-exercise blood glucose concentrations and an improved hormonal 
milieu, i.e. lower circulating insulin concentrations, during exercise would aid in preserving 
blood glucose concentrations during exercise such that post-exercise concentrations can be 
better maintained and ultimately lessen the risk o f hypoglycaemia.
4* Dose
4  hepatocyte 4insulin  mediated
suppression glucose uptake
-  t  output -----> Blood G lucose   T uptake
gluconeogenesis
&
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t
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Figure 1.6: The theoretical effects o f  reductions in insulin dose on blood glucose regulation and fuel 
m etabolism during exercise.
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Within the existing literature examining pre-exercise insulin reductions, recommendations 
have varied from >50% (Campaigne et al., 1987), 10-40% (De Feo et al., 2006), 10-50% 
(Grimm, 2005), 50-90% (Mauvais-Jarvis et al., 2003) and 50-75% (Rabasa-Lhoret et a l, 
2001; Table 1.4). Some of the variation in the recommended reduction can be accounted for 
by differences in the insulin species used by participants and the exercise model employed 
within the respective studies (Table 1.4).
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An early study by Campaigne et al. (1987; Table 1.3) was one of the first to research pre­
exercise insulin reductions, examining blood glucose responses during and after 45 minutes 
of cycling, within 9 T1DM males who were treated with a bi-daily, intermediate/short acting 
insulin mix. The authors demonstrated that despite 50% reductions in the intermediate or the 
soluble insulin prior to exercise, hypoglycaemia still occurred in 6 of the 9 subjects at some 
point during or after exercise, predominantly the night (self-reported) of the trial day. 
Additionally, Mauvais-Jarvis et al. (2003; Table 1.3) examined pre-exercise insulin 
reductions during and for 2 hours after exercise, within 12 T1DM individuals. Six of the 
participants were treated with regular insulin in the morning and at noon and NPH before 
bed, while the other 6 participants were treated with bi-daily mixed insulin regimen of 30% 
regular insulin combined with 70% NPH insulin. Participants performed 60 minutes of 
cycling at 70% VC>2max, 90 minutes after a set meal where participants administered an 
unaltered insulin dose or a 90% insulin reduction (participants on 3 daily injections) / 50% 
insulin reduction (bi-daily mixed regimen). The plasma glucose responses within the study of 
Mauvais-Jarvis et al. (2003) are presented in Figure 1.7.
5 18 .©
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Figure 1.7: Changes in plasma glucose levels during exercise and recovery performed with (H) and 
without (CH) an insulin reduction. Adapted from Mauvais-Jarvis et al. (2003).
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Eight participants had to receive an oral glucose solution during the condition without an 
insulin reduction due to rapidly falling plasma glucose concentrations. Plasma glucose levels 
were consistently higher during and for 2 hours after exercise within the insulin reduction 
trial (Figure 1.7). It was concluded that a 50-90% reduction in insulin dose, depending on 
their insulin regimen, can allow T1DM individuals to engage in intensive exercise without 
causing hypoglycaemia and worsening glycaemic control (Mauvais-Jarvis et al., 2003)
The research of Campaigne et al. (1987) and Mauvais-Jarvis et al. (2003) lacked specific 
guidelines for pre-exercise insulin reductions, i.e. dose adjustments relating to exercise 
intensity and duration. Moreover, with the increased prescription of the basal-bolus regimen 
to treat T1DM individuals, dose adjustments specific to this kind of treatment, as opposed to 
the mixed insulins of Campaigne et al. (1987) and Mauvais-Jarvis et al. (2003), needed 
investigating. In addition, the time post-exercise where the potential for monitoring blood 
glucose was just 2-12 hours (Campaigne et al., 1987; Mauvais-Jarvis et al., 2003), and as 
previously demonstrated hypoglycaemia may develop up to 24 hours after exercise 
(MacDonald, 1987; Tsalikian et al., 2005), so this window of examination needs to be greater 
to determine the effectiveness of the insulin reduction.
Research by Rabasa-Lhoret et al. (2001; Table 1.4) furthered the area, addressing the issues
of exercise intensity and duration within individuals treated with the more preferentially
prescribed, basal-bolus regimen (Ultralente with prandial insulin lispro). Participants
performed 60 minutes at 25% V02max, 30 and 60 minutes at 50% VC>2max, and 30 minutes at
75% V02max, with blood glucose concentrations monitored throughout exercise and for an
hour post-exercise. All trials were performed after administration of a full insulin dose (Full),
a 50% reduction (50%) and after a 75% reduction (25%). Rabasa-Lhoret and colleagues
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demonstrated that the drop in blood glucose that occurs with exercise at 25% V02max for 60 
minutes did not differ between Full and 50%, however, greater pre-exercise concentrations 
result in a safer glycaemic profile after exercise, i.e. a greater preservation of blood glucose. 
Plasma glucose at the end of exercise was A-2.9 ±1.1 mmol.l'1 below baseline after Full, 
compared with A-0.6 ± 0.9 mmol.l-1 after 50%. This trend followed during exercise at 50% 
V02max for 30 minutes; the decrease in plasma glucose, relative to rest, at the end of exercise 
was less under 50% (A-0.4 ± 1.3 mmol.l-1) compared with Full (A-2.1 ± 0.7 mmol.l'1) and 
resulted in greater plasma glucose concentrations during and for 1 hour after exercise. Plasma 
glucose responses revealed that the greatest preservation of post-exercise glycaemia occurred 
after a 75% reduction, when exercising at 50% VC>2max for an hour and 75% VC>2max for 30 
minutes. The 75% reduction trial resulted in a better maintenance of glycaemia during and 
after exercise (~7 -  10 mmol.l'1), with less chance of developing hypoglycaemia, compared 
to just a 50% reduced dose, which elicited post-exercise concentrations of ~4.5 -  7 mmol.l'1. 
Based on plasma glucose responses during exercise, the optimal pre-exercise insulin 
reductions recommended by Rabsa-Lhoret et al. (2001) are presented in Table 1.5.
Table 1.5: Guidelines for the reduction in pre-exercise bolus insulin dose recommended by Rabasa- 
Lhoret et al. (2001).
% Dose Reduction
Exercise Intensity 
(% V02max)
30 min of 
exercise
60 min of 
exercise
25 25 50
50 50 75
75 75 -
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When comparing blood glucose responses across studies it is evident that the choice of 
insulin species is an important factor. Currently, T1DM individuals are predominantly treated 
with the modem insulin analogues (Table 1.1) in a basal-bolus regimen; these rDNA insulins 
(e.g. insulin glargine/detemir and aspart/lispro) offer very different, more favourable, action­
time profiles and less variability than longer established insulins, such as regular human 
insulin and NPH insulin (Brange and Volund, 1999; Leopore et al., 2000; Tuominen et al.,
1995). Moreover, research has demonstrated that the uptake kinetics of modem basal 
analogues are not affected by exercise (Peter et al., 2005), however, the bolus analogues are 
(Touminen et al., 1995). With this in mind, there is no literature that has examined pre­
exercise insulin reductions using these kinds of insulins. Moreover, with the potential for 
these insulins to affect metabolism and blood glucose concentrations from 5-24 hours after 
administration (Leopore et al., 2000; Plank et al., 2002), and the potential for developing 
hypoglycaemia increased for a similar time frame after exercise (MacDonald, 1987; Tsalikian 
et al., 2005), as well as current literature only investigating blood glucose responses for just 
1 - 1 2  hours post-exercise (Campaigne et al., 1987; Mauvais-Jarvis et al., 2003; Rabasa- 
Lhoret et al., 2001), a more detailed examination of the effects of pre-exercise insulin 
reductions after exercise is required.
1.7.2 The safety of using pre-exercise insulin reductions
Exogenous insulin treatment reduces blood glucose, which prevents hyperglycaemia and risk
of ketosis (Cryer, 2001). Under normal physiological conditions ketones (acetoacetate, p-
hydroxybutyrate and acetone) are produced through hepatic fatty acid metabolism during
periods of low carbohydrate conditions. Ketogenesis allows fat-derived energy to be
generated in the liver and used by other organs, such as the brain, heart, kidney cortex and
skeletal muscle (Laffel, 1999). However, reduction or omission in insulin dose is a significant
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factor in the development of diabetic ketoacidosis accounting for 13-45% of reported DKA 
cases (Wallace and Matthews, 2004). The formation of ketone bodies above non- 
physiological levels (>1 mmol.l'1) has been proven to increase oxygen radical formation and 
cause lipid peroxidation (Jain et al., 1998; Jain et al., 1999a; 1999b) as well as induce 
metabolic acidosis (Laffel, 1999). Diabetic ketoacidosis is characterised by an absolute or 
relative deficiency of circulating insulin and combined increases in counter-regulatory 
hormones (catecholamines, glucagon, cortisol, growth hormone), particularly glucagon and 
adrenaline, hyperglycaemia and metabolic acidosis (Wallace and Matthews, 2004). 
Moreover, physical exercise also increases ketone body formation (Koeslag et al., 1980; 
Horowitz et al., 2000), alters acid-base balance and increases counter-regulatory hormones 
(Figure 1.8). Therefore, the potential for a combined effect of a pre-exercise insulin reduction 
strategy and performance of exercise might exacerbate ketogenesis and result in 
hyperketonaemia (>1.0 mmol.l1) or development of ketoacidosis (>3.0 mmol.l'1) (Laffel et 
al., 1999; Figure 1.8). However, there is limited data available to refute this hypothesis.
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Figure 1.8: Theoretical effects o f  exercising under a reduced insulin dose on ketogenesis.
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1.8 Current recom m endations for carbohydrate intake and exercise in T1DM
The literature concerning the amount of carbohydrate to consume before, during and after 
exercise to prevent hypoglycaemia within T1DM individuals has produced diverse findings. 
For example, Hernandez et al. (2000; Table 1.6) suggested that 60 - 120 g of carbohydrates 
should be consumed, in equal bolus’, before, during and immediately after exercise to prevent 
late-onset hypoglycaemia. The range in recommended carbohydrate intake is likely due to 
differences in glycogen depletion across participants (Perry and Gallen, 2009). Whereas 
Iafusco (2006) recommends consumption of 15 g of simple carbohydrates immediately 
before exercise and consumption of a hypotonic sports drink (e.g. Gatorade®, 4%  sucrose, 
2% fructose) during exercise. Conversely, Dube et al. (2005; Table 1.6) suggests just a 35 g 
bolus of dextrose is needed, immediately before exercise, to combat hypoglycaemia. Dube 
and colleagues investigated pre-exercise glucose requirements in order to preserve blood 
glucose concentrations during exercise. Three hours after consuming a standardised 
breakfast, with their usual insulin dose, participants consumed a 0, 15 or 30 g of bolus of 
glucose 15 minutes prior to 60 minutes of cycling at 50% V02max- The drop in blood glucose 
during exercise was similar across trials, however, the addition of 15 or 30 g of glucose 
prolonged the delay before glucose infusion was required (0 g ~32; 15 g ~51; 30 g ~56 min). 
During the exercise bout, 7 of 9 individuals required glucose infusion under the 0 g trial, 4 of 
9 required glucose infusion under the 15 g trial, and just 3 under the 30 g condition. Based on 
the glucose infusion requirements, the authors estimated that a beverage containing 35 g of 
glucose should be consumed immediately before exercise to maintain blood glucose during 
60 minutes of moderate intensity exercise.
In addition to the recommendations of Iafusco (2006) and the research of Dube et al. (2005),
Perrone et al. (2005; Table 1.6) addressed the concentration of the carbohydrate beverage
33
consumed immediately before and throughout the exercise bout. Participants cycled at 55- 
60% VC>2max for 60 minutes, consuming either an 8% or a 10% carbohydrate solution before 
and during exercise. Throughout the duration of the trial, blood glucose concentrations were 
lower under the 8% solution; moreover, 4 individuals experienced hypoglycaemia under this 
condition. Furthermore, blood glucose concentrations dropped ~1.8 mmol.l'1 in the hour post­
exercise, whereas concentrations remained stable under the 10% condition. Based on the 
blood glucose responses and hypoglycaemic incidences the authors recommended T1DM 
individuals consume a 10% carbohydrate solution before and during exercise to maintain 
glycaemia. Additionally, to quickly correct falling blood glucose during exercise, Gallen 
(2005) recommends consumption of a 15% carbohydrate solution.
This is interesting, as carbohydrate concentration is an important factor in post-ingestion
blood glucose responses, with research demonstrating reduced gastric emptying rates with
concentrations ranging from 6-20% (Davis et al., 1990; Jeukendrup et al., 2007; Maughan
and Leiper, 1999; Murray et al., 1997). However, this research was carried out within non-
T1DM individuals. Low blood glucose concentrations have been demonstrated to increase
gastric emptying rates within non-TlDM individuals (Schvarcz et al., 1993), thus potentially
explaining the greater concentrations, recommended by Peronne et al. (2005) and Gallen
(2005). Moreover, it should be noted that gastric emptying rates are also affected by elevated
blood glucose (Schvarcz et al., 1997). Schvarcz and colleagues demonstrated a slowing of
gastric emptying when blood glucose concentrations were clamped at just 8 mmol.l'1, in
comparison with 4 mmol.l'1, within T1DM individuals. In addition, gastric emptying rates are
also influenced by long term glycaemic control (Jing et al., 2009). Therefore, blood glucose
concentrations and long term glycaemic control may be important factors that contribute to
the optimal concentration of carbohydrates to be administered, moreover may be contributing
34
factors to inter-individual variability in blood glucose responses that may exist after 
administration of carbohydrate.
Based on the current literature it seems 15 -  35 g of simple carbohydrates should be 
consumed immediately prior to exercise. Moreover, a carbohydrate solution of 10% should 
be consumed during the exercise bout. However, the existing literature did not examine the 
influence of carbohydrate feeding on blood glucose responses in the more long term period 
after exercise. Moreover, it is important to note that none of the aforementioned research 
employed a pre-exercise insulin reduction. Potentially, employing an insulin reduction 
strategy could have resulted in very different carbohydrate requirements. Moreover, an 
optimal reduction to the insulin dose administered with the meal before exercise may even 
negate the need to consume any additional carbohydrates before, during and immediately 
after the exercise bout.
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1.8.1 Carbohydrate type: the glycaem ic index
The glycaemic index (GI; Figure 1.9) is a method of clinically classifying foods/meals 
containing carbohydrates according to glycaemic responses after ingestion (Wolever et al., 
1991). For example, carbohydrates with a high GI, such as white bread, will induce a rapid 
increase in blood glucose concentrations after ingestion (Foster-Powell et al., 2002). 
Conversely, carbohydrates with a low GI, such as peaches, will induce more gradual 
increases, and lesser peaks, in blood glucose (Foster-Powell et al., 2002).
From a diabetes management perspective, this classification of foodstuffs is useful as both 
clinicians and patients can adjust their diets to include low GI carbohydrates due to benefits 
such as a greater feeling of satiety (Foster-Powell et al., 2002), improved insulin sensitivity 
and blood lipid profiles (Jenkins et al., 1985), lower daily mean blood glucose concentrations 
(Nansel et al., 2008), reduced incidence of hypoglycaemia and reductions in HbAic (Brand et 
al., 1991; Gilbertson et al., 2001; Thomas et al., 2007). Within the study o f Nansel et al. 
(2008), consumption of low GI foodstuffs, such as peaches, kidney beans or brown rice, 
resulted in glucose concentrations (assessed using a continuous glucose monitor) being 
within a target range of 3.9 -  9.9 mmol.l'1 significantly more o f the time than under the HGI 
trial (67 vs. 47 %). Moreover, the participants elicited a lower mean blood glucose 
concentration (LGI 7.6 ± 2.0 vs. HGI 10.1 ± 2.6 mmol.l'1) and required less bolus insulin per 
lOgofCHO.
0 50 100 
I 1-------------------------1----------------- — i------------- 1------------- 1------------- 1
Water Cherry Isomaltulose Porridge Brown Rice White Rice Ice Cream Glucose
Figure 1.9: The glycaemic index.
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With regards exercise, research in non-TlDM demonstrates less change in blood glucose 
concentration during exercise after low GI carbohydrates (Demarco et al., 1999; Achten et 
al., 2007; Table 1.7). Demarco et al. (1999; Table 1.6) examined 10 trained cyclists during 2 
hours of cycling at 70% V02max, followed immediately by a time trial to exhaustion at 100% 
V02max, having consumed either a high or low GI meal before exercise. Blood glucose 
responses revealed a more gradual rise and fall in concentrations over the 120 minute 
exercise period under LGI, with concentrations at 120 minutes not different to immediate pre­
exercise values. However, concentrations under HGI had significantly dropped over the 2 
hour period. During the 120 minutes of cycling there was a greater lipid oxidation rate under 
LGI, in comparison with HGI. Moreover, despite a 60% increase in time to exhaustion, blood 
glucose concentrations were greater at the cessation of exercise under LGI. Achten et al. 
(2007) investigated plasma glucose responses to 150 minutes of cycling at ~ 60 % V02max 
after ingesting isomaltulose or sucrose with results demonstrating little change in plasma 
glucose over the duration of the protocol after consumption of isomaltulose (GI 32), 
compared to a ~1.2 mmol.l’1 greater plasma glucose concentration 15 min after sucrose 
consumption. Moreover, consumption of low GI carbohydrates alters exercising fuel 
metabolism (Achten et al., 2007; Demarco et al., 1999; Stevenson et al., 2006). Lipid 
utilisation increases and carbohydrate oxidation rates decrease during a bout of isocaloric 
exercise, in non-TlDM individuals, following consumption of a low GI meal (Achten et al., 
2007; Demarco et al., 1999; Stevenson et al., 2006). Stevenson et al. (2006) demonstrated a 
56 % greater lipid oxidation rate and 31 % lower carbohydrate oxidation during a one hour 
treadmill run at 65 % V02max 3 hours following consumption of a low (139 g CHO; GI 44) or 
high GI (139 g CHO; GI 78) meal in eight female participants. Similarly, ingestion of a 50 g 
bolus of isomaltulose (GI 32) increased lipid oxidation rate more than sucrose and reduced
38
carbohydrate oxidation rate -0.2 g.min'1 during 150 minutes of cycling at 60 % V 0 2max 
(Achten et al., 2007).
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Based on the existing literature, it seems consumption of low GI carbohydrates has the 
potential to induce less change in blood glucose before and during exercise. Moreover, low 
GI carbohydrates may suppress fat oxidation less during exercise, which may subsequently 
spare both endogenous and exogenous carbohydrate use, resulting in better preservation of 
blood glucose during and in the post-exercise period. However, there is scant research that 
has examined blood glucose and metabolic responses to exercise after different GI 
carbohydrates within T1DM. Moreover, none of the existing literature examining 
carbohydrate requirements within T1DM implemented a pre-exercise insulin reduction, 
which raises the possibility that if insulin dose is sufficiently reduced before exercise, 
additional carbohydrates may not be required before and during exercise.
1.8.2 Exogenous carbohydrate oxidation and glycaemia
As demonstrated, carbohydrate consumption prior to or during exercise is important for the 
exercising T1DM individual (Dube et al., 2005; Hernandez et al., 2000; Iafusco, 2006). 
However, it has been suggested that a greater contribution to energy turnover from exogenous 
carbohydrate sources would spare endogenous carbohydrate reserves (liver and possibly 
muscle glycogen; Jeukendrup, 2004). Keeping in mind an increased glucose uptake to 
replenish muscle glycogen stores after exercise (Wojtaszewski et al., 2002), a sparing of 
endogenous carbohydrate stores would have implications for post-exercise blood glucose 
concentrations, and potentially the development of hypoglycaemia.
According to Jeukendrup (2004) exogenous carbohydrate oxidation is influenced by the type
and amount of carbohydrate ingested and the exercise intensity, however is seemingly
unaffected by the timing of consumption, gastric emptying (Rehrer et al., 1992; Saris et al.,
1993) or solution osmalality (Shi et al., 1995). Shi and colleagues suggested that different
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forms of carbohydrate in solution (glucose, fructose, sucrose) increased carbohydrate 
absorption despite an increase in osmalality. The authors attributed the increased uptake to 
different transporters used in the uptake process, i.e. glucose is transported across the luminal 
membrane by a sodium-glucose transporter (SGLT1) and fructose is transported by GLUT-5, 
therefore there was a reduced competition for transporters and an increase in total 
carbohydrate absorption. This was confirmed by Jentjens et al. (2003) where glucose 
ingestion alone resulted in maximal exogenous carbohydrate oxidation rates, during exercise, 
of 0.83 g/min, whereas a glucose and fructose mix increased oxidation rates by -56%  (-1.26 
g/min). These factors may be important for the exercising T1DM individual; blood glucose 
concentrations are the primary concern for avoiding hypoglycaemia during exercise, 
however, if exogenous carbohydrate oxidation rates can be increased, through ingestion of 
different forms of carbohydrates, in addition to a greater contribution from lipids, a 
preservation of endogenous carbohydrate reserves may take place which may subsequently 
maintain blood glucose concentrations post-exercise. However, there is limited data to refute 
this hypothesis.
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1.9 Pre-exercise timing of carbohydrate consumption and insulin 
administration
The timing of pre-exercise carbohydrate consumption and insulin administration is largely 
dependent upon the insulin species (Table 1.1) and the altered uptake kinetics that are 
associated with exercise (Dandona et al., 1980; Femqvist et al., 1986; Touminen et al., 
1995). Research has demonstrated that exercise can result in greater peaks in insulin as well 
as increasing absorption rates and ultimately increasing the risk of hypoglycaemia (Dandona 
et al., 1980; Touminen et al., 1995). The altered rates of absorption are likely due to a 
combination of increases in blood flow (Lauritzen et al., 1980; Linde and Gunnarsson, 1985; 
Vora et al., 1993) and temperature (Koivisto et al., 1980; 1981) that are associated with 
exercise.
Animal preparations and regular human insulin interact differently with exercise (Femqvist
et al., 1986; Table 1.8). Femqvist and colleagues demonstrated that the exercise induced
peak in insulin concentrations was less with regular human insulin as apposed to porcine
insulin. Moreover, Touminen et al. (1995) demonstrated that the rDNA insulins, human
insulin and the analogue insulin lispro, also interact differently with exercise, moreover the
pre-exercise timing is particularly important in subsequent insulin and blood glucose
responses (Table 1.8). Touminen and colleagues identified that when exercise was performed
40 minutes after administration, insulin lispro induced an earlier and 56% greater peak in
insulin concentrations, consequently resulting in a greater drop in blood glucose with
exercise, when compared to regular human insulin. Moreover, when exercising this close to
administration, the exercise bout was associated with a 2.2 fold greater risk of
hypoglycaemia. However, when exercising 180 minutes post-administration, the drop in
blood glucose was less under insulin lispro, and the risk of hypoglycaemia was reduced by
43
46%, when compared to regular human insulin. This research highlights pre-exercise timing 
as an important factor to consider, as the intense rise and peak in insullin that is elicited soon 
after administration of rapid-acting insulin, results in marked increases in the risk of 
hypoglycaemia during exercise.
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The lower variability and more favourable action-time profiles of the rapid-acting insulins 
(Brange and Volund , 1999; Tuominen et al., 1995) make these analogues of insulin ideal for 
prandial use, and have been shown to significantly improve glycaemic control within T1DM 
individuals, without increasing the risk of hypoglycaemia (Tamas et al., 2001). However, the 
intense and rapid rise in insulin concentrations (peaking 45 -  60 minutes after administration, 
Plank et al., 2002) means that it is currently recommended to avoid administration of rapid- 
acting insulin within 90-120 minutes of exercise due to the risk of over-insulinisation of the 
active musculature during exercise (De Feo et al., 2006; Perry and Gallen, 2009), as 
demonstrated by the early work of Touminen et al. (1995).
At present it is currently recommended that insulin dose should be reduced before performing 
exercise, regardless of the insulin species or time before exercise (Campaigne et al., 1987; 
Muvais-Jarvis et al., 2003; Rabasa-Lhoret et al., 2001). However, to date there is no literature 
that examined pre-exercise timing as a factor to consider in subsequent blood glucose 
responses. Specifically, there is limited data available on the absorption kinetics of the insulin 
analogues when administered in reduced doses with the carbohydrate meal at different times 
prior to exercise. Within the study of Touminen et al. (1995) participants administered ~6.3 
RJ of insulin, however, if employing a heavy insulin reduction, as recommended by Rabsa- 
Lhoret et al. (2001), pre-exercise insulin dose could be as little as ~3 RJ. Therefore, there is 
potential that administering such small doses of insulin closer to the exercise bout may in fact 
not increase the risk of hypoglycaemia. However, there is limited literature available to 
confirm or refute this hypothesis.
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1.10 Hormonal factors contributing to inter-individual differences in blood 
glucose responses to exercise
When examining blood glucose responses to exercise, an important factor to consider is the 
duration of T1DM. As the disease progresses with time, T1DM individuals endure a gradual 
decline in key gluco-regulatory hormone responses to falling blood glucose (Amiel et al., 
1988; Banarer et al., 2002; Dagogo-Jack et al., 1993; Mokan et al., 1994). Therefore, the 
duration of the disease could be a contributing factor to large inter-individual differences in 
blood glucose responses when exposed to identical stimuli (e.g. exercise, diet, and insulin 
dose).
1.10.1 Glucagon responsiveness
Glucagon is a key hormone in glucose regulation during exercise however there may be large 
inter-individual variability in the glucagon response to both exercise and falling blood 
glucose. The glucagon response can be normal, impaired or totally absent (Taborsky et al., 
1998). Early research by Bolli et al. (1983) suggested that the variance in glucagon 
responsiveness between individuals could be due to the duration of the disease; newly 
diagnosed patients were found to have a normal a-cell function and those of 1 -5 years clearly 
having a blunted response. Furthermore, Gerich et al. (1973) demonstrated that the glucagon 
response was absent in patients who had T1DM for over a decade. The mechanism behind the 
loss of a-cell function with time is due to progressive loss of residual p-cell function (Fukuda 
et al., 1988) and a reduced autonomic input through progressive denervation of the a-cell 
(Tominaga et al., 1987). Therefore, residual a-cell function may be a potential explanatory 
mechanism behind between-individual differences in the blood glucose response to exercise.
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1.10.2 The sympathoadrenal influence on blood glucose
With progressive loss of the primary mechanism against falling blood glucose, glucagon, the 
adrenaline response also becomes attenuated with time (Cryer, 2002). A single 
hypoglycaemic episode can result in a reduced sympatho-adrenal input, with individuals not 
experiencing symptoms of hypoglycaemia and are unaware of dangerously low blood glucose 
concentrations. Moreover, the reduced autonomic input results in an attenuated adrenaline 
secretion (Cryer, 2002) to falling blood glucose. Antecedent hypoglycaemia has been shown 
to shift the glycaemic threshold for stimulating adrenaline release, symptomatic and cognitive 
dysfunction responses, to lower blood glucose concentrations (Dagogo-Jack et al., 1993; 
Fanelli et al., 1998). Moreover, reduced adrenomedullary stores of adrenaline have been 
demonstrated within T1DM individuals with defective adrenal responses to falling blood 
glucose (De Galan et al., 2004). Therefore, keeping in mind the importance of adrenaline on 
maintaining blood glucose concentatrations during exercise, i.e. reducing glucose clearance 
(Howlett et al., 1999), increasing breakdown of intramuscular triglycerides (Howlett et al., 
2000) and glycogen (Watt et al., 2001), and stimulating hepatic glucose output (Howlett et 
al., 1999), a reduced adrenaline secretion would have large metabolic consequences, in 
particular for the development of hypoglycaemia. Based on these data, the oxidation of blood 
glucose as a fuel would not decrease, and the promotion of intramuscular fuel sources would 
be lessened, as well as a reduced stimulation of hepatic glucose production; combining these 
factors promotes a fall in blood glucose, ultimately leading to hypoglycaemia. Therefore, 
inter-individual differences in the adrenaline response to falling blood glucose may be a 
contributing factor in the preservation/lack of preservation of blood glucose between 
individuals when exposed to the same protocol.
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1.11 Summary of thesis and experimental chapter aims
The main aim of this thesis is to examine factors that affect post-exercise glycaemia within 
T1DM individuals. This thesis will specifically examine the influence of pre-exercise insulin 
dose, the glycaemic index of the carbohydrates ingested before exercise, and the timing of the 
administration of both insulin and carbohydrate prior to exercise, on post-exercise glycaemia. 
Moreover, this thesis will examine if altering these factors is a safe strategy for the exercising 
T1DM individual to engage in.
The experimental chapters will examine:
1: The metabolic and glycaemic effects of pre-exercise reductions in rapid-acting insulin,
before, during and for 24 hours after a single bout of running exercise.
2: The metabolic and glycaemic effects of alterations to the glycaemic index of the pre­
exercise carbohydrate, before, during and for 24 hours after a single bout of running exercise.
3: The metabolic and glycaemic effects of alterations in the timing of pre-exercise 
carbohydrate consumption and insulin administration, before, during and for 24 hours after a 
single bout of running exercise.
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Chapter 2 
Methodology
50
2.1 Ethics
Ethical approval for carrying out these studies was attained from the Local Research Ethics 
Committee (LREC) of the Abertawe Bro Morgannwg NHS trust (Appendix Al).
2.2 Type 1 Diabetes participants
2.2.1 Recruitment of participants
Type 1 diabetes volunteers were sought from advertisements placed on the Swansea 
university home page and local and national newspapers. Potential participants were also 
recruited from within the Diabetes clinics in the Swansea area (Morriston and Singleton 
Hospital Diabetes Clinics, Abertawe Bro Morgannwg NHS trust). A database was created of 
all those patients interested in taking part in the research. Initial contact was made via 
telephone or through email, following which volunteers were sent a study information pack 
(Appendix A2 - A4), which included a reply form (Appendix B). Those who were willing to 
take part were screened against an inclusion/exclusion criteria (Table 2.1) and were invited to 
visit the exercise physiology laboratories.
Table 2.1: Inclusion/exclusion criteria for participants across all experimental chapters.
Aged 18 to 55 years 
HbAlc< 10%
Using a Basal-Bolus Regimen of 
modem insulin analogues
- excluding insulin glulisine (Apidra®)
No diabetic complications other than retinopathy
No medication other than insulin
Regularly exercising and able to continuously run for 45 minutes 
No muscular-skeletal problems____________________________
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2.2.2 Insulin regim en of participants
Those volunteers selected to partake in these studies were using a basal-bolus regimen and 
were taking a set number of basal units for a period of at least 3 months. Participants selected 
were being treated with once daily insulin glargine (Lantus®, Sanofi Aventis, France) or bi­
daily insulin detemir (Levemir®, NovoNordisk, Denmark) as the basal component of their 
insulin regimen. These two basal insulin analogues are promoted as equivalent, in terms of a 
peak less 24 hour insulin profile (Gulve, 2008). Furthermore, participants were using a 
prandial rapid-acting insulin of either insulin lispro (Humalog®, Lilly, USA) or aspart 
(Novorapid®, NovoNordisk, Denmark). Research has demonstrated no differences in the 
pharmacokinetic or pharmacodynamic profiles (Plank et al., 2002), or metabolic effects 
(Homko et al., 2003) of these insulin analogues. The injection site and the timing of 
administration of the basal insulin were not homogenous within the subject group; however, 
this remained unaltered between the experimental trials. Bolus insulin dose was calculated 
via the carbohydrate counting method, i.e. number of rapid-acting insulin units per 10 g of 
carbohydrate consumed (Tables 2.2 to 2.4).
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Table 2.2: Chapter 3 participant insulin regimen details.
Participant ID
Insulin 1 2 3 4 5 6 7 8 Mean ± SEM
Basal 28g 22g 44g 42g 27g 6 6 ° 30g 22g 35 ± 2
Bolus (per 10 g 
CHO) 1A 1L 2a 1.5a 1.5l 1A 1A 1A 1.3 ±0.1
Note: G = glargine, D = detemir, A = aspart, L = lispro
Table 2.3: Chapter 4 participant insulin regimen details.
Participant ID
Insulin 1 2 3 4 5 6 7 8 Mean ± SEM
Basal 28g 22g 39° 46g 29d 53g 30° 32g 35 ± 2
Bolus (per 10 g 
CHO) 1A 1A 1.5a 1L 1L 1A 0.5a 2a 1.1 ±0.1
Note: G = glargine, D = detemir, A = aspart, L = lispro
Table 2.4: Chapter 5 participant insulin regimen details.
Participant ID
Insulin 1 2 3 4 5 6 7 8 Mean ± SEM
Basal 30g 26g 64g 44g 30° 52° 40g _ 41 ± 2
Bolus (per 10 g 
CHO) © > 1L 2l 1A 1A 1A 1A 1.1 ±0.1
Note: G = glargine, D = detemir, A = aspart, L = lispro
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2.3.1 Health screening
Upon each visit to the laboratory, participants completed informed consent (Appendix D - G) 
and a physical activity and readiness questionnaire (PAR-Q; ACSM, 2006; Appendix C). 
Moreover, all procedures for the trial were clarified with every participant.
2.3.2 General study protocol
After initially attending the laboratory for prelimary testing for the quantification of V02peak 
and HRpeak, participants arrived at the exercise physiology laboratory between 6 and 8 am 
after an overnight fast, and having consumed similar evening meals between trials. 
After the collection and processing of resting blood samples, participants were given a 
carbohydrate-based meal and instructed to administer their rapid-acting (pre-determined dose 
dependent on trial) insulin (insulin lispro or aspart) into the abdomen, once fully 
administered, a stop-clock was started.
Blood samples were taken every thirty minutes, for 120 minutes post meal (in chapters 3 and 
4; the time between carbohydrate administration and exercise ranged between 30-120 
minutes within chapter 5). After the carbohydrate meal was administered, participants 
anthropometric measures, height (Holtain Stadiometer, Holtain Ltd, UK) and mass (Seca 
Digital Scales, Seca Ltd, UK), were recorded. Fifteen minutes prior to exercise the metamax - 
3b (Metamax 3b, Cortex Biophysik, Germany) was placed on the participants, along with a 
heart rate monitor (RS-400, Polar, Finland), and activity monitor (Sensewear Pro; 
Bodymedia, PA, USA) for the collection of a 15 minute resting cardio-respiratory sample. 
After the final pre-exercise blood sample was taken (Figure 2.2), participants subsequently 
performed 45 min of steady state treadmill (Woodyway, Germany) exercise at -70 %
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VC^peak- Throughout exercise respiratory parameters were collected and participants were 
closely monitored during exercise for any symptoms o f  hypoglycaemia.
At 45 minutes an immediate post-exercise sample was taken (Figure 2.3), the stop clock was 
then started for the 3 hour post-exercise period. Additional samples were taken at 5, 15, 30, 
60, 120 and 180 min post exercise. Participants remained at rest for the entire post-exercise 
period, drinking water ad libitum.
M e t a m a x - 3 b
Activity M onitor
C atheter
Figure 2.2: A T1DM individual wearing the m etamax-3b at rest and during 45 minutes o f running
-7 0 %  V 0 2peaW.
Figure 2.3: Immediate post-exercise blood sample.
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2.3.3 Preliminary Testing
2.3.3.1 Anthropometric measurements
Bioelectrical impedance analysis (BIA)
Prior to starting the procedure, the BIA (Bodystat Quadscan 4000, Bodystat Ltd, USA) unit 
was tested for accuracy by running a test against a metal of a fixed resistance (500 Ohms). 
After quantification of height (Holtain Stadiometer, Holtain Ltd, UK) and mass (Seca Digital 
Scales, Seca Ltd, UK) participants were required to remain supine for 15 minutes. 
Participants were positioned so both legs and arms were adducted at 35 - 45° angle from the 
trunk. Alcohol wipes (70 % Alcotip Swabs, Uhs, UK) were used to clean electrode sites on 
the hands and feet before two injector electrodes (red) were attached to the dorsal surface of 
the right hand and the right foot and detector electrodes (black) were placed on the ankle of 
the right foot and just below the radioulnar joint on the right hand. After 15 minutes of laying 
supine had elapsed, and participant details were entered into the BIA device, the procedure 
was started. Coefficient of variation, over 4 trials, for % body fat (BF), fat free mass (FFM) 
and total body water was 2.0 ± 0.2, 3.1 ± 0.9 and 0.7 ±0.1 %, respectively. Coefficient of 
variation for measurements of mass between trials within chapter 3 was 0.5 ± 0.03 %, chapter 
4 was 0.7 ±0.1 %, and chapter 5 was 0.6 ±0.1 %,
Table 2.5: Participant anthropometric characteristics across chapters 3 to 5.
Chapter 3 Chapter 4 Chapter 5
Height (m) 1.76 ±0.01 1.80 ±0.01 1.80 ±0.01
Mass (kg) 84.1 ±2.0 84.0 ± 1.9 84.3 ±1.3
BMI (kg/m2) 27.0 ± 0.4 26.1 ±0.3 26.3 ± 0.3
% BF 22.1 ±0.6 21.4 ±0.5 --
% FFM 78.0 ±0.6 78.2 ±0.5 -
Note: Data presented as mean ± SEM.
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2.3.3.2 Quantification of peak cardio-respiratory characteristics
Participants performed a continuous maximal incremental treadmill protocol where heart rate 
and breath-by-breath respiratory data were collected for the determination of peak rate of 
oxygen uptake (V02peak) with subsequent peak heart rate (HRpeak)-
Equipment Calibration
Respiratory parameters were collected via a portable gas analyser system (Metamax 3b, 
Cortex Biophysik, Liepzig); the Metamax 3b main principles of operation are through the 
generation of an electrical current, via an oxygen cell, which is directly proportional to the 
partial pressure of oxygen (PO2), and the quantification of PCO2 through absorption of 
infrared radiation by the carbon dioxide present in the expired air (McFarlane, 2001). 
Prior to use a two point gas calibration was performed. Ambient air was used to give a 
maximal O2 value, and a baseline CO2 value. A gas of known concentration (16 % O2, 5 % 
CO2, Brin’s Oxygen Company Ltd) was used to set a baseline O2 value and maximal CO2 
value. The volume transducer was calibrated with a 3 -  litre syringe (Hans Rudolf) and the 
pressure against the ambient barometric pressure (230 series, NovaLynx, USA).
Maximal incremental treadmill assessment
Participants arrived at the laboratory in a fed and hydrated state, with at least 2 hours after 
administering a bolus insulin dose. After self-checking blood glucose, anthropometric 
measures (height and mass) were taken, a heart rate monitor (RS-400, Polar, Finland) was 
then placed across the chest. Participants did not start the protocol if blood glucose was less 
than 6.5 mmol.I'1 (De Feo et al., 2006). Those subjects with a blood glucose concentration < 
6.5 mmol.l'1 were given 117 ml of an hypertonic drink (20 g CHO; Lucozade®, 
GlaxoSmithKline, UK) immediately prior to exercise (De Feo et al., 2006). After a 2-point
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gas calibration, the metamax-3b was placed on each participant (Figure 2.4), and breath-by- 
breath data was subsequently collected and transferred wirelessly to the laboratory computer 
(Figure 2.6).
Figure 2.4: A T1DM  individual wearing the M etamax-3b.
Participants then completed a standardised warm-up (3 minutes at 6 k m .h r ')  immediately 
before performing a graded treadmill exercise test; this protocol involved participants running 
in 3 minute blocks o f steady state exercise at a treadmill velocity o f 8 k m .h r1, a velocity 
which was increased by 1 km.hr 1 every 3 minutes (Jones and Doust, 1996; Figure 2.5). 
Participants were instructed to continue exercising until volitional exhaustion. The peak rate 
o f O 2 consumption (V02peak) was reached when RER was greater than 1.15, heart rate (HR) 
o f 220-age (bpm), RPE o f  18 and/or a distinct plateau in oxygen consumption, the velocity at 
which this point occurred was defined as Vmax. V02peak was calculated as the average VO 2 
over the final minute o f  the protocol. Throughout the protocol participants were closely 
monitored for signs o f  hypoglycaemia, through frequent questioning o f how they were 
feeling, and observing for any symptoms such as confusion and pallor. All participants were 
given lots o f verbal encouragement during exercise.
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Figure 2.5: Graphical representation of the continuous incremental treadmill test used to establish
V 02peak and HRpeai;.
Inspiratory & 
Expiratory volumes
VO->-Tim# trace
Breath-by­
breath cardio­
respiratory data
Figure 2.6: A typical screen shot of breath-by-breath data from the metamax-3b.
Table 2.6: Peak cardio-respiratory characteristics of participants across chapters 3 to 5.
Chapter 3 Chapter 4 Chapter 5
V 0 2peak (l.m in') 3.5 ±0.1 3.7 ±0.1 4.3 ±0.1
V 0 2peak (ml.kg.min1) 43.8 ± 1.0 44.9 ±0.7 50.9 ± 0.5
HRpcak (bpm) 190 ± 2 190 ± 1 192 ±2
Vniax (km.hr1) 12.0 ±0.2 11.9 ±0.2 12.5 ± 0.1
Note: Data presented as mean ± SEM.
60
Using Vmax and V02peak> the velocity that elicits 70% V02peak could be calculated, as well as 
the corresponding VO2:
i.e. V max*0 .7  = trial velocity (km.hr'1), VC>2peak*0.7 =  70%  VC>2peak (l.min'1)
This intensity and duration was chosen because it falls within the current ACSM (2 0 0 6 )  
exercise guidelines for T1DM individuals. In all chapters, exercise was performed below 
ventilatory threshold (VT) velocity (Table 2 .7 ) .
Table 2.7: Summary of the velocities at which participants reached ventilatory threshold, during the 
maximal incremental treadmill assessment, and experimental trials’ treadmill velocity.
Chapter VT(km.hr1) Trial Velocity (km.hr1)
3 10.1 ± 0.2 8.5 ±0.1
4 10.3 ±0.1 8.3 ±0.1
5 10.4 ±0.1 8.5 ±0.1
Note: Data presented as mean ± SEM
2.3.4 Experimental procedures
2.3.4.1 Catheterisation
Within each study, participants attended the exercise physiology laboratory at the same time 
(between 6 and 8 am) and 7 days apart. Prior to arrival at the laboratory all participants were 
instructed to consume 1 pint (568 ml) of water. Upon arrival to the laboratory, participants 
were seated while a 20-gauge catheter (Venflon, Becton Dickinson, Helsingborg, Sweden) 
was inserted into the ante-cubital vein, of the non-dominant arm, and secured with a Veca-C 
dressing (Venflon, Becton Dickinson, Helsingborg, Sweden). A 10 cm extension with 3-way 
stop cock was used to allow easy access for samples (Connect, Becton Dickinson, 
Helsingborg, Sweden; Figure 2.8). Saline (Sodium Chloride BP, 0.9% w/v, Braun, UK) was 
infused periodically to keep the catheter patent.
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2.3.4.2 Blood sampling
On the resting sample for each participant’s first trial, 15 ml o f blood was collected. Two 10 
ml syringes (BD 10 ml syringe, Luer-LokIM Tip, BD USA) and a 1 ml Ca2+-heparinised 
syringe (23 IU heparin, Rapidlyte, Bayer, USA) were filled with whole blood (Figure 2.7). 
One o f  the 10 ml syringes was filled with 4 ml o f blood only. Thereafter, on each sample 11 
ml o f blood was collected (one x 10 ml and one x 1 ml syringe). On the resting sample the 
syringe containing 4 ml o f whole blood was dispensed into an K7-EDTA tube (Vacuette, 
Greiner Bio-One, GmBH, Austria) which was sent to M orriston Hospital Biochemistry 
Laboratories for the analysis o f glycosylated Haemoglobin (H bA ic) by HPLC with cation 
exchange (G7, Tosoh, UK; Table 2.7). The 10 ml syringe was dispensed evenly into a serum 
separation tube (SST; Vacuette, Greiner Bio-One, GmBG, Austria) and Lithium-Heparin tube 
(Vacuette, Greiner Bio-One, GmBH, Austria).
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Figure 2.7: Withdrawal of whole blood using a 1 ml Ca2 -heparinised syringe (left) and a 10 ml 
syringe (right).
Two hundred pi o f 0.1 mol-1'1 o f both ethylene glycol bis-(|3-aminoethyl ether)-N’,N ’,N ’,N '- 
tetraacetic acid (EGTA; SIGMA, USA), as anticoagulant and glutathione (SIGMA, USA) as 
antioxidant (Appendix H), were added to the Lithium-Heparin tube before being immediately
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placed in the centrifuge (Heraeus Labofuge 400R, Kendro Laboratory Products, Germany) 
for 10 minutes at 3000 revmin"1. The sample in the SST was left to clot, on an orbital shaker 
(VSR 23, Grant, UK), for 30 minutes before also being centrifuged for 10 min at 3000 
rev-min'1; the resultant serum and plasma were extracted and placed into 5 ml aliquot tubes 
(Sarstedt, Germany) and then immediately stored at -80 °C (Innova U101, New Brunswick 
Scientific, UK; Figure 2.8).
The 1 ml Ca2+-heparinised syringe was immediately analysed for blood pH, Hct, glucose and 
lactate (GEM 3000, Instrumentation Laboratories, Warrington, UK; Appendix I) and 
haemoglobin (Hemocue AB, Sweden; Figure 2.7) and then placed on ice, in case a repeat 
sample was required. Pre and post-exercise quantification of Hb and Hct allowed plasma 
volume shifts to be calculated via the method of Dill and Costill (1974; Appendix J).
Table 2.8: Glycosylated haemoglobin values (HbA]c %) across chapters 3 to 5.
Chapter
Participant 3 4 5
1 8.4 9.8 8.5
2 8.9 - -
3 7.5 7.3 -
4 8.4 - -
5 8.2 - -
6 8.3 9.9 7.6
7 7.7 8.0 9.8
8 9.2 9.3 -
9 - 7.8 oo bo
10 - 6.1 -
11 - 5.9 -
12 - - 8.9
13 - - 8.1
14 - - 6.7
Mean ± SEM 8.3 ±0.01 8.0 ± 0.2 8.3 ±0.1
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GEM 3000 Reliability
The GEM 3000 was tested for reliability on whole blood, which was placed on ice between 
samples, ranging from very low (<3 mmolT1) to very high (>20 mmol.I'1) concentrations 
(Table 2.9). The GEM system was considered reliable with a coefficient of variation of < 10 
% at all blood glucose concentrations.
Table 2.9: GEM 3000 coefficient of variation for 3 consecutive blood glucose samples at 
concentrations ranging from hypoglycaemic to hyperglycaemic.
Blood Glucose Sample (mmol.11)
1 2 3 Mean BG (mmol.l1) SD COV (%)
2.6 2.4 2.4 2.5 0.1 4.7
3.3 3.3 3.2 3.3 0.1 1.8
4.9 4.7 4.6 4.7 0.2 3.2
7.2 7.1 7 7.1 0.1 1.4
9.3 8.3 8 8.5 0.7 8.0
11.4 11.2 10.9 11.2 0.3 2.3
15.2 14.5 14.1 14.6 0.6 3.8
16.1 16.2 15.8 16.0 0.2 1.3
23.1 22.9 22.6 22.9 0.3 1.1
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Venous Blood
10 ml syringe \ 7 1 ml Ca2+- Heparinsyringe
5 ml SST
\ 7
<£=^>
5 ml Lith-Hep
200 pi anti-oxidant
\ 7
30 min orb ital shaker
Hem ocue  
B lo o d  Hb
Centrifugation : 10 min @ 3000 rpm
GEM  3000  
Blood: 
G lucose, Lactate, 
pH, Hct
\ 7
\ 7
Placed on iceSerum  asp irated  equally P lasm a aspirated into 5
into 3 x 5ml a liquot tubes ml a liquot tube
I
\ 7
Discarded
Immediately stored at -80 °C
\ 7 \7
Serum : 
insulin , cortisol, 
trig lycerides, NEFA, 
glycerol, 
P-hydroxybutyrate
Plasm a:
glucagon,
adrenaline,
noradrenaline,
Figure 2.8: Step by step processing of venous blood samples.
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2.3.5 Quantification of blood, serum and plasma analytes
Table 2.10 provides a summary of the analysis of blood across chapters 3 to 5.
Table 2.10: Summary of blood analysis across chapters 3 to 5.
Blood Analytes
Variable Chapter 3 Chapter 4 Chapter 5
Glucose Glucose Glucose
Glycaemic
HbAic HbA]c HbAic
Lactate Lactate Lactate
Acid-Base
pH pH pH
Hct Hct Hct
Plasma Volume
Hb Hb Hb
Insulin - Insulin
Glucagon Glucagon -
Gluco-regulatory Adrenaline Adrenaline Adrenaline
Noradrenaline Noradrenaline Noradrenaline
Cortisol Cortisol Cortisol
- NEFA NEFA
Lipids - Glycerol -
- Triglyceride Triglyceride
Ketoacid P-hydroxybutyrate p-hydroxybutyrate P-hydroxybutyrate
2.3.5.1 Blood glucose and lactate
Blood glucose and lactate were analysed using the GEM 3000. The glucose and lactate
sensors are amperometric electrodes consisting of a platinum electrode poised at a positive
potential with respect to the card reference electrode. Glucose or lactate determination is
accomplished by enzymatic reaction of glucose or lactate with oxygen in the presence of
glucose oxidase or lactate oxidase and the detection of the resulting hydrogen peroxide with
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the platinum electrode. The current flow between the platinum electrode and the ground 
electrode is proportional to the rate at which hydrogen peroxide molecules diffuse to the 
platinum and are oxidised, which in turn is directly proportional to the metabolic (glucose or 
lactate) concentration:
I = (S x  metabolite) + IZ
Where I is the electrode current, S is the sensitivity, and IZ is the zero current. The value S 
and IZ can be calculated from the calibration data for the sensor. The equation can be solved 
for the metabolite concentration, where I becomes the electrode current produced by the 
blood sample. Figure 2.9 illustrates the configuration o f the glucose/lactate sensor. The 
sensor is constructed o f a 3 layer composite m embrane consisting o f an inner layer for 
screening out the interferences, the enzyme for oxidation reaction, and the outer layer for 
controlling the metabolite diffusion in the enzyme layer.
Counter electrode Enzyme electrode
Diffusion controllingEnzyme layer_______________
(G lucose or Lactate oxidase) 
Interference
layer
Sam ple pathrejection layer
Pt wireSensor well
Sensor card
S ilve r p rin t
3-electrode
potentiostat
Card reference electrode
Figure 2.9: Internal components o f the glucose and lactate sensor within the GEM 3000.
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2.3.5.2 Serum  and plasm a analytes
Samples were left to thaw to room temperature and were placed on a vortex (IKA Vortex, 
Fisher Scientific, UK) before analysis. Detailed descriptions of the methods performed for 
each analyte are presented in Table 2.11 and described below.
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2.3.5.2.1 Insulin
The assay is a two-site sandwich immunoassay, with a solid phase antibody specific to 
insulin immobilised onto microtitre wells and a soluble antibody labelled with an acridinium 
ester. The serum samples are incubated at 37 °C along with standards, quality control 
samples and the labelled antibody in the antibody coated wells. This causes the insulin to 
become ‘sandwiched’ between the 2 types of antibody molecules. The excess labelled 
antibody is then removed in a wash step before reading in a plate reader with in situ reagent 
addition capability to quantify the bound luminesence. The acridinium ester is a stable 
compound, which when oxidised under alkaline conditions, will generate light, the brightness 
of which is linked to the amount of label, and hence insulin, present.
Summary o f Procedures
Labelled insulin antibody was pipetted into all wells followed by standard, quality control 
(Lyphocheck, Biorad, UK) or serum samples. The plate was then covered with an adhesive 
plate sealer and incubated for 2 hours at 37 °C. Once incubation was complete, the plate was 
washed 3 times with an automatic plate washer (Wellwash 4, Denley Ltd, Sussex, UK.), 
before being read in a plate luminometer (Microplate luminometer LB 96P, EG&G Berthold, 
Germany). From the resultant counts, a calibration curve was set up to calculate the 
concentration of the unknown samples (Multicalc, Pharmacia Wallac, Milton Keynes, UK).
Cross-reactivity — Influence o f the insulin analogues
The Invitron assay is 100 % cross reactive with human insulin, however as T1DM individuals 
were examined, the influence of any residual P-cell function was considered negligible. 
Additionally, this assay is 100 % cross reactive with insulins lispro, aspart and glargine. 
Therefore, as insulin glargine has been demonstrated to elicit a peak less, steady 24 hour
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insulin concentration (Gulve, 2008) and is not effected by exercise (Peter et al., 2005), any 
changes in insulin concentrations detected by this assay were considered to be due to changes 
in the appearance/disappearance of insulin lispro or aspart. The Invitron assay is 300 % cross­
reactive with insulin detemir. Therefore, within chapters 3 and 5, only T1DM individuals 
using insulin glargine could be examined/recruited.
2.3.5.2.2 Glucagon
The glucagon ELA for the determination of plasma pancreatic glucagon within plasma is 
based on competitive enzyme immunoassay. The 96 well plate is coated with rabbit anti­
glucagon antibodies. Glucagon standards, samples and labelled antigen are added to the wells 
for a competitive immunoreaction. After incubation and plate washing, Horse radish 
peroxidase (HRP) labelled streptavidin (SA) is added to form HRP labelled SA-biotinylated 
pancreatic glucagon antibody complexes on the wells surface. The HRP activity is 
determined by the addition of O’phenylenediamine dihydrochloride (OPD), imitating a 
colour reaction, and pancreatic glucagon can subsequently be determined.
General Procedure
Glucagon standards or plasma samples were pippetted into the wells and incubated at 4 °C 
for 24 hours. After incubation, the wells were manually washed 3 times and the SA-HRP 
solution was added to the wells before being incubated for 1 hour at room temperature on a 
microtiter plate shaker (Microplate Orbital Shaker 115 Vac - 60 Hz, Cole-Parmer, UK). After 
incubation the wells were washed a further three times before adding OPD to the 96 wells. 
The plate was left at room temperature for 20 minutes for colour reaction, before the addition 
of stop solution. The plate was immediately read at an optical absorbance of 490 nm (Fluostar 
- Omega Plate Reader, BMG Labtech; UK) with a calibration curve created to calculate the 
concentrations of the unknown samples.
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2.3.5.2.3 Catecholamines (Adrenaline and Noradrenaline)
The CatCombi, a sandwich ELISA, was used for the determination of plasma concentrations 
of adrenaline and noradrenaline. The plate wells are coated with goat anti-rabbit antibody. 
The addition of the control and plasma samples results in the epitope of adrenaline or 
noradrenaline, within the sample, binding to the plate wells during the incubation period. The 
addition of a second antibody, which binds to a different region of the adrenaline or 
noradrenaline molecule, and substrate solution induces a colour reaction; the density of which 
is directly proportional to the amount of adrenaline or noradrenaline within the sample.
General Procedure
Phase 1- Extraction
Note: Incubation includes the plate being placed on an orbital shaker at room temperature. 
The methods describe the process for three separate plates (extraction plate, and plates for the 
separate quantification of adrenaline and noradrenaline).
Standards, controls and plasma samples were pippetted into the wells along with extraction 
buffer and incubated for 30 minutes. After removal of residual fluid, bi-distilled water was 
added to each well and the plate was incubated for 5 minutes. After removing all fluid from 
the plate wells, extraction buffer and acylation reagent was added before a 20 minute 
incubation period. After this, release buffer was added to all wells before being incubated for 
a further 30 minutes.
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Phase 2
Freshly prepared catechol-O-methyl transferase solution was added to each well along with 
the extracted standard, control and plasma samples. Next adrenaline and noradrenaline 
antiserum was added to each plate, respectively, before being incubated for 2 hours.
Phase 3 -ELISA
After incubation, the plate was washed 3 times before enzyme conjugate was added to each 
well. The plates were incubated for a further 60 minutes. Following this, the plates were 
manually washed a further three times before substrate solution was added to each well and 
the plates were incubated for 40 minutes. After incubation para-Nitrophenylphosphate stop 
solution was added to each well the plate was subsequently measured at an optical density of 
405 nm. From this, a calibration curve was created to calculate the concentrations of the 
unknown samples.
2.3.5.2.3 Cortisol
Serum cortisol was measured by routine hospital procedures using a competitive 
electrochemiluminescence immunoassay (Cortisol, Cobas-Roche, UK) on an automated 
system (Roche/Hitachi Modular P800 analyser, Roche Diagnostics, Germany).
Assay Principle
This assay makes use of the competition test principle using a polyclonal antibody which is 
specifically directed against cortisol. Endogenous cortisol in the sample which has been 
liberated from binding protein, with danazol, competes with exogenous cortisol derivative, 
which has been labelled with ruthenium complex, for the binding sites on the biotinylated 
antibody.
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2.3.5.2.4 Non-esterified fatty acids (NEFA)
Serum non-esterifled fatty acids were analysed by routine hospital procedures using an 
enzymatic colourimetric assay (NEFA-HR(2), Wako Chemicals, Germany) on an automated 
system (Roche/Hitachi Modular P800 analyser, Roche Diagnostics, Germany).
Assay Principle
NEFA within the serum sample is converted to Acyl-CoA, AMP and pyrophosphoric acid 
(PPi) by the action of Acyl-CoA synthetase (ACS), under coexistence with coenzyme A 
(CoA) and adenosine 5-triphosphate disodium salt (ATP). Obtained Acyl-CoA is oxidised 
and yields 2,3-trans-Enoyl-CoA and hydrogen peroxide by the action of Acyl-CoA oxidase 
(ACOD). In the presence of peroxidase (POD), the hydrogen peroxide formed yields a blue 
purple pigment by quantitative oxidation condensation with 3-Methyl-N-Ethyl-N-(P- 
Hydroxyethyl)-Aniline (MEHA) and 4-amino-antipyrine (4-AA). NEFA concentration is 
obtained by measuring absorbance of the blue purple pigment.
2.3.5.2.5 Triglycerides
Serum triglycerides were analysed by routine hospital procedures using an enzymatic 
colourimetric assay (Triglycerides GPO-PAP, Cobas-Roche, UK) on an automated system 
(Roche/Hitachi Modular P800 analyser, Roche Diagnostics, Germany).
Assay Principle
This assay uses a lipoprotein lipase from micro-organisms for the rapid and complete 
hydrolysis of triglycerides to glycerol followed by oxidation to dihydroxyacetone phosphate 
and hydrogen peroxide. The hydrogen peroxide produced then reacts with 4-aminophenazone 
and 4-chlorophenol under the catalytic action of peroxidase to form a red dyestuff (Trinder
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endpoint reaction). The colour intensity of the red dyestuff formed is directly proportional to 
the triglyceride concentration and can be measured photometrically.
2.3.5.2.6 Glycerol
Glycerol was analysed using an enzymatic colourimetric assay (Caymans Glycerol Assay, 
Cayman Chemical, USA).
Assay Principle
Glycerol is phosphorylated by glycerol kinase to produce glycerol-3-phophate and adenosine- 
5’-diphophate. The glycerol-3-phosphate is oxidised by glycerol phosphate oxidase 
producing dihydroxyacetone phosphate and hydrogen peroxide. Peroxidase catalyses the 
redox-coupled reaction of H2O2 with 4-aminoantipyrine (4-AAP) and N-ethyl-N-(3- 
sulfopropyl)-m-anisidine (ESPA), producing a purple product, with an absorbance maximum 
at 540 nm. The intensity of the purple colouring is proportional to the concentration of 
glycerol.
2.3.5.2.7 P-Hydroxybutyrate
Assay Principle
p-hydroxybutyrate was analysed using an ELISA assay (Ranbut, Randox Laboratories, UK). 
The assay principle relies on the production of acetoacetate and H+ after P-hydroxybutyrate 
has been oxidised by hydroxybutyrate dehydrogenase.
P-hydroxybutyrate + NAD+ — 3-hydroxybutyrate dehydrogenase — Acetoacetate + H+ 
NADH.
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The change in absorbance at 340 nm can be directly correlated with the P-hydroxybutyrate 
concentration. This assay is sensitive to 0.1 m m ol.l1 and has an intra assay reliability of 
3.7%.
2.4 Hypoglycaemia
Throughout the post-exercise period participants were constantly monitored for signs of 
hypoglycaemia. While in a rested position, research staff constantly engaged the participants 
in conversation, while looking for signs of hypoglycaemia such as confusion and pallor, 
moreover the participants were frequently asked how they were feeling and if they were 
experiencing any typical symptoms of hypoglycaemia (e.g. paraesthesia and difficulty 
focusing). If at any point in the post-exercise period blood glucose dropped below 3.5 
mmolT1 (Rabasa-Lhoret et al., 2001), 117 ml of a sports drink (20g CHO; Lucozade®, 
GlaxoSmithKline, UK) was administered.
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2.5 Pre-exercise meal
Chapter 3
Prior to testing, local and national T1DM individuals were sent questionnaires, about their 
insulin regimen and exercising habits, by email, mail and over the phone (e.g. Appendix K). 
From this information (n = 20) it seemed a typical pre-exercise meal consisted of largely fruit 
and wheat based cereals with around 60 - 80 g of CHO. In light of this, and multiple pilot 
‘tasting’ sessions, a meal of peaches and wheat was the most palatable and easy to store 
combination and caused no GI discomfort. Participants consumed a 1.12 MJ carbohydrate 
based meal (60 g CHO, 2 g Protein, 2 g Fat) of a medium glycaemic index (GI 46 - 50; 40 g 
peaches, 20 g wheat) which was blended and mixed with 50 ml of distilled water.
Chapter 4
Participants consumed 75 g of either a high GI (dextrose; My Protein, UK; GI 96) or low GI 
(Isomaltulose; Beneo Group, Germany; GI 32) carbohydrate, mixed with 750 ml of water in a 
10% solution (Peronne et al., 2005). Seventy-five g of carbohydrates were administered 
based on resting carbohydrate oxidation rates of -0.25 g.min'1 and maximal rates of 
exogenous carbohydrate oxidation during exercise o f -1 g.min'1 (Jeukendrup, 2004), i.e. rest 
period: 0.25 g x 120 = 30 g, exercise: 1 x 45 = 45 g. Dextrose and isomaltulose were chosen 
as these two carbohydrate forms represent the highest and lowest GI carbohydrates currently 
available in powdered supplement form. This made the formulation of two carbohydrate only 
solutions, at extremes of the GI scale, possible.
Chapter 5
Based on the recommended strategy of chapter 4, participants consumed 75 g of isomaltulose 
as the pre-exercise meal.
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2.6 Data collection following the laboratory testing
On each occasion, heart rate (60 s sample rate; RS-400, Polar, Finland) and the number of 
steps taken (60 s sample rate; Sensewear Pro Armband™; Bodymedia, PA, USA) were 
recorded for 21 hours after leaving the laboratory to quantify post-exercise activity. 
Participants were given blank diary sheets to record blood glucose from their own glucose 
meters, food intake and the number of units of insulin administered over the 21 hour post­
laboratory period (e.g. Appendix L). These variables allowed for calculation of glucose area 
under the curve (calculated using the method of Wolever and Jenkins (1986) and time 
averaged for the 21 hour post-exercise period), energy and carbohydrate intake (Compeat 
Pro, Nutrition Systems, UK), insulin administration and the frequency of hypoglycaemic (< 
3.5 mmol.l'1) and low blood glucose (< 4 mmol.I'1) incidents encountered.
2.6.1 Self-recorded blood glucose
Within in chapters 3 and 4, the participants’ own glucose meters were used to measure post­
laboratory blood glucose responses. Each monitor was tested for reliability, using 5 samples, 
against a 6.3 (CV 0.6 -  2.4 %) and 12.5 (CV 0.8 -  2.6 %) mmol.l’1 glucose standard, all 
monitors demonstrated adequate limits of reliability. Within chapter 5, participants were 
provided with a glucose monitor (Freestyle Lite, Abbott, UK) which was tested for reliability 
against whole blood, using 3 consecutive samples, at concentrations ranging from 
hypoglycaemic to hyperglycaemic (Table 2.12). Moreover, the device was in agreement with 
the GEM 3000 (Figure 2.10). Throughout the post-laboratory period blood glucose was self­
recorded every 2 hours until going to sleep and immediately upon awaking. Blood glucose 
was recorded 6 times on each occasion; two hour intervals were based upon data provided by 
20 T1DM individuals who were questioned as to how often they record their blood glucose 
after performing their typical activity session.
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Within the laboratory, participants received carbohydrate supplementation if blood glucose 
fell below 3.5 mmol.l'1. Therefore, hypoglycaemia was defined as a blood glucose 
concentration <3.5 mmol.l'1 within and post-laboratory (Rabasa-Lhoret et al., 2001). Due to 
inter-individual differences in blood glucose sensing, and participants regularly checking 
their blood glucose concentrations, falling blood glucose may have been corrected before 
leading to hypoglycaemia. Therefore, a blood glucose threshold of <4 mmol.l'1 was defined 
as ‘low blood glucose’.
Table 2.12: Freestyle lite® coefficient of variation for 3 consecutive blood glucose samples at 
concentrations ranging from hypoglycaemic to hyperglycaemic.
Blood Glucose Sample (mmol.l1)
1 2 3 Mean BG (mmol.l1) SD CV (%)
3.1 3.2 3.0 3.1 0.1 3.2
3.8 3.8 3.4 3.7 0.2 6.3
4.6 4.6 4.6 4.6 0 0
5.4 5.4 5.5 5.4 0.1 1.1
6.8 7.6 7.7 7.4 0.5 6.7
9.4 9.4 10.1 9.6 0.4 4.2
11.4 11.5 10.9 11.3 0.3 2.9
12.3 11.2 12.6 12.0 0.7 6.1
15.7 15.9 15.9 15.8 0.1 0.7
17.4 17.7 15.8 17.0 1.0 6.0
21.4 22.2 21.4 21.7 0.5 2.1
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Figure 2.10: Bland and Altman (1986) plot comparing the agreement between the GEM 3000 and
Freetyle lite. Note: R = 0.994.
2.6.2 Post-laboratory activity
Post-laboratory activity was assessed through 60 s sampling of heart rate and steps taken 
(Sensewear Pro Armband™; Bodymedia, PA, USA). The Sensewear Pro Armband™ (Figure 
2.11) is a two dimensional accelerometer, taking into account vertical and horizontal 
acceleration, worn on the right, upper arm. During a bout of exercise the device is highly 
reliable with coefficients of variation for steps taken of <10%. Moreover, the Sensewear Pro 
Armband™ recording of step count in free living has been shown to be in agreement with 
other valid activity monitors (Hanby et al., 2005).
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Figure 2.11: The Sensewear Pro ArmbandIM.
2.6.3 Self-recorded dietary intake and insulin administration
Before the trials began participants were provided with detailed instructions o f how to 
complete dietary assessments in the most detail possible. For example participants were given 
a demonstration o f how to obtain the dietary information from food stuffs (i.e. the nutritional 
content section on the food item). Moreover, participants were provided with example dietary 
assessment sheets (Appendix M). After completion o f each experimental trial participants 
returned the dietary sheets to the research team, all sheets were immediately checked for 
detail and if  any issues arose they could be explored further.
Participants were also instructed to record the number o f rapid-acting insulin units 
administered with each meal. Moreover, participants were required to indicate if  additional 
units had been added to correct for high blood glucose, or conversely units had been omitted 
to correct for low blood glucose.
2.7 Data analysis
2.7.1 Calculation of blood glucose area under the curve
The calculation o f  blood glucose area under the curve (BG auc) was calculated via the method 
o f W olever and Jenkins (1986) and was subsequently time averaged. Total BGAuc was 
averaged to m m ol.l" '.hour1.
17.0 n
5.0
REST 60 120
Figure 2.12: Exam ple calculation o f blood glucose area under the curve.
1) Calculations
A = (((BG6o -  B G REsT )/2)+B G REsT)*Tim e (m in )
•  (14 -  6 .2)/2 =  3.9
• 3.9 + 6.2 = 10.1
• 10.1 * 60 = 606 mmol.I"1.min"1
B = (((BG 120 -  BG6o)/2)+BG60)*Time (min)
• (14.8 -  14)/2 = 0.4
• 0 . 4 + 1 4 - 1 4 . 4
• 14.4 * 60 = 864 mmol.I"1.min"1 
Total B G au c = A + B = 1470 mmol.I"1.min"1
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2) Time Average
Total BGauc (mmol.l'1.min'1) / (total hours * 60) 
•  1470 / (2*60) = 12.3 ininol.l‘.hour1
2.7.2 Calculation of substrate oxidation rates and energy expenditure
The metasoft software (Cortex Biophysik, Liepzig) uses an automated calculation of inspired 
volume (Vi), using the Haldane Transformation method (below), to calculate inspired and 
expired VO2 and VCO2.
Haldane Transformation method:
V i=  f en 2%
_________  x VE
F iN 2%
F iN 2%  (mass N2 Inspired, constant) = 100% - 20.93 -  0.03 = 79.04 
F e N 2%  (mass N2 Expired) = 100 -  FE02 -  FECC>2 
Calculating VO2 and VCO2:
VO2 inspired = Vj x F1O2
100
VO2 expired = VE x FEC>2
100
VCO2 inspired = Vix F1CO2
100
VCO2 expired = VE x FECC>2
100
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Indirect Calorimetry
Non-protein respiratory exchange ratios were used to calculate the rates of carbohydrate and 
lipid oxidation, using the equations described by Frayn (1983).
Carbohydrate oxidation (g.min'1) = 4.55 VCO2 -  3.21 VO2
Fat oxidation (g.min'1) = 1.67 VO2 -  1.67 VCO2
Although ketone body formation can influence RER (Frayn, 1983), all individuals that took 
part in the experimental trials were being treated with a basal-bolus regimen, and only bolus 
insulin was manipulated, therefore, elevated ketone body formation was not considered an 
issue. Breath-by-breath respiratory data were time averaged to 1 minute.
Calculation o f fuel oxidation and energy expenditure
Average carbohydrate and lipid oxidation rates were obtained through an average of either 
the 15 minute resting collection or the 45 minutes of running. Time course changes in 
carbohydrate and lipid oxidation were calculated in 10 minute blocks, not including the initial 
5 minutes of the exercise bout.
Total energy expenditure was calculated through the sum of energy expended, within each 
minute, over the 45 minutes of running. For example:
• Total oxidation over 45 minutes: CHO = 110 g, lipids = 22.5 g
• (110*4) + (22.5*9) = 643 kcal
• 643*0.0042 = 2.69 MJ
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2.7.3 Sam ple size calculation
Based on the data of Rabasa-Lhoret et al. (2001) for a statistical power of 80%, 33 subjects 
were required. However, due to the strict inclusion criteria and the time commitment required 
for completion of these trials, a sample size of 33 was outside of the pool of available T1DM 
individuals. Therefore, a sample of sufficient size to perform parametric statistics was 
attained. Statistical power across chapters 3 to 5 ranged from 45 to 59%.
2.7.4 Fasting blood glucose variability
For an inference into the variability that exists in fasted blood glucose concentrations within 
T1DM individuals, participants within chapter 3 completed a 3 week diary prior to 
participation in the trials.
Table 2.13: Twenty-one day morning fasted blood glucose concentrations of participants within
chapter 3.
Participant ID Mean Blood Glucose (mmol.l1) SD Range (mmol.l1) COV (%)
1 7.9 4.6 2.2-19.8 59
2 4.8 1.9 2.7 - 8.6 39
3 7.6 3.0 2.8-13.4 40
4 6.9 2.3 4.4 - 10.8 32
5 7.1 2.9 2.5-11.7 40
6 7.0 3.5 3.4-13.3 51
7 4.6 1.4 2 .9-8 .2 29
8 7.7 4.6 2.3 - 16.3 59
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2.7.5 Statistical analysis
Statistical analysis was performed using SPSS software (version 16; SPSS Inc., Chicago, IL), 
with significance set at P<0.05. Data were tested for normal distribution (Shapiro-Wilk test) 
and subsequently analysed using repeated-measures ANOVA on two (chapter 4) or four 
(chapter 3 and 5) factors (treatment x time) with Bonferroni adjustment and dependent t-tests 
carried out where relevant. Where there were significant time and/or time*condition effects, 
P values and effect size (partial-eta2) were reported. All results were reported as the mean ± 
SEM.
Data described as the change from rest (A) were calculated by subtracting resting values 
away from all subsequent sample time-points.
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Chapter Three
The metabolic and glycaemic effects of 
reductions to pre-exercise rapid-acting insulin
dose.
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3.1 Introduction
Hypoglycaemia is a frequent occurrence in individuals with type 1 diabetes (T1DM; Cryer et 
al., 2003) and a major factor for the avoidance of exercise (Brazaeu et al., 2008). In an effort 
to better preserve blood glucose concentrations and combat the heightened risk of 
hypoglycaemia during and after exercise, individuals with T1DM are recommended to reduce 
their pre-exercise insulin dose (De Feo et al., 2006; Grimm, 2005; Mauvais-Jarvis et al., 
2003; Rabasa-Lhoret et al., 2001).
Within the research examining pre-exercise insulin reductions, recommendations have varied 
from 10-40% (De Feo et al., 2006), 10-50% (Grimm, 2005), 50-90% (Mauvais-Jarvis et al., 
2003) and 50-75% (Rabasa-Lhoret et al., 2001). Much of the variation in these findings can 
be attributed to differences in the insulin regimen used by the participants, e.g. 
regular/Neutral Protamine Hagedom insulin (Mauvais-Jarvis et al., 2003) or Ultralente with 
prandial lispro (Rabasa-Lhoret et al., 2001), and differences in the intensity and duration of 
the exercise model. Another limitation, within the existing literature, is the examination of 
T1DM individuals performing cycling exercise only. Cycling is a primarily concentric form 
of exercise i.e. the muscle shortens as it contracts. However, in many daily activity patterns 
including body weight supporting exercises such as jogging or running there is a significant 
proportion of eccentric muscle actions, where the muscle lengthens in the performance of the 
movement. Eccentric muscle actions have been demonstrated to hinder insulin action and 
glucose uptake for as long as 48 hours following exercise (Asp et al., 1995; Asp et al., 1996). 
However to date, the impact of combined concentric and eccentric movement patterns, such 
as running, on post-exercise glucose responses has been neglected. Furthermore, an important 
point of the previous research has been the limited time window of examination of the 
potential for the development of hypoglycaemia after exercise with some studies monitoring
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participants for just 1-2 hours after exercise (Mauvais-Jarvis et al., 2003; Rabasa-Lhoret et 
al., 2001). Low blood glucose, leading to hypoglycaemia may occur several hours after 
exercise (MacDonald, 1987; Tsalikian et al., 2005), so studies that increase the observation 
window following the cessation of exercise are required to characterise the impact of exercise 
on post-exercise glycaemia. Moreover, as pre-exercise insulin dose has proven implications 
for post-exercise glycaemia, and glycaemia is associated with hunger and satiety (Russell et 
al., 2001) an examination of how reductions to pre-exercise insulin dose affects the voluntary 
diet intake of T1DM individuals is also required. In addition, reduction or omission in insulin 
dose is a significant factor in the development of diabetic ketoacidosis (Wallace and 
Matthews, 2004); keeping this in mind, exercise stimulates increases in ketogenic hormones. 
Therefore, lower circulating insulin concentrations and exercise induced increases in counter- 
regulatory hormones could create a milieu for increased production of ketone bodies; 
however, there is limited data to refute this.
Therefore, this study examined the metabolic and glycaemic responses to reductions in pre­
exercise rapid-acting insulin dose for 24 hours after running in T1DM individuals.
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3.2 M ethodology
Eight T1DM individuals (7 males, 1 female, 34 ± 2 years, B M I27 ± 1 kg/m2) with a duration 
of diabetes of 16 ± 1 years and HbAic of 8.3 ±0.1%  were recruited for this study. Participant 
anthropometric (Table 2.5), glycaemic control (Table 2.8), and insulin regimen (Table 2.2) 
characteristics are presented within chapter 2.
After preliminary testing (Table 2.6) participants attended the laboratory on four occasions 
after an overnight fast and having consumed similar evening meals prior to each trial. Upon 
arrival participants received catheterisation in their non-dominant arm and resting blood 
samples were processed for glucose, lactate, pH, insulin, glucagon, adrenaline, noradrenaline, 
cortisol and p-hydroxybutyrate (section 2.3.5). Participants were then instructed to ingest a 
1.12 MJ meal (60 g carbohydrates, 2 g protein, 2 g fat; wheat and peaches) and administer 
either Full (7.3 ± 0.2 IU), 75% (5.4 ± 0.1 IU), 50% (3.7 ± 0.1 IU), or 25% (1.8 ± 0.1 IU) of 
their rapid-acting insulin dose into the abdomen (subcutaneously). Subsequent blood samples 
were taken for 2 hours before performing 45 minutes of running at 70 ± 1% V02peak and for 
three hours post-exercise (Figure 3.1). Cardio-respiratory parameters were collected at rest 
and during exercise.
Participant activity and heart rate were recorded for 24 hours after exercise; moreover, for 21 
hours after leaving the laboratory participants self-recorded blood glucose, dietary intake, 
insulin administration and hypoglycaemic incidences.
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Figure 3.1: Schematic diagram of the experimental protocol of chapter 3.
3.2.1 Statistical Analysis
Statistical analysis was performed using SPSS software (version 16; SPSS Inc., Chicago, IL), 
with significance set at P<0.05. Data were tested for normal distribution (Shapiro-W ilk test) 
and subsequently analysed using repeated-measures ANOVA on four factors (treatment x 
time) with Bonferroni adjustments and dependent t-tests carried out where relevant. Data are 
presented as mean ± SEM.
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3.3 Results
Due to insulin assay cross-reactivity with insulin detemir, only individuals treated with 
insulin glargine could be included in the analysis. Therefore, participant 6 was removed from 
analysis and n = 7.
3.3.1 Physiological responses to exercise
There were no effects of condition on the percentages of peak rate of O2 consumption (Full 
71 ± 0.6, 75% 69 ± 0.8, 50% 71 ± 0.5, 25% 70 ± 0.5 %, P = 0.48) or %HRpeak (Full 83 ± 1, 
75% 82 ± 1, 50% 83 ± 1, 25% 83 ± 1 %, P = 0.43; Table 3.1) during exercise.
Exercise intensity fell within the current ACSM guidelines for diabetes with participants on 
average exercising at 67 ± 4% of VO2 reserve and 58 ± 6% of HR reserve, during the 45 
minute treadmill run.
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3.3.2 Blood glucose responses
Absolute and delta blood glucose responses are illustrated in Figures 3.2 A-C. There were no 
differences in fasting blood glucose concentrations (Full 9.4 ± 0.5, 75% 7.5 ± 0.4, 50% 9.2 ± 
0.7, 25% 7.5 ± 0.6 mmol.l’1, P = 0.58). There were interactions between insulin dose and 
both absolute (.P = 0.014, partial-eta2 = 0.399) and delta blood glucose responses (P = 0.012, 
partial-eta2 = 0.401) (Figure 3.2).
On average, pre-exercise peak blood glucose concentrations occurred 60 minutes after meal 
ingestion and insulin administration under Full, 75% and 50%, however, occurred at 90 
minutes under 25%. Peak blood glucose concentrations under the reduction trials were 
greater than under Full (Table 3.2). At 120 min post-meal ingestion, blood glucose 
concentrations elicited under Full (+3.9 ± 0.4 mmol.l’1), were lower than 75% (P = 0.02) and 
25% (P = 0.02), but similar to 50% (P = 0.11, Table 3.2). The reduced dose trials were 
statistically similar (P>0.05, Table 3). Exercise resulted in a decrease in blood glucose 
concentrations under all conditions (P<0.01) with the decline under Full (6.1 ± 0.4 mmol.l'1) 
tending to be greater than 75% (4.3 ± 0.5 mmol.l’1, P = 0.08), and 25% (3.2 ± 0.4 mmol.l’1, P 
= 0.04) but similar to 50% (5.5 ± 0.5 mmol.l'1, P = 0.21). The insulin reduction trials were 
not different (Figure 3.2 B and C).
The change from 0 to 180 minutes was similar across conditions (Full A+0.3 ± 0.5; 75% A- 
0.3 ± 0.5; 50% A-2.2 ± 0.3; 25% A-1.4 ± 0.7 mmol.l’1, P>0.05) with blood glucose 
concentrations at 180 minutes similar to 0 minutes under all conditions (Figure 3.2 B and C). 
Post-exercise blood glucose area under the curve ( B G a u c )  was lowest under Full in 
comparison with the reduction trials (Full 7.3 ± 0.4 vs. 75% 9.2 ± 0.5; 50% 8.5 ± 0.4; 25%
11.2 ± 0.7 mmol.l'1.hour'1, P<0.05), with B G a u c  greater under 25% in comparison with all 
other trials (P<0.05).
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Hypoglycaemia and low blood glucose
During the trial period, under Full, there were 3 occasions where blood glucose reached 
hypoglycaemic concentrations (two at 0 minutes and one at 180 minutes post-exercise). 
There was a single case of low blood glucose under 75% (180 minutes post-exercise) and 
50% (180 minutes post-exercise), and one case of blood glucose reaching hypoglycaemic 
concentrations under 25% (180 minutes post-exercise).
3.3.3 Serum insulin responses
Serum insulin responses are reported in Figure 1A. There were no significant differences in 
fasting serum insulin (Full 115 ± 15, 75% 125 ± 15, 50% 127 ± 19, 25% 126 ± 13 pmol.l'1, 
P = 0.63). There was a significant time effect (P = 0.003 partial-eta2 — 0.611) and a 
significant time*condition interaction (P = 0.012, partial-eta2 = 0.321) within the serum 
insulin responses (Figure 3.2A). The peak insulin concentrations occurred 60 minutes after 
administration, regardless o f dose (Table 3, Figure 3.2A). Insulin concentrations elicited at 
this time point under Full were similar to 75% (P = 0.18) and 50% (P = 0.14), but tended to 
be greater than 25% (P = 0.06). The reduced dose trials were not statistically different 
(P>0.05, Table 3.2). Pre-exercise serum insulin concentrations were greatest under Full, 
however, these differences did not reach statistical significance (Full 112 ± 15; 75% 86 ± 10, 
50% 56 ± 7 ,25% 55 ± 5 pm ol.l1,P>0.05).
The change in serum insulin concentrations with exercise was greater under 50% and 25% 
(50% A+31 ± 5; 25% A+48 ± 9 pmol.l'1) when compared to Full and 75% (Full A+19 ± 8; 
A+15 ± 7 pmol.l'1, P<0.05). Immediate post-exercise circulating insulin was similar to pre­
exercise concentrations under Full and 75%, but tended to increase under 50% (P = 0.07)
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and 25% (P = 0.07) (Table 3.2 and Figure 3.2A). The decline in insulin in the 3 hour 
recovery period under Full (A-142 ± 13 pmol.l'1) was greater under 25% (A-92 ± 7 pmol.l'1, 
P = 0.03) and tended to be greater than 75% (A-115 ± 7 pmol.l'1, P = 0.08) but similar to 
50% (A-138 ± 15 pmol.l'1, P = 0.31); there were no statistical differences between the 
reduced dose trials. Insulin concentrations were not statistically different, between conditions, 
after 180 minutes of rest (P>0.05; Table 3.2 and Figure 3.2A).
Table 3.2: ASerum insulin and Ablood glucose responses to reductions in pre-exercise rapid-acting 
insulin dose.
Condition
Variable Full 75% 50% 25%
Peak
Insulin (pmol.l1) 125 ± 11 114 ± 8 82 ± 12* 67 ± 9*t
BG (mmol.l1) 6.0 ± 0.4 7.4 ± 0.3* 7.0 ±0.5* 9.0 ±0.6*
Pre-Exercise
Insulin (pmol.l1) 112± 15 86 ± 10 56 ± 7 55 ± 5
BG (mmol.l1) 3.5 ± 0.4* 6.2 ± 0.3* 5.6 ±0.4 7.7 ± 0.7*
0 min
Insulin (pmol.l1) 111 ± 15 87 ± 7 101 ±19 80 ± 11*
BG (mmol.l1) -2.6 ± 0.7 1.9 ±0.5* 0.1 ±0.7 4.5 ± 0.9*
180 min
Insulin (pmol.l1) 15 ± 11 8 ±  12 7 ± 12 26 ± 11
BG (mmol.l1) -2.4 ± 0.8 1.1 ±0.8 -2.1 ±0.9 4.1 ±0.6*
Data presented as means ± SEM (n = 7). * indicates difference when compared with Full (P<0.05). f indicates 
difference when compared with 75% (P<0.05). BG indicates blood glucose.
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Figure 3.2: Time-course changes in serum insulin (A) and consequent blood glucose responses in absolute 
concentrations (B) and changes from baseline (C), after reductions in pre-exercise rapid-acting insulin dose. 
Data presented as mean ± SEM. Transparent sample point within a trial indicates significant difference when 
compared to rest (P<0.05).* indicates significant difference when compared with Full at the respective time 
point (P<0.05). # indicates significant difference when compared to 0 min post-exercise under all conditions 
(P<0.05). Thatched area indicates exercise. Note: Test meal and insulin were administered immediately 
following the resting sample.
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3.3.4 C ounter-regulatory horm onal re sp o n ses
Fasting concentrations of all counter-regulatory hormones were similar across conditions 
(P>0.05; Table 3.3).
There was no time effect (P = 0.12) or effect of condition (P = 0.13) on the plasma glucagon 
response. Plasma glucagon did not differ from rest at 180 minute post-exercise, with similar 
changes with time between conditions (Full A+20 ± 4; 75% A-46 ±11; 50% A-37 ± 6; 25% 
A+10± 5 pmol.l'1; P>0.05; Table 3.3).
There was a time effect (P = 0.001, Partial-eta = 0.769), but no conditional influence (P = 
0.215) on the plasma adrenaline response. Adrenaline significantly increased with exercise 
under all trials, with the change from rest to 0 minutes similar across conditions (Full A+1.2 
± 0.1; 75% A+0.7 ± 0.1; 50% A+1.0 ± 0.1; 25% A+1.0 ± 0.1 nmol.l'1; P>0.05). Adrenaline 
concentrations decreased from 0 to 180 min under all conditions, with similar changes across 
conditions (Full A-1.0 ±0.1; 75% A-0.7 ± 0.04; 50% A-0.6 ± 0.1; 25% A-0.8 ± 0.1 nmol.l'1; 
P>0.05). At 180 minutes adrenaline concentrations were different to rest under Full only 
(P<0.05, Table 3.3).
There was a time effect (P = 0.001, Partial-eta2 = 0.816), but no conditional influence (P = 
0.14) on the plasma noradrenaline response. Noradrenaline significantly increased with 
exercise under all conditions, with the change from rest to 0 minutes similar across Full, 
75% and 25% (Full A+19.8 ± 1.5; 75% A+17.8 ± 1.7; 50% A+10.8 ± 0.9; 25% A+20.1 ± 
1.8 nmol.l'1; P>0.05); changes under 50% were less than all other trials (50% A+10.8 ± 0.9 
nmol.l'1; P<0.05). Noradrenaline concentrations decreased to resting concentrations from 0 to 
180 minutes post-exercise under all conditions (Table 3.3), with the change over this period
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less under 50% (A-8.4 ± 1.0 nmol.l'1) in comparison with all other trials (Full A-17.7 ± 1.5; 
75% A-17.6 ± 1.8; 25% A-17.7 ± 2.1 nmol.l'1; P<0.05).
There was a time effect (P = 0.001, Partial-eta2 = 0.759), but no conditional influence (P = 
0.62) on the serum cortisol response. Cortisol did not change with exercise under any 
condition (Table 3.3). However, cortisol significantly increased from 0 to 15 minutes post­
exercise under all conditions (Table 3.3). The change from 0 to peak was similar across 
conditions (Full A+54 ± 13; 75% A+48 ± 15; 50% A+86 ± 10; 25% A+84 ± 14 nmol.l'1; 
P>0.05). Cortisol concentrations declined to concentrations less than rest from 15 to 180 
minutes (Table 3.4), with the change over this period similar between conditions (Full A-400 
± 24; 75% A-342 ± 27; 50% A-338 ± 30; 25% A-397 ± 26 nmol.l'1; P>0.05).
Table 3.3: Counter-regulatory hormonal responses to reductions in pre-exercise rapid-acting insulin 
dose.
Sample Point
Hormone Rest 0 min 15 min 180 min
Full 184 ±29 - - 205 ± 32
Glucagon (pmol.l1) 75% 176 ± 29
_ 130 ±20
50% 226 ± 36 - - 189 ±34
25% 175 ±30 - - 166 ±28
Full 0.56 ±0.01 1.75 ±0.10* - 0.73 ± 0.02*
Adrenaline (nmol.l1) 75% 0.60 ± 0.02 1.26 ±0.04* 0.54 ±0.0150% 0.84 ±0.01 1.83 ±0.07* - 1.27 ±0.08
25% 0.57 ± 0.03 1.57 ± 0.11* - 0.80 ± 0.08
Full 3.43 ±0.18 23.22 ± 1.25* - 5.54 ±0.18
Noradrenaline (nmol.l'1) 75% 3.91 ±0.38 21.75 ± 1.96* - 4.17 ± 0.1550% 3.64 ±0.37 14.44 ±0.90* - 6.03 ±0.31
25% 2.51 ±0.18 22.59 ± 1.89* - 5.41 ±0.65
Full 610 ± 20 585 ± 18 657 ± 20*f 265 ± 19*f
Cortisol (nmol.l1)
75% 637 ± 24 574 ± 14 632 ± 19*t 298 ± 29 *t
50% 596 ±19 486 ± 19 591 ± 22*f 261± 19*t
25% 650 ± 20 592 ± 14 685 ± 22*t 295 ± 21*f
Data presented as means ± SEM (n = 7). * indicates significant difference when compared with rest (P<0.05). f 
indicates difference when compared to 0 min post-exercise (P<0.05).
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3.3.5 Serum  p-hydroxybutyrate re sp o n ses
There was a significant time effect (P = 0.003, partial-eta2 = 0.630) within the serum p- 
hydroxybutyrate responses to alterations in rapid-acting insulin dose (Figure 3.3), however, 
there were no conditional differences (P = 0.58; Figure 3.3). There were small declines from 
rest to 120 minutes post-ingestion under all conditions (Full A-0.15 ± 0.03; 75% A-0.07 ± 
0.01; 50% A-0.03 ± 0.01; 25% A-0.03 ± 0.01 mmol.l'1; P>0.05). Concentrations did not 
change with exercise under any condition (Full A+0.06 ± 0.01; 75% A+0.04 ± 0.01; 50% 
A+0.04 ± 0.01; 25% A+0.03 ± 0.01 mmol.l'1; P>0.05; Figure 3.3), however, there was a 
transient increase in concentrations over the three hour recovery period, with concentrations 
at 120 and 180 minutes significantly greater than both rest and 0 minutes post-exercise under 
all conditions (P<0.05; Figure 3.3). The change from 0 to 180 minutes post-exercise was 
similar across conditions (Full A+0.31 ± 0.04; 75% A+0.24 ± 0.02; 50% A+0.27 ± 0.03; 
25% A+0.39 ± 0.05 mmol.l'1; P>0.05).
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Figure 3.3: Time-course changes in serum (3-hydroxybutyrate after reductions in pre-exercise rapid- 
acting insulin dose. Data presented as mean ± SEM. Transparent sample point within a trial indicates 
a significant difference when compared to rest (P<0.05), # indicates significant difference from 0 min 
post-exercise under all conditions (P<0.05). Thatched area indicates exercise. Note: Test meal and 
insulin were administered immediately following the resting sample.
3.3.6 Blood pH and lactate re sp o n ses
Time course-changes in blood pH and lactate are presented in Figure 3.4 A and B. There was 
a significant time effect (P = 0.002, partial-eta2 = 0.674) and a significant time*treatment 
interaction (P = 0.002, partial-eta = 0.251) within the blood pH responses. There were no 
conditional differences in blood pH responses during the pre-exercise period (Figure 3.3 A). 
Blood pH increased significantly from the pre-exercise sample to 0 minutes post-exercise 
under all conditions (P<0.05). However, the change in pH with exercise was less under 25% 
when compared to the other trials (Full A+0.07 ± 0.01; 75% A+0.06 ± 0.01; 50% A+0.06 ± 
0.01; 25% A+0.02 ± 0.01), but was only statistically different to Full (P = 0.03). Blood pH 
under 25% at 0 and 5 minutes post-exercise was significantly lower than both Full and 75% 
(Figure 3.4A). Moreover, after the 5 minute post-exercise sample, blood pH was not different 
between conditions for the remainder of the 180 minute recovery period (Figure 3.4A). Blood 
pH decreased from 0 to 180 minutes under Full, 75% and 50%, but not under 25%. 
Moreover, the change in blood pH from 0 to 180 min was greatest under Full (Full A-0.07 ± 
0.01; 75% A-0.05 ± 0.01; 50% A-0.05 ± 0.01; 25% A-0.03 ± 0.01), however, only Full and 
25% were statistically different (P = 0.04).
There was a significant time effect within the blood lactate response to the protocol (P =
r\
0.024, partial-eta = 0.532). However, there were no effects of insulin dose on the blood 
lactate responses (P = 0.27). There were no conditional differences in blood lactate 
concentrations within the pre-exercise period, with concentrations just before exercise similar 
across conditions (Full 1.1 ± 0.03; 75% 1.0 ± 0.03; 50% 1.0 ± 0.4; 25% 1.1 ± 0.03 mmol.l'1, 
P>0.05). The change in blood lactate concentrations, with exercise, was greatest under 25%; 
however, there were no statistical differences between the conditions (Full A+3.1 ± 0.4; 75% 
A+3.3 ± 0.5; 50% A+3.1 ± 0.04; 25% A+4.3 ± 0.4 m m ol.l1; P>0.05). Blood lactate
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concentrations decreased with time after 0 minutes under all conditions and the change from 
0 to 180 minutes was similar across trials (Full A-3.5 ± 0.4; 75% A-3.5 ± 0.5; 50% A-3.3 ± 
0.0.4; 25% A-4.5 ± 0.5 mmol.l'1; P>0.05; Figure 3.4 B).
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Figure 3.4: Time-course changes in blood pH (A) and lactate (B), in absolute values, after reductions 
in pre-exercise rapid-acting insulin dose. Data presented as mean ± SEM. Transparent sample point 
within a trial indicates a significant difference when compared to rest (P<0.05). * indicates 
significantly different to Full and 75% (P<0.05). # indicates significantly different to 0 min post- 
exercise under all conditions (P<0.05). Thatched area indicates exercise. Note: Test meal and insulin 
were administered immediately following the resting sample.
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3.3.7 P atterns of carbohydrate and lipid oxidation
There was no significant effect of insulin dose on resting or exercising fuel metabolism with 
similar rates of carbohydrate and lipid oxidation between conditions (P = 0.21; Table 3.4). 
Moreover, when expressing substrate oxidation rates as a change from rest to exercise, no 
conditional differences were evident (P = 0.13; Table 3.4).
Table 3.4: Substrate oxidation responses to reductions in pre-exercise rapid-acting insulin dose at rest 
and during exercise.
Rest Exercise
Full 75% 50% 25% Full 75% 50% 25%
LHO (g.min'1) 
Lipids (g.min"1)
[ACHO (g .m in '1)
ALipids (g .m in '1)
0.25 ±0.01 0.23 ±0.06 0.25 ±0.1 0.23 ±0.01 2.67 ±0.08* 2.35 ±0.05* 2.50 ±0.09* 2.56 ±0.07*
0.05 ±0.02 0.08 ±0.01 0.07 ±0.01 0.07 ±0.01 0.15 ±0.01* 0.30 ±0.07* 0.27 ±0.03* 0.21 ± 0.02*
2.41 ±0.07* 2.15 ±0.08* 2.24 ±0.09* 2.32 ±0.07*
0.10 ±0.01* 0.24 ±0.01* 0.20 ±0.02* 0.06 ±0.03*
Data presented as means ± SEM (n = 7). * indicates a significant increase when compared with rest CP<0.05).
Energy expended during exercise was similar across trials (Full 2.26 ± 0.04; 75% 2.29 ± 
0.05; 50% 2.34 ± 0.04; 25% 2.29 ± 0.04 MJ, P = 0.51). The contribution to energy demand 
from carbohydrates (Full 87.8 ±1.1;  75% 76.9 ± 1.5; 50% 80.0 ± 2.2; 25% 83.4 ± 1.4 %, P 
= 0.61) and lipids (Full 12.2 ± 1.1; 75% 23.1 ± 1.5; 50% 20.0 ± 2.2; 25% 16.6 ± 1.4 %, P = 
0.61) were similar across conditions.
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3.3.8 Post-laboratory activity and self-recorded glycaem ia and dietary intake
During the 21 hours after leaving the laboratory, low blood glucose and hypoglycaemia were 
encountered under all trials (Low blood glucose: Full 9 hours; 75% 7 and 19 hours; 25% 5 
and 22 hours post-laboratory: Hypoglycaemia: Full 1, 2, 8 and 9 hours; 75% 18 hours; 50% 
1, 6, and 12 hours; Table 3.5). Furthermore, participants consumed more energy under Full 
and 75% compared with 25%. Participants consumed lower amounts of carbohydrate under 
25% when compared to Full (P = 0.02), with similar trends under 75% (P = 0.09) and 50% 
(P = 0.08). There were no conditional differences in the percentage contribution to total 
energy from carbohydrate (Full 49 ± 1.4; 75% 50 ± 1.8; 50% 49 ± 1.4; 25% 50 ± 0.9 %; 
P>0.05), protein (Full 17 ± 0.7; 75% 19 ± 0.3; 50% 16 ± 0.7; 25% 19 ± 0.4 %; P>0.05) or 
fats (Full 35 ± 1.1; 75% 31 ± 1.9; 50% 34 ± 1.4; 25% 28 ± 1.0 %; P>0.05). There were no 
differences in the number of rapid-acting insulin units administered or activity patterns 
between trials, as average heart rate and steps taken were similar (P>0.05; Table 3.5).
Table 3.5: Twenty-one hour post-laboratory blood glucose, dietary intake and activity patterns.
Condition
Variable Full 75% 50% 25%
BGauc (mmol.l1.hour'1) 7.0 ± 0.3 6.8 ± 0.2 7.5 ± 0.3 8.0 ± 0.3f
CHO intake (g) 180 ± 7 169 ± 7 148 ±7* 124 ±7*
Protein intake (g) 64 ± 3 63 ± 4 48 ± 3 48 ± 3
Fat intake (g) 60 ± 4 49 ± 5 50 ± 4 31 ±2*
Energy intake (MJ) 6.3 ± 0.3 5.6 ±0.3 5.2 ± 0.2* 4.1 ±0.2*t
Rapid-acting insulin (U) 20 ± 1 22 ± 1 24 ± 1 23 ± 1
Frequency BG < 4.0 mmol.l'1 1 2 - 2
Frequency BG <3.5 mmol.l'1 4 1 3 2
Average heart rate (bpm) 74 ± 1 82 ± 1 74 ± 1 76 ± 1
Average steps taken 4017 ±267 6382 ± 682 5223 ± 382 6473 ± 420
Data presented as means ± SEM (n = 7). * indicates significantly different from 100% (P<0.05), f indicates 
significantly different from 75% (P<0.05). BGAUC indicates blood glucose area under the curve.
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3.4 D iscussion
The aim of this study was not to examine hypoglycaemia per se, but to examine the effects of 
the currently recommended pre-exercise insulin reductions on metabolic and glycaemic 
responses for 24 hours after running in T1DM individuals. The results demonstrate the most 
severe reduction to pre-exercise rapid-acing insulin dose (75%) best preserved blood glucose 
responses for 24 hours following running, without increasing the risk of developing 
ketoacidosis. Furthermore, less energy and carbohydrates were consumed under this trial over 
the same time period.
Rapid-acting insulin concentrations peaked 60 minutes after injection across all trials with the 
lowest peak values occurring under the most severe insulin reduction condition (Figure 1 A). 
Our results are similar to other researchers’ findings (Homko et al., 2003; Plank et al., 2002) 
and demonstrate the relationship between injected dose and resultant serum concentration as 
well as the consistency of modem rapid-acting analogues to reach peak effect in spite of 
differences in anthropometric (body fat percentage, body mass index), or physiological 
(subcutaneous blood flow) parameters (Kolendorf et al., 1983). Similar to other researchers 
(Mauvais-Jarvis et al., 2003; Rabsa-Lhoret et al., 2001), the effect of the reduction in insulin 
dose was to increase blood glucose concentrations such that, in our study, blood glucose was 
highest immediately prior to running under the 25% condition. (15.2 ± 0.6 mmol.l'1) (Figures
3.2 B and C, Table 3.2).
Running pace was predominantly aerobic being performed at 70% of maximal oxygen
uptake, which corresponded to -67% and -58%  of participants’ VO2 and HR reserves,
respectively. This resulted in completion of an isocaloric 2.6 MJ bout of exercise across
trials, comprised of carbohydrate and lipid oxidation rates of approximately 2.5 and 0.23
g.min'1, respectively. The total carbohydrate breakdown o f -113 g would have necessitated a
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significant contribution from liver and muscle glycogen stores whereas the relatively low 
contribution of lipids oxidised (~10 g) during running suggest minimal contribution from 
adipose tissue and/or intramuscular depots. Respiratory data revealed there were no 
differences in carbohydrate or lipid oxidation rates during running between any of the trials. 
It has been demonstrated that decreases in circulating insulin concentrations provide a milieu 
for increased rates of lipid oxidation (Chokkalingam et al., 2007), but this was not evident 
from our data. The high pre-exercise blood glucose concentrations (13-15 mmol.l'1), 
irrespective of condition, may have caused an equal but elevated carbohydrate oxidation rate 
(Jenni et al., 2008) suppressing any shifts in the pattern of lipid oxidation.
There were no treatment effects on the gluco-regulatory hormones. Within the 
pathophysiology of T1DM is a progressive loss of a-cell function over time, potentially due a 
loss of p -  a cell signalling (Banarer et al., 2002), such that after 5 years of diagnosis falling 
blood glucose will fail to stimulate the release of this key hormone (Mokan et al., 1994). 
Although glucagon was only measured at two time points across trials, it is unlikely that any 
conditional changes would occur. Furthermore, the glycaemic threshold for the initiation of a 
counter-regulatory hormonal response is typically shifted to lower concentrations, compared 
to non-diabetics, in T1DM individuals (Cryer et al., 2001). Within this study, out of 28 trials, 
there were only 4 occasions where blood glucose fell below 3.5 mmol.l'1, therefore 
concentrations were simply not low enough to augment the counter-regulatory hormonal 
response, thus explaining the lack of conditional differences in these hormones.
There was a large decline in insulin concentrations in the immediate post-exercise period 
across all trials (Figure 3.2A) which may have been due to an increased insulin clearance rate 
(Tuominen et al., 1997). This rapid reduction in insulin concentration may have lessened its 
inhibitory effects on the circulating counter-regulatory hormones; glucagon, adrenaline,
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noradrenaline and cortisol. Despite similar concentrations of insulin in the 3 hour post­
exercise period, the preservation of blood glucose was greatest under 25% over the same 
time period.
There were no conditional differences in blood lactate or serum p-hydroxybutyrate responses 
to the trials. As the exercise stimulus was the same across trials it was unlikely that a 
conditional difference in blood lactate appearance would be evident. With regards to p- 
hydroxybutyrate; although ketone formation is associated with reduced insulin concentrations 
and hyperglycaemia, the participants’ basal insulin dose remained unaltered across 
conditions. One of the primary roles of the basal dose is to restrain ketogenic enzymes 
(Barnett, 2003), moreover, as there were no differences in important ketone stimulating 
hormones, such as glucagon and adrenaline (Laffel, 1999); it was unlikely that differences in 
p-hydroxybutyrate would be present. The conditional differences in pH demonstrated under 
25% may be related to an increased glycoltyic flux due to elevated blood glucose 
concentrations (Coyle et al., 1997; Jenni et al., 2008). Coyle et al. (1997) identified that an 
increased glucose availability, such as under hyperglycaemic conditions, results in an 
increased glycolytic flux. Moreover, multiple stages of the glycolytic pathway results in the 
generation of H+ (Robergs et al., 2004); of which some may leave the cell in exchange with 
Na+ (Peronnet and Aguilaniu, 2006). Potentially, the hyperglycaemic conditions under 25% 
resulted in an increased glycolytic flux and release of H+, resulting in a lesser rise in pH 
during the exercise bout. An increased glycoltyic flux may be a potential explanation for the 
slightly, but non-significant, elevated peak lactate concentrations under this condition 
immediately after exercise.
The greatest incidence of post-exercise low blood glucose following exercise occurred in the 
full rapid-acting insulin dose condition, a finding similar to that of Rabasa-lhoret et al.
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(2001). Furthermore, the most severe insulin reduction condition, the 25% trial, resulted in 
the greatest preservation of blood glucose. Despite this, one participant, who experienced 
hypoglycaemia on three of four trials within the laboratory, still experienced hypoglycaemia 
after a 75% reduction to pre-exercise insulin (180 minutes post-exercise), suggesting 
individuals differ in their sensitivity to exercise with an additional large rate of glucose 
uptake for a small increase in circulating insulin. This is an important factor to consider in 
future research as a source of variability in T1DM individuals. Participants consumed fewest 
carbohydrates under 25%, yet still administered a similar number of rapid-acting insulin 
units. As blood glucose was elevated leaving the laboratory (11.0 ± 0.7 m m ol.l1), the insulin 
units administered, as a corrective measure for high blood glucose, combined with an 
increased sensitivity to insulin following exercise (Wojtaszewski et al., 2001), may explain 
the low blood glucose encountered in the post-laboratory period by some individuals under 
this trial.
Similar to the 3 hours following exercise, the self-reported data in the post-laboratory period 
revealed the 75% reduction in pre-exercise insulin resulted in the greatest post-exercise blood 
glucose area under the curve. Furthermore, over the remaining 21 hour of the trial 
participants consumed ~2.2 MJ less energy, notably as a result of 54 g less carbohydrate and 
30 g less fat intake, however, there were no differences in the percentage composition of 
energy intake as there were no differences between the total energy intake from 
carbohydrates (49-50%), fats (29-35%) and proteins (16-19%), across any of the trials. 
T1DM individuals have been suggested to over-consume food in order to avoid 
hypoglycaemia (Jacob et al., 2006), but the reduced food intake within the 25% trial may be 
evidence of a reduced need to consume additional foodstuffs as a compensatory approach to 
maintain blood glucose and avoid hypoglycaemia following exercise. In addition, the greater
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blood glucose concentrations may have contributed to a greater feeling of satiety and reduced 
participants’ hunger over the course of the day (Russell et al., 2001).
A potential limitation to this study was that participants monitored their blood glucose more 
frequently than they would typically perform on a daily basis which is likely a contributing 
factor to why there was only ~1.2 mmol.l'1.hour'1 range between the highest and lowest blood 
glucose area under the curve over the 21 hour post-laboratory periods. Although it is 
established that frequent monitoring of blood glucose can improve glycaemic control (Evans 
et al., 1999) through normalising blood glucose concentrations, it is important to recognise 
that this data is based upon T1DM individuals in everyday situations. We questioned T1DM 
individuals who were physically active, and it was evident that after exercise there is a 
tendency to increase the frequency of monitoring; moreover, the number and frequency of 
blood glucose measurements was consistent across trials. Furthermore, although there were 
small differences in blood glucose area under the curve between conditions, the frequent 
monitoring of blood glucose allowed participants to adapt their insulin administration and 
dietary intake, which was detectable in their diaries and ultimately in this chapters findings. 
Participants were provided with sufficient information and examples of how to complete the 
dietary diaries accurately. Moreover, it should be noted that this method of monitoring the 
patients’ diet is currently employed across diabetes clinics in the UK.
A limitation to this study is its lack of statistical power. Based on the data of Rabasa-Lhoret 
et al. (2001), for 80% power we would have needed a sample size of ~33 subjects. Due to our 
strict inclusion criteria (Table 2.1), the large time commitment required for the trials and we 
were limited to individuals using glargine as their basal insulin, due to assay cross reactivity 
with insulin detemir, we could only examine 7 participants. As a result this study had a 
statistical power of 57%. Future research in this area should be done so with a larger sample
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size. However, despite this, the data is of clinical importance, in that there is a clear and 
consistent preservation of blood glucose when a severe pre-exercise rapid-acting insulin 
reduction is employed. Employing this strategy may allow T1DM individuals the ability to 
regularly exercise without experiencing a hypoglycaemic incident during and after exercise. 
Furthermore, with a greater preservation of blood glucose and a lesser risk of hypoglycaemia, 
T1DM individuals may not feel the need to over consume carbohydrates in the post-exercise 
period.
In conclusion, this study examined the effects of reductions in pre-exercise rapid-acting 
insulin dose on metabolic and glycaemic responses for 24 hours after running in T1DM 
individuals. These data demonstrate that reducing pre-exercise, rapid-acting insulin dose by 
75% improved blood glucose responses for 24 hours following running, without increasing 
the risk of developing diabetic ketoacidosis.
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Chapter Four
The metabolic and glycaemic effects of 
alterations in the glycaemic index of the 
carbohydrate ingested before exercise.
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4.1 Introduction
Exercise causes large reductions in blood glucose concentrations in type 1 diabetes 
individuals (T1DM). Reductions to the pre-exercise insulin dose help preserve blood glucose 
during and after exercise (De Feo et al., 2006; Mauvais-Jarvis et al., 2003; Rabasa-Lhoret et 
al., 2001). Furthermore, current research advocates the consumption of carbohydrates before 
exercise to prevent falls in blood glucose during and after a bout of exercise (De Feo et al., 
2006; Hibbert-Jones and Regan, 2005; Maahs et al., 2009). However, specific factors related 
to the physical and chemical composition of carbohydrates, such as the glycaemic index, 
have been under researched.
The effects of changes in the type of carbohydrate consumed by T1DM, before performing 
exercise, on blood glucose responses following exercise has been under researched. 
Carbohydrates with a low glycaemic index (LGI) digest at slower rates than high glycaemic 
index (HGI) carbohydrates and are unable to cross the mucosal cell membrane within the 
small intestine and enter the bloodstream unless hydrolysed into monosaccharides (Thomas et 
al., 2007). Research has established the importance of including LGI carbohydrates into the 
daily diets of T1DM, with observed benefits such as lower daily mean blood glucose (Nansel 
et al., 2008) and reduced incidence of hypoglycaemia and reductions in HbA]c (Gilbertson et 
al., 2001; Thomas et al., 2007). Within the study of Nansel et al. (2008), consumption of LGI 
foodstuffs, such as peaches, kidney beans or brown rice, resulted in glucose concentrations 
(assessed using a continuous glucose monitor) being within a target range of 3.9 -  9.9 
mmol.l’1 significantly more of the time than under the HGI trial (67 vs. 47 %). Moreover, the 
participants elicited a lower mean blood glucose concentration (LGI 7.6 ± 2.0 vs. HGI 10.1 ± 
2.6 mmol.l'1) and required less bolus insulin per 10 g of carbohydrate. There is limited data
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examining the post-exercise metabolic and glycaemic responses of T1DM following 
ingestion of differing glycaemic index carbohydrates.
In addition to the potential to improve glycaemia, research has demonstrated that LGI 
carbohydrates alter exercising fuel metabolism. Following consumption of a LGI meal, 
carbohydrate oxidation rates have been shown to increase less, with a concomitant lesser 
suppression of lipid utilisation, during a bout of isoenergetic exercise in non-TlDM 
individuals (Achten et al., 2007; Stevenson et al., 2006). Stevenson et al. (2006) 
demonstrated a 31 % lower carbohydrate oxidation rate and 56 % greater lipid oxidation rate 
during a one hour treadmill run at 65 % V02max 3 hours following consumption of a LGI or 
HGI meal in eight female participants. Similarly, ingestion of a 50 g bolus of isomaltulose 
reduced carbohydrate oxidation rate by ~0.2 g.min'1 and increased lipid oxidation more than 
sucrose during 150 minutes of cycling at 60 % V02max (Achten et al., 2007). This raises the 
possibility that consumption of an LGI carbohydrate source may spare both endogenous and 
exogenous carbohydrate reserves and increase fat oxidation in T1DM during exercise, 
resulting in better preservation of blood glucose during the post-exercise period.
With the potential for LGI carbohydrates to offer improved glycaemia and fuel oxidation in 
T1DM; it would also be prudent to examine the role of the glycaemic index of the pre­
exercise carbohydrate on the incidence of hypoglycaemia after exercise, when a heavily 
reduced insulin dose is implemented (findings of chapter 3). Potentially, in the avoidance of 
hypoglycaemia after exercise the glycaemic index of the pre-exercise carbohydrate may be 
secondary in importance to a heavy reduction in pre-exercise insulin dose. Therefore, the aim 
of this study was to examine the effects of ingesting a high and low glycaemic index 
carbohydrate, in combination with a heavily reduced insulin dose, on metabolic and 
glycaemic responses before, during, and for 24 hours after running in T1DM individuals.
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4.2 M ethodology
Eight participants with T1DM (7 males, 1 female, 35 ± 2 years, BMI 26 ± 0.3 kg/m2) with 
duration of diabetes of 14 ± 1 years and HbAjc of 8.0 ± 0.2 % volunteered to participate in 
this study. Participant anthropometric (Table 2.5), glycaemic control (Table 2.8), and insulin 
regimen (Table 2.3) characteristics are presented chapter 2.
After preliminary testing (Table 2.6) participants attended the laboratory on two occasions 
after an overnight fast and having consumed similar evening meals prior to each trial. Upon 
arrival participants received catheterisation in their non-dominant arm and blood samples 
were processed for glucose, lactate, pH, glucagon, adrenaline, noradrenaline, cortisol, p- 
hydroxybutyrate, triglycerides, non-esterified fatty acids and glycerol (section 2.3.5). 
Participants were then required to consume, in a randomised and counterbalanced fashion, 75 
g of either a high GI (HGI; Dextrose; GI 96) or low GI (LGI; Isomaltulose; GI 32) 
carbohydrate, mixed with 750 ml of water (10 % solution, Perrone et al., 2005). Immediately 
before ingestion, participants were instructed to administer their rapid-acting insulin, which 
had been reduced by 75 % (2.1 ± 0.2 IU) into the abdomen (findings from chapter 3; Rabasa- 
Lhoret et al., 2001). Subsequent blood samples were taken for 2 hours before performing 45 
minutes of running at 80 ± 1% VC>2peak and for three hours post-exercise (Figure 4.1). Cardio­
respiratory parameters were collected at rest and during exercise.
Participant activity and heart rate were recorded for 24 hours after exercise; moreover, for 21 
hours after leaving the laboratory participants self-recorded blood glucose, dietary intake, 
insulin administration and hypoglycaemic incidences.
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Figure 4.1: Schematic diagram of the experimental protocol of chapter 4.
4.2.1 Statistical Analysis
Statistical analysis was performed using SPSS software (version 16; SPSS Inc., Chicago, IL), 
with significance set at P<0.05. Data were tested for nonnal distribution (Shapiro-W ilk test) 
and subsequently analysed using repeated-measures ANOVA on two factors (treatment x 
time) with Bonferroni adjustments and dependent t-tests carried out where relevant. Data are 
presented as mean ± SEM.
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4.3 R esults
4.3.1 Physiological re sp o n ses  to exercise
The physiological responses to LGI and HGI are reported in Table 4.1. There were no 
differences in the resting rates of oxygen consumption or carbon dioxide production between 
LGI and HGI (P>0.05). Participants exercised at a similar exercise intensity under both 
conditions with similar %V02peak (LGI 80.8 ± 0.9% vs. HGI 78.2 ± 0.9 % V02peak, P = 0.12) 
and HRpeak (LGI 85 ± 1% vs. HGI 83 ± 1 % VCbpeak, P = 0.12) elicited during the 45 minutes 
of running. However, there was a tendency for a greater rate of oxygen use during exercise 
under LGI (P = 0.05; Table 1). Resting and exercising heart rates were similar between 
conditions (Table 4.1).
Table 4.1: Cardio-respiratory responses, at rest and during exercise, following pre-exercise ingestion 
of LGI or HGI.
Rest Exercise
HGI LGI HGI LGI P  (Ex)
HR (bpm) 65 ± 1 68 ± 1 159 ±2* 163 ±2* 0.12
VE (l.min'1) 10.8 ±0.2 10.5 ±0.5 73.8 ± 1.5* 75.5 ± 1.1* 0.28
VO2 (ml.kg'1.min'1) 5.2 ±0.1 5.3 ±0.1 34.6 ±0.5* 35.8 ±0.6* 0.05
VCO2 (ml.kg. '.min1) 4.7 ±0.1 4.9 ±0.1 33.6 ±0.6* 34.0 ±0.6* 0.32
RER 0.91 ±0.01 0.93 ±0.01 0.97 ±0.01* 0.95 ±0.01* 0.14
Data are presented as mean ± SEM (n = 8). P  (Ex) demonstrates paired-samples t-test on exercising data only.* 
indicates significant differences from rest (P<0.01).
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4.3.2 Blood g lucose resp o n ses
Fasted blood glucose concentrations were not different between conditions (LGI 7.6 ± 0.2 vs. 
HGI 6.2 ± 0.3 mmol.l'1, P = 0.11). The absolute and relative blood glucose responses to LGI 
or HGI ingestion are reported in Figure 4.2. There were no conditional differences when 
blood glucose was examined in absolute concentrations (Figure 4.2A); however, when 
expressed as change from baseline, significant conditional differences in blood glucose 
responses were evident (Figure 4.2B).
Peak blood glucose under LGI (A+4.5 ± 0.4 mmol.l'1), occurred 120 minutes post-ingestion 
and was less than HGI (A+9.1 ± 0.6 mmol.l'1, P<0.01) which peaked at 90 minutes. The drop 
in blood glucose with exercise was similar between conditions (LGI 4.4 ± 0.4 vs. HGI 5.8 ± 
0.3 mmol.l'1, P = 0.11). The drop in blood glucose under LGI was not as great as HGI in 6 of 
8 participants. Immediately after exercise, blood glucose concentrations under LGI were 
significantly lower than HGI and were not different from resting concentrations (Figure 
4.2B).
In the 3 hour post-exercise period, blood glucose concentrations under LGI were lower than 
those under HGI at all time points (Figure 4.2B). Blood glucose concentrations did not 
change from 0 to 180 minutes under either condition (LGI A+0.1 ± 0.3: HGI A+1.3 ± 0.3 
mm ol.l1, P = 0.46). The post-exercise blood glucose area under the curve (B G a u c ;  LGI 7.9 ± 
0.5: HGI 10.0 ± 0.5 mmol.l1.hour'1, P = 0.03) and mean blood glucose (LGI +3.4 ± 0.3: 
HGI +0.5 ± 0.5 mmol.l'1, P = 0.03) concentration, over the 180 minute recovery period, was 
21 ± 3 % and 3.0 ± 0.4 mmol.l'1, lower, respectively, under LGI in comparison to HGI 
(P<0.05).
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Figure 4.2: (A) Time-course changes in blood glucose following pre-exercise ingestion of LGI or HGI. There 
was a significant time effect (P = 0.001 partial-eta2 = 0.601), there was a tendency for a treatment effect (P = 
0.054, partial-eta2 = 0.432), but no time*treatment interaction (P>0.05). (B) Time-course changes in blood 
glucose, relative to rest, following ingestion of LGI or HGI. There was a significant time (P = 0.001, Partial- 
eta2 = 0.617) and treatment effect (P = 0.006, Partial-eta2 = 0.686) and a significant time*treatment interaction 
(P = 0.04, Partial-eta2 = 0.225). Data presented as mean ± SEM (n = 8). Transparent sample points indicate 
significant difference from rest (P<0.05). * indicates significant difference when compared to LGI (P<0.05). f 
indicates a trend when compared to LGI (P<0.1). Thatched area indicates exercise. Note: Insulin and 
carbohydrate solution was administered immediately following resting sample.
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Hypoglycaemia
There were no incidences of hypoglycaemia during the 2 hour rest period or during treadmill 
running. In the post-exercise period, there were two occasions where blood glucose fell 
below 3.5 mmol.r1 under both HGI (5 and 120 minutes post-exercise) and LGI trials (30 and 
180 minutes post-exercise). One participant experienced a hypoglycaemic encounter on both 
occasions (LGI 120 minutes; HGI 180 minutes post-exercise).
4.3.3 Counter-regulatory hormonal responses
There were no conditional effects on any of the counter-regulatory hormonal responses to the 
trials (Table 4.2).
Plasma glucagon was not affected by time (P = 0.32) or condition (P = 0.46). Plasma 
glucagon remained similar to resting concentrations after exercise (Table 4.2), with similar 
changes from rest to 0 min post-exercise between conditions (LGI A+4 ± 6; HGI A-16 ± 4 
pmol.f1; P = 0.44). Moreover, after 180 minutes post-exercise glucagon concentrations did 
not differ from rest or 0 minutes post exercise under either condition (Table 4.2); the change 
from 0 to 180 minutes was similar between conditions (LGI A+5 ± 1; HGI A-5 ± 1 pmol.f1; 
P = 0.72).
There was a significant time effect (P = 0.02, Partial-eta2 = 0.77) but no effect of condition (P 
= 0.77) on the plasma adrenaline response. Plasma adrenaline peaked at 0 minutes post­
exercise (Table 4.2), with the no conditional differences in peak concentrations. Moreover, 
the change in concentrations from rest to 0 minutes post-exercise was similar between 
conditions (LGI A+1.47 ± 0.12; HGI A+1.72 ± 0.26 nmol.f1; P = 0.81). Plasma adrenaline 
concentrations were similar at 180 minutes post-exercise, and not different to rest under both
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conditions (Table 4.2). Moreover, the change over the 180 minute post-exercise period was 
similar between conditions (LGI A-l .27 ± 0.12; HGI A-1.88 ± 0.28 nmol.l"1; P = 0.58).
There was a significant time effect (P = 0.01, Partial-eta2 = 0.76) but no effect of condition (P 
= 0.28) on the plasma noradrenaline response. Plasma noradrenaline peaked at 0 minutes 
post-exercise (Table 4.2), with the no conditional differences in peak concentrations. 
Moreover, the change in concentrations from rest to 0 minutes post-exercise was similar 
between conditions (LGI A+14.82 ± 0.93; HGI A+13.32 ± 1.19 nmol.l'1; P = 0.49). Plasma 
noradrenaline concentrations were similar at 180 minutes post-exercise, and not different to 
rest under both conditions (Table 4.2). Moreover, the change over the 180 minute post­
exercise period was similar between conditions (LGI A-14.46 ± 1.02; HGI A-l 1.23 ± 1.08 
nm ol.l1; P = 0.22).
There was a significant time effect (P = 0.02, Partial-eta = 0.71) but no effect of condition (P 
= 0.44) on the serum cortisol response. Cortisol did not rise with exercise; however, 
concentrations began to increase immediately following exercise, peaking at 15 minutes post­
exercise. Peak cortisol concentrations at 15 minutes (LGI 590 ± 16; HGI 595 ± 22 nmol.l'1; 
P = 0.46) were not different from rest or 0 minutes post-exercise under either condition. At 
180 minutes post-exercise serum cortisol concentrations were significantly lower than rest 
(LGI 276 ± 18; HGI 197 ± 6 nmol.l'1; P = 0.20) under both conditions (P< 0.05; Table 4.2). 
Moreover, the change in concentrations from peak to 180 minutes were similar between 
conditions (LGI A-315 ± 29; HGI A-399 ± 25 nmol.l'1; P = 0.20).
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Table 4.2: Counter-regulatory hormonal responses following pre-exercise ingestion of LGI or HGI.
Sample Point
Hormone Rest 0 min 15 min 180 min
HGI 93 ± 9 75 ± 10 78 ± 10
Glucagon (pmol.l )
LGI 97 ± 9 87 ± 12 - 94 ± 10
HGI 0.28 ± 0.03 2.00 ± 0.28* 0.73 ± 0.02
Adrenaline (nmol.l )
LGI 0.20 ± 0.03 1.67 ±0.12* - 0.40 ± 0.05
HGI 2.64 ±0.13 23.22 ± 1.25* 4.73 ± 0.35
Noradrenaline (nmol.l )
LGI 3.66 ±0.29 18.48 ±0.10* - 4.02 ±0.13
HGI 532 ± 7 516 ±22 595 ± 22* 197 ± 6*t
Cortisol (nmol.l )
LGI 553 ± 6 523 ±21 590± 16* 276 ±18*f
Data presented as mean ± SEM (n = 8).* indicates significant difference when compared with rest (P<0.05). f 
indicates difference when compared to 0 min post-exercise (P<0.05).
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4.3.4 Serum  p-hydroxybutyrate re sp o n ses
The serum P-hydroxybutyrate responses to alterations in the GI of the pre-exercise 
carbohydrate are presented in Figure 4.3. Following carbohydrate ingestion and insulin 
administration there were small declines from rest to 120 minutes post-ingestion under both 
conditions (LGI A-0.09 ± 0.011 vs. HGI A-0.02 ± 0.005 mmol.l'1, P>0.05). Concentrations 
did not change with exercise under either condition (LGI A+0.03 ± 0.004 vs. HGI +0.03 ± 
0.004 mmol.r1, P>0.05), however, there was a transient rise in concentrations over the three 
hour recovery period, with concentrations at 180 minutes significantly greater than both rest 
and 0 minutes post-exercise under both conditions (Figure 4.3). The change from 0 to 180 
minutes post-exercise was similar between conditions (LGI A+0.28 ± 0.033 vs. HGI A+0.38 
±0.041 mmol.l'1, P = 0.52).
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Figure 4.3: Time-course changes in serum P-hydroxybutyrate following pre-exercise ingestion of LGI 
or HGI. There was a significant time effect (P = 0.005, partial-eta2 = 0.601) but no effect of condition 
(P = 0.414). Data presented as mean ± SEM. Transparent sample point within a trial indicates a 
significant difference when compared to rest (P<0.05). # indicates significantly different from 0 min 
post-exercise under both conditions (P<0.05). Thatched area indicates exercise. Note: Test meal and 
insulin were administered immediately following the resting sample.
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4.3.5 Blood lactate and pH
The blood lactate responses are presented in Figure 4.4. After carbohydrate and insulin 
administration blood lactate increased from resting concentrations up to the pre-exercise 
sample under LGI (Figure 4.4). However, blood lactate under HGI remained similar to rest 
for the entire pre-exercise period (Figure 4.4). Two hours after consumption of the test meal 
the blood lactate concentration under LGI was 0.5 ± 0.1 mmol.l'1 greater than HGI (LGI 1.4 
± 0.1 vs. HGI 0.9 ± 0.03 mmol.l'1, P = 0.02; Figure 4.4). These differences disappeared with 
exercise as similar peak lactate concentrations were observed immediately after exercise 
(LGI 4.5 ± 0.4 vs. HGI 4.4 ± 0.3 mmol.l'1, P = 0.31). After exercise blood lactate 
concentrations decreased transiently, with similar declines in concentrations from 0 to 180 
minutes post-exercise between conditions (LGI A-3.7 ± 0.4 vs. HGI A-3.6 ± 0.3 mmol.l'1, P 
= 0.66). There were no differences in blood lactate concentrations between conditions over 
the post-exercise period (Figure 4.4).
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Figure 4.4: Time-course changes in blood lactate following pre-exercise ingestion of LGI or HGI. 
There was a significant time (P = 0.01, Partial-eta2 = 0.623) and treatment effect (P = 0.04, Partial-eta2 
= 0.366) and a significant time*treatment interaction (P = 0.04, Partial-eta2 = 0.221). Data are 
presented as mean ± SEM (n = 8). Transparent sample points indicate significant difference from rest 
(P<0.05). * indicates significant conditional difference (P<0.05). # indicates significantly different 
from 0 min post-exercise under both conditions (P<0.05). Thatched area indicates exercise. Note: 
Insulin and carbohydrate solution was administered immediately following resting sample.
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The blood pH responses are presented in Figure 4.5. After carbohydrate and insulin 
administration blood pH concentrations did not change from rest over the pre-exercise period 
(Figure 4.5). Exercise resulted in an increase in blood pH, however, the change with exercise 
was similar between conditions (LGI A+0.05 ± 0.01 vs. HGI A+0.06 ± 0.01, P = 0.68). 
Blood pH remained greater than rest for 30 minutes post-exercise under both conditions 
(Figure 4.5), before reaching resting levels at 60 minutes. The change in pH from 0 to 180 
min post-exercise was similar between conditions (LGI A-0.05 ± 0.01 vs. HGI A-0.03 ± 
0.01, P = 0.39).
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Figure 4.5: Time-course changes in blood pH following pre-exercise ingestion of LGI or HGI. There 
was a significant time (P = 0.01, Partial-eta2 = 0.981) but no effects of condition (P = 0.805). Data are 
presented as mean ± SEM (n = 8). Transparent sample points indicate significant difference from rest 
(P< 0.05). * indicates significant conditional difference (P<0.05). # indicates significantly different to 
0 min post-exercise under both conditions (P<0.05). Thatched area indicates exercise. Note: Insulin 
and carbohydrate solution was administered immediately following resting sample.
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4.3.6 Serum triglyceride and NEFA resp o n ses
The serum triglyceride (TG) responses to alterations in the GI of the pre-exercise 
carbohydrate are reported in Figure 4.6A. Resting TG were not statistically different between 
the conditions (LGI 1.20 ± 0.10 vs. HGI 1.03 ± 0.06 mmol.l'1). After carbohydrate 
consumption and insulin administration there were significant reductions in TG under LGI 
from rest up to 120 minutes (LGI A-0.30 ± 0.03 mmol.l'1; P = 0.01), however, TG did not 
change under HGI (LGI A-0.03 ±0.03 mmol.l'1; P = 0.78). Serum TG significantly increased 
with exercise under both conditions, with the change between conditions similar (LGI A0.24 
± 0.01 vs. HGI A0.19 ± 0.02 mmol.l'1, P = 0.47). After exercise serum TG declined over the 
three hour post-exercise period, with the change from 0 to 180 minutes similar between 
conditions (LGI A-0.16 ± 0.03 vs. HGI A0.24 ± 0.03 mmol.l'1, P = 0.49; Figure 4.6A). There 
were no conditional differences in serum TG concentrations.
The serum NEFA responses to alterations in the GI of the pre-exercise carbohydrate are 
reported in Figure 4.6B. Resting NEFA concentrations were similar (LGI 0.39 ± 0.03 vs. 
HGI 0.36 ± 0.02 mmol.l"1, P = 0.71); after carbohydrate consumption and insulin 
administration there was no change in circulating NEFA concentrations up to 120 minutes 
(LGI A-0.10 ± 0.03 vs. HGI A-0.01 ± 0.02 mmol.l'1, P>0.05). Moreover, serum NEFA 
concentrations did not increase when measured immediately after exercise (P = 0.60; Figure 
4.6B), however, 5 minutes after the cessation of exercise there was a 2-fold increase in NEFA 
concentrations under both conditions (P<0.05; Figure 4.6B), with a similar increase in 
concentrations between conditions (LGI A+0.30 ± 0.02 vs. HGI A+0.37 ± 0.02 mmol.l'1, P = 
0.36). NEFA concentrations peaked at 3 hours post-exercise (LGI 0.86 ± 0.04 vs. HGI 0.92 
±0.04 mmol.l'1, P = 0.22).
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Figure 4.6: Time-course changes in serum triglyceride (TG; A) and non-esterified fatty acids (NEFA; 
B) following pre-exercise ingestion of LGI or HGI. There was a significant time effect on both TG 
(P<0.01, Partial-eta2 = 0.45) and NEFA (P<0.01, Partial-eta2 = 0.72), however, there were no effects 
of condition (P>0.05). Data are presented as mean ± SEM (n = 8). Transparent sample points indicate 
significant difference from rest (P<0.05). # indicates significantly different from 0 min post-exercise 
under both conditions (P<0.05). Thatched area indicates exercise. Note: Insulin and carbohydrate 
solution was administered immediately following resting sample.
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4.3.7 Serum  glycerol re sp o n ses
Serum glycerol responses to alterations in the GI of the pre-exercise carbohydrate are 
presented in Figure 4.7. Resting serum glycerol concentrations were similar (LGI 12.2 ± 0.7 
vs. HGI 12.2 ± 0.4 mg.l'1, P = 0.68). After carbohydrate consumption and insulin 
administration glycerol concentrations declined up to 60 minutes under both conditions, 
however, concentrations remained similar for the remainder of the pre-exercise period under 
HGI, but continued to decline under LGI (Figure 4.7). Despite slight differences in pre­
exercise time-course changes, pre-exercise concentrations were similar between conditions (P 
= 0.09; Figure 4.7). Glycerol concentrations increased with exercise under both conditions 
(LGI A+12.5 ± 0.6 vs. HGI A+10.7 ± 0.7 mg.l'1, P = 0.46), before transiently declining over 
the post-exercise period under both conditions (Figure 4.7). The decline in glycerol 
concentrations from 0 to 180 minutes post-exercise was similar between conditions (LGI A- 
9.6 ± 0.6 vs. HGI A-8.7 ± 0.8 mg.l'1, P = 0.68).
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Figure 4.7: Time-course changes in serum glycerol following pre-exercise ingestion of LGI or HGI. 
There was a significant time effect (P<0.01; Partial-eta2 = 0.79), however, there were no treatment or 
treatment*time interactions (P>0.05). Data are presented as mean ± SEM (n = 8). Transparent sample 
points indicate significant difference from rest (P<0.05). # indicates significantly different from 0 min 
post-exercise under both conditions (P<0.05). Thatched area indicates exercise. Note: Insulin and 
carbohydrate solution was administered immediately following resting sample.
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4.3.8 Patterns of carbohydrate and lipid oxidation
The carbohydrate and lipid oxidation rates during rest are presented in Table 4.3 and 
oxidation rates during exercise are presented in Table 4.3 and Figure 4.8A. There were no 
conditional differences in resting rates of carbohydrate (P = 0.36) or lipid oxidation (P = 0.34; 
Table 4.3). When expressing oxidation rates as changes from rest, there was a tendency for a 
lower carbohydrate oxidation rate under LGI (P = 0.08) with a concomitant greater rate of 
lipid oxidation (P = 0.03; Table 4.3) when compared with HGI. As exercise progressed, there 
was a lower CHO and greater lipid oxidation rate, such that by the last 10 minutes 
carbohydrate and lipid oxidation rates were significantly different under LGI compared to 
HGI, respectively (Figure 4.8B).
Table 4.3: Substrate oxidation responses, at rest and during exercise, following pre-exercise ingestion 
o f  LG I or HGI.
Rest Exercise
LGI HGI LGI HGI
CHO (g .m in 1) 0.38 ±  0.02 0.34 ± 0 .01 2.90 ± 0.06* 3.08 ± 0 .0 6 *
Lipids (g.min'1) 0.06 ±0.01 0.08 ± 0 .01 0.22 ± 0 .03* 0.16 ± 0 .0 3 *
ACHO (g.min'1) - - 2.52 ±  0.04* 2.74 ±  0.05*
ALipids (g.min"1) - - 0.23 ±  0.03*f 0.09 ±  0.02*
Data presented as means ± SEM (n = 8). * indicates a significant increase when compared with rest (P<0.05). f 
indicates difference to HGI (P<0.05).
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Figure 4.8: (A) Carbohydrate and lipid oxidation rates during 45 minutes of exercise after pre-exercise ingestion 
of LGI or HGI. (B) Carbohydrate and lipid oxidation rates over the final 10 minutes of exercise. Data are 
presented as mean ± SEM (n = 8). * indicates significant differences between LGI and HGI (P<0.05).
The energy expended in both trials was similar (LGI 2.67 ± 0.04 vs. HGI 2.63 ± 0.04 MJ, P 
= 0.41) with energy from carbohydrates similar between the conditions (LGI 2.18 ± 0.04 vs. 
HGI 2.32 ± 0.05 MJ, P = 0.13) and energy from lipids tending to be greater under LGI (LGI 
0.49 ± 0.05 vs. HGI 0.31 ± 0.04 MJ, P = 0.06). There was a tendency for a lower percentage 
contribution to total energy expenditure from carbohydrate (LGI 83 ± 2 vs. HGI 89 ± 2 %, P 
= 0.07) and greater contribution from lipids (LGI 17 ± 2 vs. HGI 11 ± 2 %, P = 0.07) under 
LGI.
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4.3.9 Post-laboratory activity and self-recorded glycaem ia and dietary intake
There were no differences between conditions in any of the variables collected over the 21 
hour post-laboratory period (Table 4.4). There were no conditional differences in the 
percentage contribution to total energy from carbohydrate (LGI 52 ± 1.5; HGI 49 ± 1.7 %; 
P>0.05), protein (LGI 19 ± 0.6; HGI 20 ± 0.6 %; P>0.05) or fats (LGI 37 ± 4.2; HGI 33 ± 
1.8 %; P>0.05). There were 2 incidents of both low blood glucose (both 6 hours post 
laboratory) and hypoglycaemia (19 and 14 hours post-exercise) under HGI and 1 low blood 
glucose (19 hours post-laboratory) and 3 hypoglycaemic incidents under LGI (5, 16 and 19 
hours post-laboratory).
Table 4.4: Twenty-one hour post-laboratory blood glucose, dietary intake and activity patterns.
Condition
Variable HGI LGI P
BGauc (mmol. I'1. hour"1) 7.7 ±0.3 7.0 ±0.3 0.31
CHO intake (g) 164 ± 10 193 ± 9 0.47
Protein intake (g) 62 ± 3 71 ± 3 0.48
Fat intake (g) 52 ± 5 46 ± 4 0.63
Energy intake (MJ) 5.7 ±0.3 6.1 ±0.3 0.70
Rapid-acting insulin (U) 19.8 ± 1.4 21.1 ± 1.4 0.23
Frequency BG < 4.0 mmol.l'1 2 1 -
Frequency BG <3.5 mmol.l'1 2 3 -
Average heart rate (bpm) 76 ± 1 78 ± 1 0.73
Average steps taken 6197 ±578 6295 ± 427 0.94
Data presented as mean ± SEM (n = 8).
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4.4 D iscussion
We compared the metabolic and glycaemic responses to ingestion of either a high GI or low 
GI carbohydrate before, during and after running in T1DM. The results demonstrate that 
compared to HGI, LGI increased blood glucose concentrations less before exercise and 
maintained blood glucose better for 24 hours after running. Furthermore, carbohydrate 
oxidation was reduced and lipid oxidation increased following LGI ingestion, during the 
latter stages of running.
There was a smaller increase in blood glucose under LGI compared to HGI in the pre­
exercise period. Blood glucose concentrations increased above resting values by A+8.7 ± 0.5 
mmol.l'1 under HGI, whereas blood glucose increased to just half of this under LGI (A+4.5 ± 
0.4 mmol.l'1). The hydrolysation rate of LGI (isomaltulose) is very slow and only 20-25% of 
that of sucrose (Gunther and Heymann, 1998). Thus, the slow hydrolysation of LGI, into 
glucose and fructose, and subsequent absorption at the brush border membrane within the 
gastro-intestinal passage explains the later and lower peak in blood glucose in comparison 
with HGI (Lina et al., 2002). HGI can quickly cross via SGLT1 (sodium-glucose transporter 
1), and can rapidly increase blood glucose concentrations (Figure 4.2). The reduced post­
prandial glucose excursions under LGI prevented blood glucose reaching hyperglycaemic 
concentrations, as opposed to HGI. This is an important finding as maintaining glycaemia 
close to euglycaemic concentrations is the fundamental component in the management of 
T1DM (Cryer et al., 2003), especially when incorporating physical exercise into the lives of 
T1DM individuals.
There were greater lactate concentrations under LGI in the pre-exercise period (Figure 4.4). 
LGI (isomaltulose) is digested via the same sucrase/isomaltase complex, within the gastro­
intestinal passage, as sucrose (Goda and Hosoya, 1983). During this process, within the
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cytosol of the small intestine, some fructose derived from LGI is converted to lactate, 
however; most is metabolised within the liver (Ahlborg and Bjorkman, 1990). As fructose 
bypasses the phosphofructokinase regulatory point in glycolysis, there is an increased flux 
through the glycolytic pathway which results in an increased formation and subsequent 
release of lactate (Kaye et al., 1958; Sahebjami and Scalettar, 1971).
As exercise progressed there was a significantly lower carbohydrate oxidation rate evident 
under LGI, compared to HGI. This reduced carbohydrate oxidation rate under LGI, may, in 
part, be due to differences in blood glucose concentrations before and during exercise. Two 
hours following ingestion, blood glucose concentrations under LGI were near 
hyperglycaemic (12.2 ± 0.5 mm ol.l1), whereas those under HGI were ~ 3 mmol.l'1 greater at 
the beginning of exercise. This may have limited substrate oxidation to predominantly 
carbohydrates (Jenni et al., 2008). Jenni et al. (2008) demonstrated that when T1DM 
individuals perform prolonged exercise under blood glucose concentrations clamped at 11 
mmol.l'1 fuel metabolism was dominated by carbohydrate oxidation with concomitantly 
lower rates of lipid oxidation, compared with a euglycaemia condition; an effect due to the 
mass action of elevated blood glucose concentrations (Coyle et al., 1997). As blood glucose 
dropped A-4.4 ± 0.4 mmol.l1 with exercise under LGI, the blood glucose concentrations in 
the later stages of running returned to euglycaemic conditions sooner when compared to 
HGI, suggesting a lesser effect of high blood glucose concentrations in promoting 
carbohydrate combustion, and increasing the likelihood of observing differences in substrate 
oxidation in the latter stages of exercise.
As exercise progressed there was a greater lipid oxidation during exercise under LGI, in 
comparison with HGI, which became significantly greater during the final 10 minutes of 
exercise. Similar findings have been reported previously by Trenell et al. (2008) who found
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low GI, pre-exercise, carbohydrate-based meals increased lipid oxidation by 10 % during 90 
minutes of cycling at 70%VC>2max, in comparison to isoenergetic, high GI carbohydrate 
meals. Within our study, the increase in the combustion of lipids, with time, is possibly due to 
an increased mobilisation of intramuscular triglyceride stores, as NEFA concentrations did 
not differ between conditions. A potential mechanism behind the differences in lipid 
oxidation demonstrated in the latter stages of exercise may be related to differences in blood 
glucose concentrations between the conditions (Coyle et al., 1997). Coyle et al. (1997) 
investigated lipid oxidation, during 40 minutes of cycling at 50% V02peak in non-TlDM 
individuals, in a fasted state or having consumed 1.4 g/kg body mass of glucose. An 
examination of substrate oxidation revealed that an increased glucose availability and an 
increased glycolytic flux, and ultimately carbohydrate oxidation, directly suppresses lipid 
metabolism. Relating the findings of Coyle and colleagues to our study, the bolus of HGI 
ingested prior to exercise may have caused a similar suppression of lipid oxidation during 
exercise. Moreover, combining an increase in skeletal muscle hormone sensitive lipase 
activity (Watt et al., 2003) and lower glucose availability under LGI may have provided a 
milieu where the oxidation of intramuscular NEFAs was not as suppressed, compared to 
HGI, during exercise. Serum non-esterified fatty acid concentrations did not change with 
exercise; an effect likely the result of a reduction in adipose tissue blood flow, with exercise 
intensities >70% VC>2max, reducing the removal of NEFA (Jones et al., 1980; Romjin et al., 
1995). A redistribution of blood flow to adipose tissue is also the likely mechanism behind 
the rapid rise in NEFA concentrations after the cessation of exercise (Romijn et al., 1995).
Post-exercise glycaemia was lower under LGI, compared with HGI, with B G auc  and mean 
blood glucose being 21 ± 3 % and 3.0 ± 0.4 mmol.l"1 lower, respectively, over the three hour 
recovery period. There were similar changes in blood glucose within each condition. The
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preservation of blood glucose might potentially be due to exercise-induced increases in 
skeletal lipoprotein lipase activity (Kiens et al., 1989), increasing triglyceride breakdown and 
NEFA availability. Furthermore, the similar concentrations of counter-regulatory hormones 
may help explain the similar preservation of blood glucose with time, across conditions. 
From a T1DM individuals perspective this is important, as avoiding high blood glucose 
concentrations following exercise is not only beneficial for improved glycaemic control, but 
may also help avoid the occurrence of hypoglycaemia, as individuals are less likely to have to 
administer corrective insulin units, which in a post-exercise insulin-sensitised state could 
cause unexpected falls in blood glucose. Both types of carbohydrate were equally effective at 
preventing hypoglycaemia over the 3 hour recovery period, with two episodes under each 
condition. Despite the increased appearance of lactate under LGI during the pre-exercise 
period, the conditional differences in this metabolite were not evident after running was 
completed. Potentially, greater lactate concentrations under LGI resulted in lactate being 
channelled into oxidative pathways within the heart (Gertz et al., 1988) and the active 
musculature (Mazzeo et al., 1986), and/or hepatic gluconeogenesis (Ahlborg and Felig, 
1982).
When leaving the laboratory blood glucose was near euglycaemic under LGI (~8 mmol.f1) 
and still elevated under HGI (~11 mmol.l'1). However, despite this there were no statistical 
differences in 21 hour post-laboratory period B G a u c , carbohydrate intake or insulin 
administration. Moreover, there were similar incidences of low blood glucose and 
hypoglycaemia under both conditions. Potentially, there was an elevated blood glucose 
uptake under HGI in comparison with LGI, due to lower post-exercise glycogen stores under 
HGI. Jenni et al. (2008) demonstrated that T1DM individuals elicit an increased 
intramuscular glycogen breakdown rate when exercising under hyperglycaemic conditions.
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Potentially, as the exercise bout under HGI was under hyperglycaemic concentrations and 
was fuelled predominantly by carbohydrate oxidation (Coyle et al., 1991), blood glucose 
uptake to restore muscle glycogen stores may have been elevated under HGI; consequently 
resulting in a gradual reduction in blood glucose concentrations over the post-laboratory 
period. Additionally/conversely, participants were administering ~1 IU of insulin per 10 g of 
carbohydrates; however, ~20 IU were administered with ~164 g of carbohydrates under HGI. 
Potentially some participants applied corrective insulin units under the HGI condition to 
return glycaemia to normal.
In conclusion, this study examined the effects of consuming a low GI and high GI 
carbohydrate on metabolic and glycaemic responses before, during and for 24 hours after 
running in T1DM individuals. These data demonstrate that consuming a low GI carbohydrate 
improves blood glucose responses during and after exercise through reduced carbohydrate 
and increased lipid oxidation during exercise. Regularly employing this strategy could be 
beneficial for long-term glycaemic control within exercising T1DM individuals.
141
Chapter Five
The metabolic and glycaemic effects of 
alterations in the pre-exercise timing of 
carbohydrate and insulin administration.
142
5.1 Introduction
Individuals with type 1 diabetes (T1DM) are encouraged to engage in aerobic exercise due to 
the potential to improve long-term glycaemic control, i.e. reduce their HbAjc percentage 
(Sideraviciute et al., 2006), however, impaired gluco-regulatory responses results in an 
increased risk of hypoglycaemia during and after exercise. Hypoglycaemia, during or after 
exercise, is a major concern for individuals with T1DM (Brazeau et al., 2008). Current 
strategies to help combat the heightened risk of hypoglycaemia, associated with exercise, 
focus on reductions in insulin dose (De Feo et al., 2006; Rabasa-Lhoret et al., 2001;) as well 
as pre-exercise carbohydrate consumption (De Feo et al., 2006; Hibbert-Jones and Regan, 
2005).
The type of carbohydrate consumed before performing exercise may be an important factor in 
blood glucose responses to exercise, within T1DM. Carbohydrates with a low glycaemic 
index (LGI) digest at slower rates than high glycaemic index (HGI) carbohydrates and are 
unable to cross the mucosal cell membrane within the small intestine and enter the 
bloodstream unless hydrolysed into monosaccharides (Southgate, 1995). Research has 
established the importance of including LGI carbohydrates into the daily diets of T1DM, with 
observed benefits such as lower daily mean blood glucose (Nansel et al., 2008) and reduced 
incidence of hypoglycemia and reductions in HbAic (Gilbertson et al., 2001; Thomas et al., 
2007). As demonstrated within chapter 4, peak blood glucose responses were twice as great 
after consumption of a HGI carbohydrate in comparison with a LGI carbohydrate (Figure 4.2; 
moreover, blood glucose area under the curve was 21 % lower after a LGI carbohydrate for 3 
hours post-exercise. Therefore, a low GI carbohydrate source may be beneficial for 
maintaining blood glucose within normal ranges after exercise.
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Another important factor in preserving post-exercise blood glucose concentrations is reducing 
insulin dose prior to exercise. Within the research examining pre-exercise insulin reductions 
on blood glucose concentrations following exercise, results have demonstrated improved 
glucose concentrations following reductions of 10-40% (De Feo et al., 2006), 10-50% 
(Grimm, 2005), 50-90% (Mauvais-Jarvis et al., 2003) and 50-75% (Rabasa-Lhoret et al., 
2001; findings of chapter 3). Much of the variation in these findings can be attributed to 
differences in the insulin regimen used by participants, e.g. regular/Neutral Protamine 
Hagedom insulin (Mauvais-Jarvis et al., 2003) or Ultralente with prandial insulin lispro 
(Rabasa-Lhoret et al., 2001). The choice of insulin species is important when examining 
blood glucose responses to reductions in insulin. The rDNA insulins currently available (e.g. 
insulin aspart/lispro) offer very different, more favourable, action-time profiles and less 
variability than longer established insulins, such as regular human insulin (Brange and 
Volund, 1999; Tuominen et al., 1995). These insulin analogues are structured such that they 
remain in the monomeric form (i.e. the form that diffuses across the capillary wall into 
circulation) at the subcutaneous injection site, and have a lesser tendency to convert into 
dimmers and hexamers (Brange and Volund, 1999). As a result these insulins elicit intense 
and rapid increases in insulin concentrations, taking peak effect just 45 -  60 minutes after 
administration (Plank et al., 2002). It is for these reasons that it is currently recommended to 
avoid administration of rapid-acting insulin within 90-120 minutes of exercise due to the risk 
of over-insulinisation of the active musculature during exercise (De Feo et al., 2006; Perry 
and Gallen, 2009). However, with current research demonstrating improved blood glucose 
concentrations with reductions in rapid-acting insulin dose by 75% (Rabasa-Lhoret et al., 
2001; findings of chapter 3), there is potential that low doses of insulin administered within 
90-120 minutes of exercise may not increase the risk of developing hypoglycaemia during or 
after exercise.
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At present, to our knowledge, there is no literature that has examined the metabolic effects of 
alterations in the timing of a combined LGI carbohydrate and reduced rapid-acting insulin 
strategy before exercise. In light of this, the aim of this study was to examine metabolic and 
glycaemic responses to alterations in the timing of a combined LGI carbohydrate and insulin 
reduction strategy before, during and for 24 hours following running in individuals with 
T1DM.
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5.2 M ethods
Seven participants with T1DM (7 males, 31 ± 2 years, BM1 26 ± 0.3 kg/m ) with a duration 
of diabetes of 19 ± 2 years and HbAic of 8.3 ± 0.1 % volunteered to participate in this study. 
Individual participant anthropometric (Table 2.5), glycaemic control (Table 2.8), and insulin 
regimen characteristics (Table 2.4) are presented in chapter 2.
After preliminary testing (Table 2.6) participants attended the laboratory on four occasions 
after an overnight fast and having consumed similar evening meals prior to each trial. Upon 
arrival participants received catheterisation in their non-dominant arm and blood samples 
were processed for glucose, lactate, pH, adrenaline, noradrenaline, cortisol, p- 
hydroxybutyrate, triglycerides and non-esterified fatty acids (section 2.3.5). Participants were 
then required to consume 75 g of a low GI carbohydrate (Isomaltulose; GI 32; findings from 
chapter 4), mixed with 750 ml of water (10 % solution, Perrone et al., 2005). Immediately 
before ingestion, participants were instructed to administer their rapid-acting insulin, which 
had been reduced by 75 % (2.1 ± 0.1 IU) into the abdomen (Rabasa-Lhoret et al., 2001; 
findings from chapter 3). After carbohydrate and insulin administration participants remained 
at rest for 120 (120min), 90 (90min), 60 (60min) or 30 minutes (30min) before completing 
45 minutes of running at 71 ± 1% VC^ peak- Blood samples were taken every 30 minutes in the 
pre-exercise period and for three hours post-exercise (Figure 5.1). Cardio-respiratory 
parameters were collected at rest and during exercise.
Participant activity and heart rate were recorded for 24 hours after exercise; moreover, for 21 
hours after leaving the laboratory participants self-recorded blood glucose, dietary intake, 
insulin administration and hypoglycaemic incidences.
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DIET---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- <,-----------------►
INSULIN-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------«-----------------►
Figure 5 .1 : Schematic diagram of the experimental protocol of chapter 5 . N o te :  Double line indicates 
changes in pre-exercise sample point.
5.2.1 Data Analysis
Statistical analysis was performed using SPSS software (version 16; SPSS Inc., Chicago, IL), 
with significance set at P<0.05. Data were tested for normal distribution (Shapiro-Wilk test) 
and subsequently analysed using repeated-measures ANOVA on two factors (treatment x 
time) with Bonferroni adjustment and dependent t-tests carried out where relevant. Blood 
glucose area under the curve ( B G a u c )  was calculated using the method of Wolever and 
Jenkins (1988) and subsequently time averaged. Data are presented as mean ± SEM.
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5.3 R esults
5.3.1 Physiological re sp o n ses  to  exercise
The physiological responses to the trials are presented in Table 5.1. Resting rates of oxygen 
consumption and CO2 production were significantly greater under 30min, when compared to 
all other trials (Table 5.1). There were no differences in the resting rates of oxygen 
consumption or carbon dioxide production across 120min, 90min and 60min (P>0.05; Table 
5.1).
Participants exercised at a similar exercise intensity with similar %V02peak (120min 72 ± 3; 
90min 70 ± 5; 60min 71 ± 7; 30min 71 ± 8 %V02peak; P = 0.62) and HRpcak (120min 81 ± 4; 
90min 82 ± 4; 60min 82 ± 4; 30min 83 ± 4 %HRpeak; P = 0.59) elicited across trials.
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5.3.2 Blood g lucose resp o n ses
The absolute and relative blood glucose responses are presented in Table 5.2 and Figure 5.2. 
Pre-exercise responses are reported in Table 5.2. Fasted blood glucose concentrations were 
similar between conditions (P = 0.23; Table 5.2). After consumption of the LGI carbohydrate 
there were increases in blood glucose under all conditions, with immediate pre-exercise 
values lowest under 30min (30min A+2.8 ± 0.2; 60min A+3.9 ± 0.2; 90min A+4.3 ± 0.2; 
120min A+4.1 ± 0.6 mmol.T1; Figure 5.2; Table 5.2); concentrations under 30min were only 
statistically different to 120min and 90min (P<0.05; Figure 5.2B).
On average, the drop in blood glucose with exercise was least under 30min (30min 3.7 ± 0.4 
vs. 60min 5.0 ± 0.7; 90min 5.4 ± 0.5; 120min 6.4 ± 0.3 mmol.T1), however, only 30min and 
120min were statistically different (P = 0.02). When looking at the participants blood glucose 
responses to exercise individually, five of seven elicited the lowest drop in BG under 30min.
In the 3 hour post-exercise period blood glucose concentrations were greater under 30min
and 60min, when compared to 120min (Figure 5.2B). However, these differences were only
significant for 60 minutes post-exercise (Figure 5.2B). Blood glucose concentrations
significantly increased from 0 to 60 minutes under both 30min and 60min (Figure 5.2), with
the change under 30min greater (30min A+3.1 ± 0.2 vs. 60min A+1.7 ± 0.3 mmol.T1, P =
0.02). Blood glucose concentrations under both 90min and 60min remained similar to 0
minutes under both conditions (Figure 5.2). Mean post-exercise blood glucose was lowest
under 120min, in comparison all other trials (120min 5.9 ± 0.5 vs. 90min 7.6 ± 0.3; 60min
10.1 ± 0.6; 30min 9.0 ± 0.5 mmolT'1; P<0.05). Blood glucose area under the curve (BGAuc)
for the 3 hour post-exercise period under 120min and 90min were lower than 60min and
30min (120min 6.0 ± 0.5; 90min 7.0 ± 0.3 vs. 60min 9.4 ± 0.6; 30min 7.8 ± 0.5 mmol.T
’.hour1; P<0.05); B G a u c  under 60min and 30min were not different (P = 0.32).
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Figure 5.2: Time-course changes in blood glucose after alterations in the pre-exercise timing of carbohydrate 
and insulin administration, presented as absolute concentrations (A) and relative to rest (B). Under both absolute 
and relative concentrations there was a significant time effect (P = 0.001, partial-eta2 = 0.794) and a significant 
time*condition interaction (P = 0.002, partial-eta2 = 0.307). Data presented as mean ± SEM. * indicates 
significantly different from 60min and 30min at the respective time point (P<0.05). f  indicates different to 
120min and 90min at the respective time point (P<0.05). Transparent sample points indicate significant change 
from 0 min post exercise (P<0.05). Thatched area indicates exercise.
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Hypoglycaemia
There were no hypoglycaemic occurrences under 30min, however, there was 1 under 60min 
(60 minutes post-exercise), 2 under 90min (1 at 30 and 1 at 120 minutes post-exercise) and 5 
under 120min (1 at 5, 1 at 30 and 3 at 60 minutes post-exercise).
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5.3.3 Serum  insulin resp o n ses
The serum insulin responses are presented in Table 5.2 and Figure 5.3. There were no 
differences in fasting serum insulin concentrations across conditions (Table 5.2). There were 
significant increases in serum insulin concentrations after administration of the rapid-acting 
dose with the change from rest to pre-exercise similar across conditions (120min A+25 ± 3; 
90min A+18 ± 3; 60min A+27 ± 6; 30min A+20 ± 5 pmol.l"1; P>0.05; Table 5.2). Moreover, 
there were no significant changes in serum insulin concentrations between 30 minutes post­
administration and the pre-exercise sample under 120min, 90min and 60min (120min A+5 ± 
2; 90min A+6 ± 3; 60min A+13 ± 7 pmol.l'1; P>0.05).
Serum insulin concentrations significantly increased with exercise under all conditions, with 
the change under 120min and 90min significantly greater than the changes under 60min and 
30min (120min A+83 ± 7; 90min A+81 ± 12 vs. 60min A+49 ± 9; 30min A+48 ± 3 pmol.l'1, 
P<0.05); changes within 120min and 90min were similar (P = 0.52), moreover, the changes 
within 60min and 30min were also similar (P = 0.62).
In the three hour post-exercise period serum insulin concentrations followed similar time- 
course changes under each condition (Figure 5.3). However, the change in concentrations 
from 0 to 180 minutes was greater under 120min and 90min, in comparison with 30min 
(120min A-101 ± 9; 90min A-107 ± 9 vs. 30min A-69 ± 6 pmol.l'1, P<0.05); changes under 
60min were not statistically different to all other trials (60min A-78 ± 16, P>0.05).
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Table 5.2: Pre-exercise blood glucose and serum insulin responses, in absolute concentrations and 
changes (A) from rest, to alterations in the pre-exercise timing of carbohydrate and insulin 
administration.
Sample Point
Trial Variable Rest 30 60 90 120
120min BG (mmol.l1) 7.9 ± 0.4 10.7 ±0.5* 11.9 ±0.7* 12.4 ±0.7* 12.0 ±0.8*
ABG - 2.8 ± 0.2* 4.1 ±0.4* 4.5 ±0.5* 4.1 ± 0.6*
Serum insulin (pmol.l1) 114 ± 6 134 ±7* 128 ±8* 129 ±5* 139 ±7*
ASerum insulin - 20 ±3* 14 ±3* 15 ±2* 25 ±3*
90min BG (mmol.l1) 8.9 ± 0.4 11.4 ±0.4* 12.9 ±0.4* 13.2 ±0.4*
ABG - 2.5 ± 0.2* 4.1 ±0.2* 4.3 ± 0.2*
Serum insulin (pmol.l1) 123 ± 7 135 ±5* 133 ±4* 141 ±6*
ASerum insulin - 12 ±4* 10 ±5* 18 ± 3*
60min BG (mmol.l1) 10.3 ±0.7 12.7 ±0.8* 14.2 ±0.9*
ABG - 2.3 ±0.1* 3.9 ±0.2*
Serum insulin (pmol.l1) I l l  ± 8 126± 14* 139 ±9*
ASerum insulin - 14 ± 10* 27 ±6*
30min BG (mmol.l1)
ABG
Serum insulin (pmol.l1) 
ASerum insulin
9.4 ± 0.6 
107 ± 8
12.2 ± 0.6* 
2.8 ±0.2* 
127 ±11* 
20 ±5*
Data presented as mean ± SEM (N = 7). * indicates difference when compared to rest (P<0.05).
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Figure 5.3: Time-course changes in serum insulin, relative to rest, after alterations in the pre-exercise 
timing of carbohydrate and insulin administration. There was a significant time effect (P = 0.009, 
partial-eta2 = 0.627) however, there were no significant time*condition interactions (P = 0.354). Data 
presented as mean ± SEM. Transparent sample points indicate significant change from 0 min post 
exercise (P<0.05). Thatched area indicates exercise.
155
5.3.4 Counter-regulatory hormonal re sp o n ses
There were no conditional effects on any of the counter-regulatory hormonal responses to the 
trials (Table 5.3). Moreover, there were no differences in fasting concentrations of all 
measured counter-regulatory hormones (Table 5.3).
There were changes with time (P = 0.001, partial-eta2 = 0.778), however no effects of 
condition (P = 0.62) on the plasma adrenaline response. Plasma adrenaline peaked at 0 
minutes post-exercise (Table 5.3), with no differences in peak concentrations across 
conditions (P = 0.47). Moreover, the change in concentrations from rest to 0 minutes post­
exercise was greatest under 120min, however, there were no significant differences across 
conditions (120min A+1.15 ± 0.16; 90min A+1.07 ± 0.23; 60min A+0.90 ± 0.16; 30min 
A+0.64 ±0.11 nmol.T1, P = 0.13). Plasma adrenaline concentrations were greatest under 
120min at 60 and 180 minutes post-exercise under all conditions, however were not 
significantly different to the other conditions; moreover at 180 minutes, concentrations were 
not different to rest under 90min, 60min, and 30min, but remained elevated under 120min 
(Table 5.3). The change over the 3 hour post-exercise period was similar across conditions 
(120min A-1.47 ± 0.17; 90min A-1.76 ± 0.22; 60min A-2.48 ± 0.13; 30min A-1.24 ± 0.15 
nmol.l'1, P>0.05).
There was a significant time effect (P = 0.01, Partial-eta2 = 0.781) but no effect of condition
(P = 0.28) on the plasma noradrenaline response. Plasma noradrenaline peaked at 0 minutes
post-exercise (Table 5.3), with peak concentrations similar across conditions (P = 0.22).
Moreover, the change in concentrations from rest to 0 minutes post-exercise was similar
between conditions (120min A+2.79 ± 0.07; 90min A+2.28 ± 0.19; 60min A+2.09 ± 0.18;
30min A+2.35 ± 0.46 nmol.l'1, P>0.05). Plasma noradrenaline concentrations were similar at
60 and 180 minutes post-exercise under all conditions; moreover at 180 minutes,
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concentrations were not different to rest under 90min, 60min, and 30min, but remained 
elevated under 120min (Table 5.3). The change over the 3 hour post-exercise period was 
similar between conditions (120min A-1.39 ± 0.10; 90min A-1.57 ± 0.18; 60min A-1.16 ± 
0.18; 30min A-1.53 ± 0.47 nmol.l'1, P>0.05).
There was a significant time effect (P = 0.002, Partial-eta = 0.784) but no effect of condition 
(P = 0.44) on the serum cortisol response. Cortisol did not rise with exercise; however, 
concentrations began to increase significantly immediately following exercise, peaking at 15 
minutes post-exercise. Peak cortisol concentrations at 15 minutes (Table 5.3) were not 
different from rest but were greater than 0 minutes post-exercise, under all conditions. 
Concentrations decreased with time under all conditions with similar concentrations at 60 
minutes post-exercise (Table 5.3). At 180 minutes post-exercise serum cortisol concentrations 
were significantly lower than rest (Table 5.3) under all conditions (P<0.05; Table 5.3). 
Moreover, the change in concentrations from peak to 180 minutes were similar between 
conditions (120min A-281 ± 21; 90min A-277 ± 21 ; 60min A-332 ± 23; 30min A330 ± 27 
nmol.l'1, P>0.05).
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Table 5.3: Counter-regulatory hormonal responses to alterations in the pre-exercise timing of
carbohydrate and insulin administration.
Sample Point
Trial Rest 0 15 60 180
120min 1.33 ±0.11 2.47 ±0.15* - 1.17 ± 0.10 1.00 ±0.09*
Adrenaline (nmol.l1) 90min 1.22 ±0.14 2.29 ±0.19* - 0.93 ±0.07 0.61 ±0.0560min 1.96 ±0.14 2.86 ±0.14* - 0.84 ± 0.03 0.38 ±0.03
30min 1.17 ± 0.10 1.81 ±0.11* - 0.65 ± 0.05 0.38 ± 0.07
120min 0.90 ± 0.09 3.79 ±0.09* - 1.64 ±0.14 2.30 ±0.15*
Noradrenaline (nmol.l'1) 90min60min
1.15 ± 0.10 
0.51 ±0.06
3.48 ±0.21* 
2.61 ±0.17*
- 1.81 ±0.14 
0.98 ± 0.06
1.86 ±0.12 
1.45 ±0.17
30m in 0.89 ± 0.09 3.77 ± 0.48* - 1.21 ±0.14 1.71 ±0.12
120min 560 ± 10 496 ± 18 579 ±16f 378± 12* 215 ±128f
Cortisol (nmol.l1)
90min 540 ± 20 533 ±29 598 ± 35f 419 ±24* 275 ±12*t
60 m in 497 ±21 532 ± 23 590±21f 395 ±14* 200 ± 7*t
30min 580 ± 17 592 ± 19 617 ±17f 414 ± 8* 263 ±16*t
Data presented as mean ± SEM (N = 7). * indicates significantly different from rest (P<0.05). f indicates
significantly different from 0 min post-exercise (P<0.05).
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5.3.5 Serum  p-hydroxybutyrate re sp o n ses
The serum p-hydroxybutyrate responses are presented in Table 5.4 and Figure 5.4. There 
were small declines from rest to pre-exercise under all conditions (120min A-0.05 ± 0.01; 
90min A-0.08 ± 0.01; 60min A-0.06 ± 0.01; 30min A-0.02 ± 0.01 mmol.l'1), however, only 
under 120min, 90min and 60min was the decline significant (P<0.05; Table 5.4). p~ 
hydroxybutyrate concentrations did not change with exercise under any condition (P>0.05; 
Figure 5.4), however, there was a transient increase in concentrations over the three hour 
recovery period, with concentrations at 120 minutes only greater than rest and 0 post-exercise 
under 120min (Figure 5.4). At 180 minutes, concentrations were significantly greater than 
both rest and 0 minutes post-exercise under all conditions (P<0.05; Figure 3). The change 
from 0 to 180 minutes post-exercise was similar across conditions (120min A+0.07 ± 0.013; 
90min A+0.13 ±0.015; 60min A+0.09 ± 0.019; 30min A+0.07 ±0.015 mmol.l'1; P>0.05).
Table 5.4: Pre-exercise serum P-hydroxybutyrate (P-OHB) responses to alterations in the pre-exercise 
timing of carbohydrate and insulin administration.
Sample Point
Trial Variable Rest 30 60 90 120
120min p-OHB (mmol.l1) 0.09 ± 0.006 0.10 ±0.009 0.06 ±0.003* 0.06 ±0.03* 0.04 ±0.002*
90min P-OHB (mmol.l*1) 0.13 ±0.013 0.07 ± 0.006* 0.05 ± 0.004* 0.04 ±0.003*
60min p-OHB (mmol.l*1) 0.13 ±0.009 0.11 ±0.007* 0.08 ±0.005*
30min p-OHB (mmol.l*1) 0.15 ±0.012 0.13 ±0.014
Data presented as mean ± SEM (N = 7). * indicates significantly different from rest (P<0.05).
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Figure 5.4: Time-course changes in serum P-hydroxybutyrate after alterations in the pre-exercise 
timing of carbohydrate and insulin administration. There was a significant time effect (P = 0.002, 
Partial-eta2 = 0.646) but no effect of condition (P = 0.569). Data are presented as mean ± SEM (n = 
7). Transparent sample points indicate significant difference from 0 min post-exercise (P<0.05). 
Thatched area indicates exercise.
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5.3.6 Blood lactate and pH re sp o n ses
The blood lactate responses are presented in Table 5.5 and Figure 5.5. There were no 
differences in fasting blood lactate and pH across conditions (Table 5.4). After carbohydrate 
and insulin administration blood lactate increased from resting concentrations at 90 minutes 
post-ingestion under both 90min and 120min (Table 5.5). However, remained unchanged 
under 60min and 30min (Table 5.5). Pre-exercise concentrations were lowest under 30min, 
however, were not statistically different to the other trials (P>0.05; Figure 5.5). Blood lactate 
increased with exercise under all conditions, peaking at 0 minutes post-exercise (120min 3.0 
± 0.3; 90min 3.9 ± 0.7; 60min 3.2 ± 0.3; 30min 2.9 ± 0.3 mmol.l'1; P>0.05), the change with 
exercise was similar between conditions (120min A+1.6 ± 0.3; 90min A+2.7 ± 0.7; 60min 
A+1.8 ± 0.4; 30min A+2.1 ± 0.3 mmol.l'1; P>0.05). After exercise blood lactate 
concentrations decreased transiently, with similar declines in concentrations from 0 to 180 
minutes post-exercise between conditions (120min A-2.2 ± 0.3; 90min A-3.1 ± 0.7; 60min A- 
2.5 ± 0.4; 30min A-2.2 ± 0.3 mm ol.l1; P = 0.57; Figure 5.5).
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Figure 5.5: Time-course changes in blood lactate after alterations in the pre-exercise timing of 
carbohydrate and insulin administration. There was a significant time effect (P = 0.01, Partial-eta2 = 
0.420) but no effect of condition (P = 0.79). Data are presented as mean ± SEM (n = 7). Transparent 
sample points indicate significant difference from 0 min post-exercise (P< 0.05). Thatched area 
indicates exercise.
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The blood pH responses are presented in Table 5.5 and Figure 5.6. After carbohydrate and 
insulin administration blood pH concentrations did not change from rest over the pre-exercise 
period under all conditions (Table 5.5). Exercise resulted in an increase in blood pH, 
however, the change with exercise was similar across conditions (120min A+0.07 ± 0.01; 
90min A+0.01 ± 0.02; 60min A+0.04 ±0.01; 30min A+0.04 ±0.01; P>0.05). Over the post­
exercise period, there were no differences in blood pH responses between conditions; at 180 
minutes post-exercise blood pH was similar across conditions (Figure 5.6). The change from 
0 to 180 minutes post-exercise was similar across conditions (120min A-0.06 ± 0.01; 90min 
A+0.01 ± 0.02; 60min A-0.04 ± 0.01; 30min A-0.03 ± 0.01; P = 0.51).
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Figure 5.6: Time-course changes in blood pH after alterations in the pre-exercise timing of carbohydrate and 
insulin administration. There was a significant time effect (P = 0.002, Partial-eta2 = 0.397) but no effect of 
condition (P = 0.518). Data are presented as mean ± SEM (n = 7). Transparent sample points indicate significant 
difference from 0 min post-exercise (P<0.05). Thatched area indicates exercise.
Table 5.5: Pre-exercise blood lactate and pH responses to alterations in the pre-exercise timing of 
carbohydrate and insulin administration.
Sample Point
Trial Variable Rest 30 60 90 120
120min Lactate (mmol.l'1) 0.7 ± 0.02 1.0 ±0.05 1.3 ±0.07 1.4 ±0.04* 1.3 ±0.03*
PH 7.36 ± 0.004 7.38 ± 0.004 7.37 ± 0.004 7.36 ± 0.004 7.35 ± 0.002
90min Lactate (mmol.l'1) 0.7 ± 0.05 1.1 ±0.08 1.4 ± 0.12 1.3 ±0.07*
pH 7.38 ± 0.004 7.38 ± 0.003 7.38 ± 0.003 7.35 ±0.002
60min Lactate (mmol.l'1) 0.7 ± 0.05 1.0 ±0.04 1.4 ±0.08
pH 7.38 ±0.004 7.37 ± 0.003 7.37 ± 0.003
30min Lactate (mmol.l'1) 0.6 ± 0.02 0.8 ± 0.02
pH 7.36 ± 0.002 7.36 ±0.003
Data presented as mean ± SEM (N = 7). * indicates significantly different from rest (P<0.05).
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5.3.7 Serum  triglyceride and NEFA re sp o n ses
The serum triglyceride (TG) responses are presented in Table 5.6 and Figure 5.7. After 
consumption of the LGI carbohydrate and insulin administration there were no changes in TG 
concentrations from rest to pre-exercise under all conditions (Table 5.6). However, serum TG 
concentrations increased with exercise under all conditions (Figure 5.7, P<0.05), with the 
change in serum TG similar across conditions (120min A+0.2 ± 0.01; 90min A+0.2 ± 0.01; 
60min A+0.2 ± 0.01; 30min A+0.2 ± 0.01 mmol.l'1; P = 0.91). After exercise, serum TG 
concentrations decreased over the 180 minute post-exercise period under all conditions 
(Figure 5.7); the change from 0 to 180 minutes was similar across conditions (120min A-0.0 
± 0.03; 90min A-0.1 ± 0.02; 60min A-0.2 ± 0.03; 30min A-0.2 ± 0.02 mmol.l'1; P = 0.66).
The serum NEFA responses are presented in Table 5.6 and Figure 5.8. After carbohydrate 
consumption and insulin administration there was no change in NEFA concentrations from 
rest to pre-exercise under 30min (A-0.06 ± 0.01 mmol.l'1, P = 0.32), however, concentrations 
declined under 120min, 90min and 60min (120min A-0.18 ± 0.03; 90min A-0.17 ± 0.03; 
60min A-0.19 ± 0.02 mmol.l'1; P<0.05; Table 5.6). The change from rest to pre-exercise was 
less under 30min when compared to the other trials (P<0.05). There were no changes in 
NEFA concentrations with exercise; however, there were large increases in concentrations 
from 0 to 5 minutes post-exercise (Figure 5.8). After 5 minutes post-exercise, NEFA 
concentrations increased transiently over the remainder of the post-exercise period (Figure 
5.8).
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Table 5.6: Pre-exercise serum triglyceride and NEFA responses to alterations in the pre-exercise 
timing of carbohydrate and insulin administration.
Sample Point
Trial Variable Rest 30 60 90 120
120min Triglyceride (mmol.l1) 
NEFA (mmol.l1)
0.8 ± 0.05 
0.39 ± 0.5
0.9 ± 0.06 
0.36 ± 0.04
0.8 ± 0.04 
0.23 ± 0.02*
0.7 ± 0.05 
0.20 ± 0.02*
0.7 ± 0.04 
0.22 ±0.03*
90min Triglyceride (mmol.l'1) 
NEFA (mmol.l1)
1.0 ±0.07 
0.47 ± 0.02
1.0 ±0.06 
0.37 ± 0.02*
0.9 ± 0.07 
0.24 ±0.01*
0.9 ± 0.06 
0.30 ± 0.02*
60min Triglyceride (mmol.l1) 
NEFA (mmol.l1)
0.9 ± 0.06 
0.46 ±0.02
0.8 ± 0.05 
0.35 ± 0.02
0.8 ± 0.05 
0.20 ±0.02*
30min Triglyceride (mmol.l'1) 
NEFA (mmol.l1)
1.0 ±0.05 
0.46 ±0.04
0.8 ± 0.05 
0.40 ± 0.04
Data presented as mean ± SEM (N = 7). * indicates significantly different from rest (P<0.05).
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Figure 5.7: Time-course changes in serum triglycerides (TG) after alterations in the pre-exercise 
timing of carbohydrate and insulin administration. There was a significant time effect (P = 0.001, 
partial-eta2 = 0.900) however, there were no significant time*condition interactions (P = 0.635). Data 
presented as mean ± SEM. Transparent sample points indicate significant change from 0 min post 
exercise (P<0.05). Thatched area indicates exercise.
166
0.7
0.6
is 0.5
es
ew
0.2
0.1
0.0
180PRE 0 5 15 30 60 120
Sample Point
Figure 5.8: Time-course changes in serum NEFA’s after alterations in the pre-exercise timing of 
carbohydrate and insulin administration. There was a significant time effect (P = 0.001, partial-eta2 = 
0.808) however, there were no significant time*condition interactions (P = 0.334). Data presented as 
mean ± SEM. Transparent sample points indicate significant change from 0 min post exercise 
(P<0.05). Thatched area indicates exercise.
167
5.3.8 P atterns of carbohydrate and lipid oxidation
Resting lipid and carbohydrate oxidation rates were greater and lower, respectively, under 
30min, when compared to all other trials (Table 5.7). During exercise lipid oxidation was 
greater and carbohydrate oxidation was lower under 30min, when compared with 120min 
(Table 5.7). When expressed as the change from rest, lipid oxidation was greater under 
60min and 90min, in comparison with 120min (Table 5.7). Moreover, carbohydrate 
oxidation was greater under 120min, in comparison with all other trials (Table 5.7).
The energy expended across trials was similar (120min 3.56 ± 0.09; 90min 3.21 ± 0.03; 
60min 3.24 ± 0.05; 30min 3.14 ± 0.04 MJ, P = 0.32), however, there was a greater 
contribution to energy expenditure from lipids under 30min, when compared with 120min 
(30min 5.9 ± 0.7 vs. 120min 2.0 ± 0.4 %, P = 0.02). This was also the case for carbohydrate 
contribution to energy demand (30min 94.1 ± 0.7 vs. 120min 98 ± 0.4 %, P = 0.02). There 
were no between trial statistical differences in percentage contribution to energy demand 
from lipids and carbohydrates under 90min and 60min (lipids: 90min 7.9 ± 1.1 60min 4.9 ± 
1.3 %; carbohydrates: 90min 92.1 ± 1.1 60min 95.1 ± 1.3 %; P>0.05).
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5.3.9 Post-laboratory activity and self-recorded glycaem ia and dietary intake
Over the 2 1 -hour post-laboratory period B G auc  under 120min and 90min was lower than 
60min and 30min (P<0.05; Table 5.8). With regards diet, participants consumed less 
carbohydrates under 60min and 30min, in comparison with 120min, moreover, participants 
consumed less fat under 30min, in comparison with 120min (Table 5.8). As a result, total 
energy intake was lower under 60min and 30min in comparison with 120min (Table 5.8). 
There were no conditional differences in the percentage contribution to total energy from 
carbohydrates (120min 52 ± 1.3; 90min 51 ± 1.5; 60min 49 ± 1.5; 30min 53 ± 1.1 %; P = 
0.62) and protein (120min 22 ± 0.7; 90min 21 ± 0.8; 60min 21 ± 0.9; 30min 23 ± 0.8 %; P = 
0.59), however, the contribution from fats under 30min was lower than 90min and 60min 
(30min 23 ± 0.9 vs. 90min 27 ± 1.2; 60min 29 ± 1.1 %; P<0.05), but not 120min (120min 
25 ± 0.9 %, P = 0.22).
There were 3 incidents of hypoglycaemia (8, 15 and 17 hours post-laboratory) and 1 low 
blood glucose (6 hours post-laboratory) under 120min. There were 2 incidents’ of 
hypoglycaemia under 90min (5 and 11 hours post-laboratory) and 1 incident of both 
hypoglycaemia (4 hours post-laboratory) and low blood glucose (20 hours post-laboratory) 
under 60min. Under 30min there were 2 incidents of hypoglycaemia (both at 4 hours post­
laboratory). One participant experienced hypoglycaemia, in the post-exercise period, twice 
under 90min and 30min. There were no differences in rapid-acting insulin administration or 
participant activity, with similar average heart rate and steps taken over the 21 hour post­
laboratory period (Table 5.8).
170
Table 5.8: Twenty-one hour post-laboratory blood glucose, dietary intake and activity patterns.
Condition
Variable 120min 90min 60min 30min
BGauc (mmol.I"1.hour'1) 8.0 ±0.1 6.9 ±0.2 8.9 ±0.3# 9.0 ± 0.2#
CHO intake (g) 160 ±4 144 ±4 131 ± 5* 137 ±4*
Protein intake (g) 66 ±3 59 ±3 55 ±3 60 ±3
Fat intake (g) 34 ±2 33 ±2 35 ±2 2 7 ± 2 |
Energy intake (MJ) 5.1 ±0.8 4.6 ± 0.9 4.4 ±0.1* 4.3 ±0.1*
Rapid-acting insulin (U) 16 ± 1 15 ± 1 16 ± 1 16 ± 1
Frequency BG < 4.0 mmol.I'1 1 0 1 0
Frequency BG <3.5 mmol.l'1 3 2 1 2
Average heart rate (bpm) 79 ± 1 78 ± 1 78 ± 1 80 ± 1
Average steps taken 4826 ± 293 3153 ±394 7469 ± 560 5525 ± 402
Data presented as means ± SEM (n = 7). * indicates significantly different from 120min (P<0.05). # indicates 
different from 120min and 90min. f  indicates significantly different from all other trials (P<0.05). BGAuc 
indicates blood glucose area under the curve.
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5.4 D iscussion
This study examined the metabolic and glycaemic effects of alterations in the timing of 
carbohydrate feeding and insulin administration prior to running in individuals with T1DM. 
Results demonstrate that administration of both a LG I carbohydrate and a 75% reduction in 
rapid-acting insulin dose 30 minutes before exercise results in reduced carbohydrate and 
increased lipid oxidation during exercise and improved blood glucose responses after 
exercise.
Pre-Exercise
Resting carbohydrate oxidation was lower and lipid oxidation higher under 30min, in 
comparison with 120min. The slow digestion of the LGI carbohydrate, and a delayed gastric 
emptying (Achten et al., 2007), evident with lower pre-exercise blood glucose concentrations 
under 30min, results in a slow absorption rate of glucose. With this in mind, after just 15-30 
minutes, the slow digestion, and ultimately slow delivery of carbohydrate, resulted in a need 
for a greater contribution from lipids to meet energy demand. Conversely, after 105-120 
minutes greater carbohydrate availability would have directly suppressed lipid oxidation 
(Coyle et al., 1997). Prior to exercise, blood glucose was lowest under 30min in comparison 
with 120min. As demonstrated in Chapter 4, blood glucose peaked 120 minutes after 
ingestion of an LGI carbohydrate (isomaltulose). Based on these data, just before starting 
running the LGI carbohydrate would not have been fully digested under 30min. There were 
no significant differences in pre-exercise insulin concentrations, despite the manipulation of 
time prior to exercise. An investigation in to time-course changes in rapid-acting insulin has 
demonstrated these insulin analogues peak at 45 to 60 minutes after subcutaneous
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administration, and decrease to 50% of peak concentrations at 120 minutes post 
administration (Plank et al., 2002). Within our study, peak insulin concentrations varied 
between 30 -  120 minutes after administration, across trials. Moreover, within 120min, 
90min and 60min, concentrations did not significantly change within the pre-exercise period 
after the 30 minute sample (Table 5.2). Within the research of Plank et al. (2002), participants 
received a bolus of 7.1 ± 1.3 IU of insulin aspart or lispro, whereas participants within this 
study administered just 2.1 ± 0.1 IU. To our knowledge there is no literature that has 
examined the pharmacokinetics of insulin aspart and lispro when administered at such low 
doses. Potentially, smaller doses may result in altered uptake kinetics and/or increased inter 
and intra individual variability in its appearance in circulation.
During Exercise
During exercise, oxidation rates of carbohydrate and lipids were lower and greater,
respectively, under 30min in comparison with 120min. The differences in lipid oxidation
were likely due to increased combustion of intramuscular derived lipids as serum NEFA
responses were not different across trials (Figure 5.8). Two hours after ingestion would have
been sufficient time for complete digestion of the LGI carbohydrate, resulting in a greater
availability of carbohydrate to the active tissue, which may have resulted in a promotion of
carbohydrate oxidation (Coyle et al., 1997); potentially lipid metabolism was directly
suppressed by greater glucose availability (Coyle et al., 1997). Therefore, under 30min the
delayed absorption, similar to a fasted state, may have promoted lipid combustion. The drop
in blood glucose with exercise was less under 30min than 120min. A lesser increase in serum
insulin and a reduced carbohydrate oxidation rate and a greater contribution to energy
demand from lipids would have aided in preserving blood glucose concentrations under
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30min Running resulted in an increase in serum insulin concentrations under all conditions. 
This is in accordance with previous research which has demonstrated exercise to increase the 
appearance of exogenous insulin (Dandona et al., 1980). Within our study concentrations 
increased 1.5-fold with exercise across conditions, with the increase with exercise under 
30min less than 120min. According to Gallen (2003), after administration, exogenous insulin 
can lie trapped as a subcutaneous depot, which may take time to absorb and dissipate. 
Potentially, the bolus of insulin under 30min would have had less time to dissipate and be 
absorbed into circulation at rest; this may potentially explain the tiered insulin concentrations 
after exercise, i.e. concentrations were greatest (but not significantly) under 120min and 
lowest under 30min. Serum non-esterified fatty acid concentrations did not change with 
exercise; an effect likely the result of a reduction in adipose tissue blood flow, with exercise 
intensities at and above 70% V02max, reducing the removal of NEFA (Jones et al., 1980; 
Romijn et al., 1995).
Post-Exercise
After exercise, blood glucose concentrations under 30min were greater than 120min and also
significantly increased for 60 minutes post-exercise. The rise in glucose availability may be
important in preventing post-exercise hypoglycaemia, as an increased glucose availability
would aid in replenishing both muscle and liver glycogen stores. It has been suggested that
preferential repletion of muscle glycogen over liver glycogen stores, resulting in hepatic
glucose production being unable to meet glucose demand by the exercised tissue, is a
contributing factor in the development of post-exercise hypoglycaemia (Steppel and Horton,
2003). Although the blood glucose responses under 30min and 60min are similar, the
prevention of hypoglycaemia under 30min is important in establishing the optimal pre-
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exercise strategy. Over the post-exercise period, there were no differences in serum insulin 
responses with a similar and transient decline over the 3 hour post-exercise period. This is 
likely related to an increased insulin clearance that occurs in both T1DM and non-TlDM 
individuals after exercise (Tuominen et al., 1997); post-exercise insulin clearance is 
important for removing the inhibitory effects of insulin on the actions of counter-regulatory 
hormones (e.g. adrenaline, noradrenaline and cortisol). The sharp rise in NEFA 
concentrations from 0 to 5 minutes, under all conditions, is likely due to a redistribution of 
blood flow back to the adipose tissue at the cessation of exercise (Romijn et al., 1995).
Upon leaving the laboratory blood glucose concentrations were lowest under 120min in 
comparison with 60min and 30min (120min 6.3 ± 0.6; 60min 9.6 ± 0.6; 30min 8.1 ± 0.5 
mmol.r1). Over the 2 1  hour post-laboratory period B G a u c  was greater under 60min and 
30min in comparison with 120min, moreover, despite the greater blood glucose 
concentrations participants consumed less carbohydrates and overall less energy under both 
60min and 30min, when compared to 120min (Table 5.8). Participants were familiar with 
carbohydrate counting, administering ~ 1 IU of insulin per 10 g of carbohydrates; this 
reflected in the -160 g of carbohydrate consumed under 120min, with -16 IU of insulin. 
However, under 60min and 30min, 131 and 137 g of carbohydrates, respectively, were 
consumed with -  16 IU of insulin. The two participants who experienced hypoglycaemia 
under 30min left the laboratory with elevated blood glucose concentrations of 10.4 and 12.5 
mmol.r1, and both experienced hypoglycaemia within 4 hours of leaving the laboratory, 
suggesting a rapid fall in blood glucose occurred, potentially due to administration of 
corrective insulin units. The contrasting post-laboratory blood glucose responses under 
120min and 30min are both indicative of a lack of knowledge of increased post-exercise 
insulin sensitivity (Table 5.8). As blood glucose concentrations were lower after 120min,
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participants may have benefited from lowering their insulin to carbohydrate ratio in the hours 
after exercise, as recommended by De Feo et al. (2006). Conversely, under 30min, applying 
corrective insulin units in a post-exercise insulin sensitised state may have caused unexpected 
falls in blood glucose.
This study has modified the existing strategies available to T1DM individuals that help 
combat hypoglycaemia during and after exercise. For the greatest protection against 
hypoglycaemia, our data suggest that a 75% reduced dose of rapid-acting insulin (Chapter 3; 
Rabasa-Lhoret et al., 2001), combined with a low GI carbohydrate (Chapter 4), should be 
administered 30 minutes before exercise. Moreover, despite administering a rapid-acting 
insulin dose so close to an intense, full body exercise bout, there were no incidences o f 
hypoglycaemia under 30min. These findings are of clinical importance as current 
recommendations do not advocate the administration of rapid-acting insulin less than 2 hours 
before exercise (De Feo et al., 2006). Moreover, current research demonstrates heavy pre­
exercise insulin reductions are effective at avoiding exercise induced hypoglycaemia, 
however, may increase blood glucose concentrations such that individuals are exposed to pre 
and post-exercise hyperglycaemia (Rabsa-Lhoret et al., 2001); this could be detrimental to 
long-term glycaemic control if employed on a regular basis. Based on this study’s findings, 
consumption of a LGI carbohydrate source and administration of a 75% reduced insulin dose 
30 minutes before exercise reduces exposure to high blood glucose before exercise, promotes 
lipid combustion and reduces carbohydrate usage during exercise, preserving blood glucose 
concentrations such that both hyper- and hypoglycaemia are avoided after exercise.
In conclusion, this study examined blood glucose and serum insulin responses to alterations 
in the timing of carbohydrate feeding and insulin administration prior to running in 
individuals with T1DM. These data demonstrate that the T1DM individual may expect
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improved glycaemic control after exercise and higher lipid oxidation rates during exercise if 
the pre-exercise rest period is restricted to 30 minutes following administration of a low 
glycaemic index carbohydrate and reduced insulin dose.
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Chapter Six 
General Discussion
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6.1 Sum m ary of aim s and findings
The overarching aim of this thesis was to examine factors that affect post-exercise glycaemia 
and contribute to minimising the risk of hypoglycaemia after exercise. An inability to 
regulate circulating insulin concentrations is considered the primary gluco-regulatory defect 
within T1DM. Therefore, the aim of chapter 3 was to examine the effects of pre-exercise 
rapid-acting insulin reductions on blood glucose responses before and after running in T1DM 
individuals, to test the hypothesis that reducing pre-exercise insulin dose may help preserve 
post-exercise glycaemia. The results demonstrate that a 75% reduction to pre-exercise rapid- 
acing insulin dose best preserved blood glucose before and after exercise, without increasing 
the risk of ketoacidosis, and reduced the risk of hypoglycaemia in free living conditions for 
24 hours following running.
An important factor determining blood glucose concentrations and subsequent patterns of 
fuel oxidation is the rate of appearance of carbohydrate into the circulation. Potentially, low 
GI carbohydrates may raise blood glucose less and increase the percentage contribution of 
lipids as a fuel because of a slower digestion. Therefore, the aim of chapter 4 was to examine 
the metabolic and blood glucose responses to ingestion of a high or low GI carbohydrate, 
combined with a 75% reduced insulin dose, before, during and for 24 hours after running. 
The results demonstrate that compared to a high GI carbohydrate, the low GI carbohydrate 
increased blood glucose concentrations less before exercise and maintained blood glucose 
better for 24 hours after running, via lower carbohydrate and higher lipid oxidation rates 
during the latter stages of running.
After manipulating both the insulin dose and the pre-exercise carbohydrate GI, to improve
post-exercise blood glucose concentrations, the timing of the ingestion of carbohydrate
(alongside a reduced insulin dose) before exercise is an important factor which may further
179
refine these strategies. Therefore, chapter 5 examined the metabolic and blood glucose 
responses to alterations in the timing of carbohydrate feeding and insulin administration prior 
to running. Our results demonstrated that administration of both a reduced rapid-acting 
insulin dose and low GI carbohydrate 30 minutes before exercise improved glycaemia for 24 
hours after running, by reductions in carbohydrate oxidation, leading to increased 
carbohydrate availability post-exercise.
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6.2 Impact of insulin reductions, carbohydrate administration and timing on 
glycaemia before and after running
Within T1DM, the primary defect in blood glucose regulation during exercise is the inability 
to regulate circulating insulin concentrations (Steppel and Horton, 2003). In chapter 3 pre­
exercise insulin dose was reduced such that blood glucose concentrations were elevated 
above rest to a greater extent under the largest insulin reduction trial. Reducing pre-exercise 
insulin dose by 75% resulted in reductions in peak (and pre-exercise) insulin concentrations 
(25% 55 vs. Full 112 pmol.l'1), and elevated blood glucose by ~4 mmol.r1 before exercise 
(25% A+7.7 vs. Full A+3.5 mmol.I’1). Manipulating the available insulin before exercise 
resulted in a reduced clearance of glucose into insulin sensitive tissues after ingestion of the 
meal and elevated blood glucose prior to exercise (Figure 6.1).
This difference in pre-exercise insulin concentrations is of importance, as with the same 
exercise bout the drop in blood glucose with exercise was less under 25% due to the 
synergistic effect of insulin and contracting muscle (Nesher et al., 1985; Plough et al., 1984) 
being less under this condition. This would have reduced peripheral uptake of blood glucose 
and subsequent use by the exercising musculature (Chokkalingam et al., 2007), increasing 
hepatic glucose output through reduced inhibition at the adipocyte and hepatocyte allowing 
greater mobilisation of gluconeogenic substrate and less inhibition of hepatic enzymes 
involved in glycogenolysis (Cherrington et al., 2007). Keeping this in mind, higher pre­
exercise blood glucose concentrations and a lesser drop in blood glucose during exercise 
under 25% meant a preservation of blood glucose above resting concentrations was elicited, 
similar to the findings of Rabasa-Lhoret et al. (2001) (Figure 6.1; 6.2; 6.3).
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Chapter 4 aimed to manipulate the glycaemic index of the administered carbohydrate given in 
conjunction with a reduced bolus insulin dose. The consumption of HGI resulted in a rapid 
rise in blood glucose, with peak concentrations double that of LGI occurring at 90 min post­
ingestion, compared to 120 min under LGI. In contrast to chapter 3, where pre-exercise 
insulin concentrations were important in subsequent blood glucose responses during and after 
exercise, within chapter 4 gross differences in pre-exercise blood glucose concentrations had 
implications for subsequent glycaemic responses. Six of eight participants experienced a 
smaller drop in blood glucose under LGI. A potential mechanism behind this may be related 
to the hyperglycaemic blood glucose concentrations elicited under HGI at the onset of 
exercise. Research has demonstrated that when T1DM individuals exercise under 
hyperglycaemic conditions they elicit an increased disposal of blood glucose (Coyle et al., 
1991; Jenni et al., 2008). The research of Jenni et al. (2008) demonstrated that when 
hyperglycaemic (11 mmol.r1), as under HGI (~15 mmol.r1), T1DM individuals elicit greater 
rates of glucose disposal and lower rates of endogenous glucose production. The mechanisms 
behind the greater drop in blood glucose under HGI may be due to blood glucose becoming 
the primary fuel source for the exercising muscles (Coyle et al., 1991). Other contributing 
factors to the lower drop in blood glucose during exercise under LGI may include a reduced 
oxidation of blood glucose by the active musculature due to a greater oxidation of lipids, and 
potentially fructose (Adopo et al., 1994). A further contributing mechanism could be greater 
rates of hepatic glucose output under LGI, due to the metabolism of fructose into glucose 
(Wahren et al., 1975; Ahlborg and Bjorkman, 1990) and the use of lactate as a gluconeogenic 
substrate (Ahlborg and Felig, 1982). Therefore, under LGI lower pre-exercise blood glucose 
concentrations and a lesser drop in blood glucose during exercise resulted in blood glucose 
concentrations being closer to euglycaemia, when compared to HGI, post-exercise (Figure 
6.2; Figure 6.3).
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Both types of carbohydrate were equally effective at preventing hypoglycaemia over the 3 
hour recovery period, with two incidences under each condition. Based on this, for the 
prevention of hypoglycaemia it seems the glycaemic index of the carbohydrate consumed 
prior to exercise is secondary in importance to the 75% reduction in pre-exercise insulin dose. 
However, comparing the post-exercise glycaemia of chapter 3 and chapter 4 (Figure 6.2), it is 
apparent that the 75% reduction in insulin dose is important for the preservation of post­
exercise blood glucose, regardless of carbohydrate type, however, less change in blood 
glucose under LGI with more euglycaemic concentrations post-exercise may be a more 
efficacious strategy for the T1DM individual, without an increased risk if hypoglycaemia.
As demonstrated within chapter 4, after consumption of the LGI carbohydrate blood glucose 
peaked at 120 minutes post-ingestion. Therefore, manipulation of pre-exercise timing would, 
as expected, result in a graded effect on pre-exercise blood glucose concentrations, i.e. lowest 
under 30min and greatest under 120min. Similar to the progression from chapter 3 to 4, 
where the exposure to high pre-exercise blood glucose concentrations was lessened; 
employing the 30min strategy reduced blood glucose excursions further (pre-exercise blood 
glucose: chapter 3 25% A+9.0; chapter 4 LGI A+4.5; chapter 5 30min A+2.8 mmol.r1). 
Moreover, it is reasonable to suggest a similar tiered effect on serum insulin responses would 
be present; however, this was not the case. Pre-exercise insulin concentrations were similar 
across conditions, suggesting timing of administration of a heavily reduced insulin dose is 
secondary in importance to timing of carbohydrate consumption on pre-exercise blood 
glucose responses.
The incomplete digestion of the low GI carbohydrate at the onset of exercise under 30min 
has important implications for blood glucose regulation during exercise. Two hours after
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ingestion would have been sufficient time for complete digestion of the LGI carbohydrate 
under 120min, resulting in a greater availability of carbohydrate to the active tissue, which 
may have resulted in a promotion of carbohydrate oxidation and a direct suppression of lipid 
metabolism (Coyle et al., 1997; Spriet, 2002). Therefore, under 30min the delayed 
absorption, similar to a fasted state, may have allowed continued lipid combustion. The drop 
in blood glucose with exercise was less under 30min than 120min, with 5 of 7 participants 
experiencing a lesser drop under 30min. A lesser increase in serum insulin concentrations, 
resulting in a lower rate of insulin mediated glucose uptake (Figure 6.1), lower rates of 
carbohydrate oxidation and a greater contribution to energy demand from lipids would have 
aided in preserving blood glucose concentrations under 30min.
The drop in blood glucose with exercise is seemingly not just dependent upon a reduction in 
circulating insulin. When employing a 2 hour rest period between insulin and carbohydrate 
feeding and exercise (i.e. chapters 4 and 5), Full resulted in a blood glucose decline of ~6.1 
mmol.f1, however, a 75% (25%) insulin reduction resulted in a drop in blood glucose of ~3.2 
mmol.r1, with slightly greater declines thereafter under LGI and HGI (LGI -4.4; HGI -5.8 
mmol.l"1). However, the manipulation of pre-exercise timing also resulted in a range in drops 
in blood glucose (30min -3.7; 60min -5.0; 90min -5.4; 120min -6.4 mmol.l1). Potentially, 
factors such as pre-exercise blood glucose concentrations, substrate oxidation and appearance 
of both insulin and carbohydrate in circulation may play a role in the drop in blood glucose 
with exercise. Moreover, based on the differences in the drop in blood glucose and the 
incidence of hypoglycaemia between LGI and 120min, the duration of T1DM may be an 
important factor.
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120min, being exactly the same protocol as the LGI trial of chapter 4, resulted in 5 of 7 
participants experiencing hypoglycaemia within the laboratory, whereas just 2 of 8 
experienced hypoglycaemia within the laboratory under LGI. Participants had similar 
anthropometric characteristics (chapter 4; body mass 84 ± 2; chapter 5; body mass 84 ± 1 kg) 
and were in similar glycaemic control (chapter 4; HbAic 8.0 ± 0.2; chapter 5; HbAic 8.3 ± 0.2 
%), however, the duration of T1DM was different between studies (chapter 4; 14 ± 2; chapter 
5; 19 ± 2 years), with duration of T1DM ranging from 1 - 34 years within chapter 4 and 6 - 
35 years within chapter 5. Specifically, within chapter 4 half of participants had a duration of 
T1DM of less than 7 years, whereas there was just 1 individual under chapter 5. Therefore, 
there is potential that the longer duration of T1DM within chapter 5 meant participants within 
this study had a greater impairment of gluco-regulatory responses. Within the 
pathophysiology of T1DM is a progressive loss of a-cell function over time, and the glucagon 
response, potentially due a loss of p -  a cell signalling (Banarer et al., 2002), such that after 5 
years of diagnosis falling blood glucose will fail to stimulate the release of this key hormone 
(Mokan et al., 1994). Based on this research and the glucagon responses within chapters 3 
and 4, differences in the release o f this key hormone are unlikely to explain the different 
glycaemic responses and incidences of hypoglycaemia between the trials.
The differences in the glycaemic responses between 120min and LGI may be related to 
adrenaline secretion. In addition to a-cell failure, T1DM experience progressive attenuation 
of autonomic, sympathetic neural and adrenomedullary responses (Cryer, 2002), with the 
adrenaline response becoming attenuated (Amiel et al., 1988; Bolli et al., 1983; Dagogo-Jack 
et al., 1993) (the attenuation of these responses is the likely explanation behind the lack of 
conditional differences in gluco-regulatory hormonal responses across conditions, despite 
gross differences in blood glucose responses). Moreover, there is potential that longer
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duration T1DM individuals have lower adrenomedullary stores of adrenaline (De Galan et al., 
2004). Although different participants, when examining the adrenaline response to exercise 
there was -30%  lesser rise in adrenaline, to the same exercise model, under chapter 5 when 
compared to chapter 4 (chapter 4 A+l.l ±0.16 vs. chapter 5 A±1.5 ± 0.02 nmol.f1). When 
considering the role of adrenaline in reducing blood glucose uptake (Howlett et al., 1999), 
increasing breakdown of intramuscular triglycerides and glycogen (Watt et al., 2001), and 
stimulating hepatic glucose output (Howlett et al., 1999), there may have been more reliance 
on blood glucose as a fuel during the 120min condition, evident with a greater drop in blood 
glucose concentrations during exercise under 120min in comparison with LGI (120min -6.4 
vs. LGI -4 .4  mmol.l'1).
After exercise, blood glucose concentrations under 30min were greater than 120min and also 
significantly increased for 60 minutes post-exercise. As there were similar concentrations of 
gluco-regulatory hormones (e.g. insulin, catecholamines and cortisol) and blood lactate 
across conditions post-exercise, it is reasonable to suggest that the time-course changes in 
blood glucose concentrations under 30min and 60min are due to the appearance of ingested 
glucose, as opposed to changes in endogenous glucose production (Figure 6.1). At the 
cessation of exercise, a redistribution of blood flow back to the digestive system may have 
resulted in a flux of glucose into circulation, which raised blood glucose concentrations for 
60 minutes. When comparing the conditions where a 25% insulin dose was employed (i.e. 
25%, chapter 4 and chapter 5) despite mean delta post-exercise blood glucose concentrations 
of just —0.4 mmol.l'1, 30min elicited the lowest incidences of hypoglycaemia, completely 
preventing hypoglycaemia. Moreover, 60min elicited mean post-exercise blood glucose o f—
0.2 mmol.l'1, yet only elicited 1 hypoglycaemic incident (Figure 6.2). Potentially, the rise in 
blood glucose after exercise is important in preventing post-exercise hypoglycaemia, as
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increased glucose availability would aid in replenishing both muscle and liver glycogen 
stores, which may reduce the susceptibility to post-exercise hypoglycaemia (Steppel and 
Horton, 2003).
The maintenance of blood glucose (i.e. blood glucose concentrations did not decline below 
concentrations elicited at 0 minutes over the 3 hour post-exercise period) elicited in the post­
exercise period under all conditions and chapters is potentially primarily regulated by 
decreasing insulin concentrations with time (Figure 6.1). Glucagon, the primary counter- 
regulatory hormone did not change with time or condition across chapters 3 and 4; moreover, 
the catecholamines and cortisol, also not different across conditions and chapters, decreased 
with time (Figure 6.1). Therefore, the decrease in insulin concentrations, likely due to an 
increased insulin clearance (Tuominen et al., 1997), resulted in the suppressive effect of 
insulin at the adipocyte and hepatocyte being lessened with time (Zinman et al., 1977; Figure
6.1) and concomitantly reducing insulin-stimulated blood glucose uptake (Figure 6.1). As 
glucose uptake would have been elevated to replenish glycogen stores within the exercised 
musculature (Wojtaszewski et al., 2002; Steppel and Horton, 2003), declining insulin 
concentrations would compensate for increased post-exercise insulin sensitivity 
(Wojtaszewski et al., 2002) and reduce the synergistic promotion of glucose uptake. 
Although NEFA concentrations were not measured within chapter 3, concentrations are 
assumed to follow similar time course changes as within studies 4 and 5. Moreover, p- 
hydroxybutyrate, which is the result of NEFA metabolism within the hepatocyte (Laffel, 
1999) increased with time (Figure 6.1). The increase in NEFA concentrations, likely due to 
increased triglyceride breakdown and potentially lipolysis (Figure 6.1), and p- 
hydroxybutyrate concentrations may be important in providing an alternative energy substrate
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for the exercised tissue (Laffel, 1999; Tuominen et al., 1997), and reducing the reliance on 
blood glucose as a fuel.
When examining the progression in the pre-exercise strategies from chapter 3 to 5 and their 
influence on post-exercise glycaemia (Figure 6.2; 6.3), it is evident that a heavy insulin 
reduction preserves post-exercise glycaemia the most, however, combining a 75% reduced 
insulin dose with a low GI carbohydrate preserves blood glucose less, but results in less 
change in blood glucose before and after exercise, and results in more euglycaemic 
concentrations after exercise, which may be beneficial for glycaemic control. However, this 
strategy was not fully effective at combating hypoglycaemia. Implementing the 
recommendations of chapter’s 3 and 4 30 minutes before exercise results in less change in 
blood glucose before and after exercise, and completely prevented hypoglycaemia (Figure
6.2). Although 60min also reduces the risk of hypoglycaemia and displays similar post­
exercise glycaemic responses, it is the improved fuel oxidation, a lesser drop in blood glucose 
during exercise and the prevention of hypoglycaemia post-exercise which makes 30min the 
recommended strategy. Furthermore, under 30min the average fasting blood glucose of 
participants was ~8.5 mmol.l'1, therefore, a mean decline in post-exercise blood glucose of 
~0.4 mmol.l'1 is negligible considering participants had completed 45 minutes of running and 
a further three hours of recovery, without feeding, yet did not experience hypoglycaemia.
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6.2.1 Post-laboratory  glycaem ia
Determining the long-term effectiveness of our interventions following exercise based on the 
incidence of hypoglycaemia is difficult as participants resumed their normal daily routines. 
Participants were required to indicate if additional insulin units were added/or units were 
omitted to attempt to correct their blood glucose concentrations (e.g. correcting blood glucose 
from low to high, high to low or to maintain concentrations). Self-recorded data indicate that 
some participants administered additional units to correct for high blood glucose, e.g. under 
25% and HGI (evidenced by an insulin to carbohydrate ratio of more than 1 IU to 10 g of 
carbohydrate or administration of insulin units without feeding), moreover, when 
concentrations were within more euglycaemic concentrations, such as under LGI, 120min, 
90min and 30min, participants administered their usual insulin dose with the meal after 
exercise. Therefore, a lack of knowledge of increased post-exercise insulin sensitivity may 
have led to unexpected falls in blood glucose. This factor likely explains the incidences of 
low blood glucose and hypoglycaemia that were experienced by some participants under 
trials with well preserved blood glucose concentrations, e.g. LGI, 60min and 30min. 
Therefore, T1DM individuals need a greater awareness of an increase in insulin sensitivity 
after exercise, i.e. an increased potency of their rapid-acting insulin, and the importance of 
reducing their insulin to carbohydrate ratio after exercise (De Feo et al., 2006).
The effectiveness of our strategies was assessed based on a combination of glycaemic and 
metabolic responses during the laboratory period and post-laboratory period glycaemia and 
dietary intake. As a result, 30min was deemed the most effective pre-exercise strategy for 
T1DM individuals to engage in. Implementing this strategy offers the T1DM individual 
improved resting and exercising fuel oxidation, lesser drops in blood glucose with exercise 
and improved blood glucose concentrations for 24 hours post-exercise.
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6.3 C hanges in the  pattern of su b stra te  oxidation
Making direct across chapter comparisons on the rates of substrate oxidation may be difficult 
due to different participants. However, it is important to recognise the within-chapter 
improvements in substrate oxidation and the preservation of blood glucose post-exercise.
Rest
Within chapter 3, despite alterations to insulin dose, and ultimately glycaemia, respiratory 
data revealed no differences in resting carbohydrate and lipid oxidation rates. This is in 
contrast to other literature that has demonstrated that gross alterations in insulin dose can 
significantly alter resting substrate metabolism within T1DM (Chokkalingham et al., 2007). 
Chokkalingham and colleagues demonstrated that low insulin concentrations, in comparison 
with high, can reduce resting carbohydrate oxidation by -40%  and increase lipid oxidation by 
-80%. Moreover, within chapter 4 alterations to the GI of the ingested carbohydrate did not 
alter resting fuel metabolism. The lack of differences in fuel oxidation rates within chapters 3 
and 4 can be explained by a similar mechanism. According to Jenni et al. (2008) 
hyperglycaemic blood glucose concentrations suppress lipid oxidation (Jenni et al., 2008) 
through a mass action effect of glucose (Coyle et al., 1997). Therefore, within chapter 3 a 
reduction in insulin dose and a concomitant rise in blood glucose, and hyperglycaemic (>11 
mmol.l"1; Jenni et al., 2008) blood glucose concentrations under both conditions within 
chapter 4, may have suppressed any changes in oxidation rates.
The mechanism behind the suppression of lipid oxidation may be related to a suppression of 
P-oxidation through a reduced transport of long chain fatty acids (LCFA) into the 
mitochondria (Coyle et al., 1997; Sidossis et al., 1996; Rasmussen et al., 2002). Figure 6.4 
below describes the transport of LCFA into the matrix of the mitochondria for p-oxidation.
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The carnitine palmitoyltransferase (CPT) complex, consisting of CPT 1, acylcamitine 
transferase and CPT II, has a major regulatory role in the transport of LCFA into the 
mitochondria for subsequent P-oxidation in skeletal muscle (Figure 6.4; McGarry and Brown, 
1997). CPT1, located on the outer surface of the outer mitochondrial membrane, catalyses the 
transfer of a variety of LCFA acyl groups from CoA to carnitine (Figure 6.4). The generated 
acylcamitine can then permeate the inner membrane, via acylcamitine/camitine translocase 
(described as translocase in Figure 6.5). The acyl-CoA is then reformed in the matrix of the 
mitochondria by CPT II. This enzyme is located on the inner mitochondrial membrane and 
catalyses the transfer of the acyl group from carnitine to CoA and the reformed acyl-CoA 
enters the p-oxidation pathway (McGarry and Brown, 1997). CPT1 is considered the rate 
limiting step in the oxidation of LCFA and is reversibly inhibited by malonyl-CoA (Spriet, 
2002). It has been demonstrated that hyperglycaemia and hyperinsulinaemia reduce LCFA 
oxidation through an inhibition of CPT1 (Sidossis et al., 1996). Moreover, hyperglycaemia 
has been demonstrated to increase the concentration of malonyl-CoA, and suppress LCFA 
transport into the mitochondria (Rasmussen et al., 2002). Therefore, an increased glycolytic 
flux, resulting in an increase in malonyl-CoA (Figure 6.5), may result in an inhibition of 
CPT1 and a concomitant suppression of lipid oxidation.
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Figure 6.4: Schematic diagram o f the formation o f m alonyl-CoA from glucose and the regulation o f 
free fatty acid transport into the m itochondria (process within the red outline) by carnitine 
palm itoyltransferase l (CPT1) and 2 (CPT II) (adapted from Spriet, 2002).
W ithin chapter 5, resting carbohydrate oxidation was lower and lipid oxidation higher under 
30min, in comparison with 120min. The greater lipid oxidation under 30min is likely related 
to lower blood glucose concentrations (Jenni et al., 2008). The lower blood glucose 
concentrations under 30min are most likely due to the slow digestion o f the LGI 
carbohydrate, which is the result o f  slower rates o f hydrolysis within the gastrointestinal tract
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(Lina, 2002). Therefore, after just 15-30 minutes, the slow digestion, and ultimately slow 
delivery of carbohydrate, resulted in a need for a greater contribution from lipids to meet 
energy demand. Specifically, less delivery of carbohydrate to the musculature would have 
resulted in less glycolytic flux, which would result in less citrate formation within the matrix 
of the mitochondria and subsequently result in a reduction in malonyl-CoA (Figure 6.4) and 
allow LCFA to enter the mitochondria for p-oxidation (Figure 6.4). Conversely, after 105- 
120 minutes greater carbohydrate availability would have directly suppressed lipid oxidation; 
through similar mechanisms involving the inhibition of LCFA transport into the mitochondria 
through increases in malonyl-CoA (Rasmussen et al., 2002). The increase in lipid oxidation 
prior to exercise under 30min, may have contributed to a sparing of both endogenous and 
exogenous carbohydrate sources before exercise, increasing available carbohydrate reserves 
during exercise.
Based on the resting data, it seems that substrate oxidation is mainly influenced by blood 
glucose concentrations, as serum NEFA concentrations were not different across any of the 
studies. The rise in blood glucose associated with a reduced insulin dose suppresses any shift 
in fuel metabolism. Moreover, the digestion and ultimately the delivery of carbohydrate to 
resting musculature effects fuel oxidation more so than gross reductions in insulin dose or 
alterations in the glycaemic index of the ingested carbohydrate.
Exercise
Within chapter 3 the hyperglycaemia associated with reducing insulin dose suppressed any
shifts in exercising fuel oxidation rates. Although prior research has demonstrated the role of
insulin in promoting carbohydrate oxidation and suppressing lipid utilisation during exercise
(Chokkalingham et al., 2007), this research did not address blood glucose concentrations.
Within the research of Chokkalingham et al. (2007) reductions in insulin concentrations
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provided a milieu for increased rates o f lipid oxidation, however blood glucose was clamped 
at 8 mmol.l'1 (Chokkalingam et al., 2007). Relating these data to that of this thesis, the 
hyperglycaemia associated with reducing insulin dose (13-15 mmol.l'1), irrespective of 
condition, may have caused an equal but elevated carbohydrate oxidation rate (Jenni et al., 
2008; Rasmussen et al., 2002; Figure 6.4) suppressing any shifts in the pattern of lipid 
oxidation, regardless of alterations to insulin concentrations. As previously described, 
hyperglycaemia and an increased glycolytic flux may have directly suppressed lipid oxidation 
through reducing mitochondrial fatty acid transport (Figure 6.4).
The importance of blood glucose concentrations on fuel oxidation was demonstrated further 
within chapter 4 where a low GI carbohydrate increased lipid oxidation and reduced 
carbohydrate oxidation towards the latter stages of exercise. These data are the first to 
demonstrate that a low GI carbohydrate improves fuel oxidation rates within T1DM 
individuals. These findings are similar to research examining the influence of the glycaemic 
index on exercising fuel metabolism within non-TlDM individuals (Demarco et al., 1999; 
Stevenson et al., 2006). The differences in substrate oxidation pattern are likely related to 
blood glucose concentrations during the exercise bout (Jenni et al., 2008). At the beginning of 
exercise blood glucose concentrations were hyperglycaemic under both conditions, however, 
were ~3 mmol.l'1 lower under LGI, in comparison with HGI. The high blood glucose 
concentrations may have limited fuel use to predominantly carbohydrates under HGI (Jenni 
et al., 2008). Moreover, towards the later stages of running blood glucose concentrations 
would have been lower and more euglycaemic under LGI in comparison with HGI, 
removing the mass action effect of glucose, and reducing glycolytic flux and lessening its 
inhibitory effect on lipid metabolism (Coyle et al., 1997; Jenni et al., 2008). Reductions in 
glycolysis would result in a decreased formation of malonyl-CoA (Figure 6.4) and increase
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LCFA transport into the mitochondria and ultimately reduce carbohydrate oxidation and 
concomitantly increase lipid oxidation towards the latter stages of exercise under LGI. The 
increase in lipid oxidation during exercise would have contributed to a sparing effect on 
carbohydrate reserves (Figure 6.1), potentially reducing the oxidation of blood glucose and 
explaining the lesser drop in concentrations experienced by 75% of participants under LGI.
Similar mechanisms are responsible for the changes in fuel oxidation demonstrated within 
chapter 5. During exercise, oxidation rates of carbohydrate and lipids were lower and greater, 
respectively, under 30min in comparison with 120min. The difference between these two 
trials is likely related to differences in the digestion of the LGI carbohydrate and ultimately 
its delivery to the active tissue. Under 120min, two hours would have been sufficient time for 
complete digestion o f the LGI carbohydrate, resulting in a greater availability of carbohydrate 
to the active tissue, which may have resulted in a promotion o f carbohydrate oxidation and 
suppression of lipid metabolism due to greater glucose availability (Coyle et al., 1997; Spriet, 
2002). Conversely, 30 minutes after ingestion would not have been sufficient time for 
complete digestion of the LGI carbohydrate, as demonstrated within blood glucose responses 
of chapter 4 and the lower pre-exercise concentrations within this study. As such under 
30min the delayed absorption, similar to a fasted state, would have resulted in a lesser 
glycolytic flux (Figure 6.4), and promoted lipid combustion. This improved fuel use may 
have contributed to a sparing effect on carbohydrate reserves, promoting the preservation of 
blood glucose in the post-exercise period.
Ultimately, the progressively lower blood glucose concentrations within chapters 4 and 5 
(pre-exercise concentrations: chapter 3 25% A+9.0; chapter 4 LGI A+4.5; chapter 5 30min 
A+2.8 mmol.l'1) resulted in an increased contribution from lipids to energy expenditure 
during exercise. A reduced reliance on carbohydrate for fuel helped preserve blood glucose
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concentrations, as blood glucose oxidation and potentially disposal (Coyle et al., 1997) would 
have been less, evidenced by lower drops in blood glucose during exercise under LGI and 
30min, such that concentrations were more euglycaemic and similar to rest for 3 hours post­
exercise under both conditions. Based on this thesis’ data, improved fuel oxidation, through 
lower blood glucose concentrations, promotes a preservation of carbohydrate reserves which 
contributes to improving post-exercise glycaemia.
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6.4 The effects of insulin reductions and carbohydrate consumption on 
ketogenesis
Low insulin concentrations with concomitant rises in counter-regulatory hormones create a 
milieu that promotes ketone body formation (Laffel, 1999). In addition, exercise has been 
demonstrated to induce hyperketonaemia (>1 mmol.r1) within non-TlDM individuals 
(Koeslag et al., 1980). Therefore, within the T1DM individual there is potential that 
reductions in insulin dose, exercise and concomitant increases in counter-regulatory 
hormones could create a milieu where ketogenesis could increase after exercise (Figure 1.8). 
However, data from this thesis refutes this hypothesis.
When fasting, ketones play a role in reducing glucose utilisation (Balasse and Fery, 1989); 
however, insulin restrains ketogenic enzyme activity and increases their uptake into extra- 
hepatic tissue (Laffel, 1999). Moreover, after feeding, an increase in glucose availability 
leading to an increased glycolytic flux results in an increased availability of oxaloacetate, 
which condenses with acetyl CoA, ultimately diverting acetyl CoA from ketone forming 
pathways (Laffel, 1999). Therefore, the consumption of a bolus of carbohydrates and 
administration of rapid-acting insulin at rest resulted in a transient reduction in p- 
hydroxybutyrate concentrations. Therefore, exercise took place under elevated blood glucose 
concentrations, and insulin concentrations still elevated above rest, which potentially created 
a restraining effect over ketogenesis.
With regards chapter 3, changes in insulin dose did not result in conditional changes in p-
hydroxybutyrate concentrations. This is an important finding as reductions in insulin dose or
omission of insulin dose is a significant factor in the development o f diabetic ketoacidosis
(Wallace and Matthews, 2004). Moreover, despite reduced insulin concentrations and an
exercise induced increase in ketogenic hormones, such as adrenaline, p-hydroxybutyrate did
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not reach concentrations anywhere near that which could be defined as hyperketonaemia (>1 
mmol.l'1), let alone reach ketoacidosis (>3 mmol.l1; Laffel, 1999), with peak concentrations 
reaching -0.5 mmol.l'1. A potential explanation for this may be related to unaltered basal 
insulin administration. The basal insulin dose has a primary role of restraining excessive 
hepatic glucose output (Barnett, 2003) and a consequence of this is a similar effect on 
ketogenesis. As basal insulin remained unaltered across trials, and studies, and with only 
small alterations in rapid-acting insulin dose, it suggests a milieu that differences in P- 
hydroxybutyrate synthesis could take place was not created.
The transient rise in p-hydroxybutyrate concentrations over the recovery period is likely due 
to a combination of factors. After an overnight fast, participants subsequently utilised -2.6 
MJ of energy during running, having only consumed ~1.1 -  1.3 MJ, across studies, this 
energy deficit created by the active musculature needed to be restored through utilisation of 
endogenous liver, muscle and adipose tissue energy stores. Furthermore, without feeding for 
the 3 hour recovery period the energy deficit would be magnified with time. Moreover, the 
increased insulin clearance after exercise (Tuominen et al., 1997) would have resulted in a 
transient reduction in insulin’s restraint on enzymes involved in both hepatic glucose 
production and ketogenesis (Figure 6.1). p-hydroxybutyrate concentrations peaked 3 hours 
after exercise under all conditions (~0.3 - 0.5 m m ol.l1, across studies). These values, 
alongside acid-base values, were within the normal physiological range.
Additionally, it should be noted that although insulin concentrations were declining, basal 
insulin dose remained unchanged. As previously mentioned, an important role of the basal 
dose is it to prevent unregulated ketogenesis (Barnett, 2003). Keeping this in mind, glucagon, 
a key stimulator of ketogenesis (Laffel, 1999), did not increase after exercise, moreover there 
were no conditional differences in other key hormones in ketogenesis, the catecholamines
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(Laffel, 1999). Thus, a hormonal milieu which may have led to post-exercise 
hyperketonaemia or ketoacidosis was not created.
From a patient safety perspective, a heavy pre-exercise insulin reduction in combination with 
carbohydrate ingestion does not result any in adverse physiological changes. There is no 
increased risk o f developing diabetic ketoacidosis, with ketone body formation and blood pH 
within clinically acceptable ranges for the duration of all trials within all studies. Employing 
our strategy of a 75% reduced rapid-acting insulin dose and a low glycaemic index 
carbohydrate, administered 30 minutes before exercise has the potential to induce post- 
prandial/pre-exercise hyperglycaemia, however this will dissipate with exercise.
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6.5 General conclusions
The results of this thesis have demonstrated that:
1. The factors most likely to contribute to reducing hypoglycaemia after exercise are a 
75% reduction to pre-exercise rapid-acting insulin dose, combined with a low 
glycaemic index carbohydrate, administered 30 minutes prior to exercise.
2. The reduced incidence of hypoglycaemia after exercise is achieved by alterations in 
blood glucose concentrations and substrate metabolism.
3. Results suggest no greater risk of developing ketoacidosis by engaging in these 
protocols. Indeed, by optimising these strategies there was an improvement in post­
exercise glycaemia and a concomitant reduced incidence of hypoglycaemia in 
individuals with type 1 diabetes mellitus.
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6.6 Limitations
A potential limitation is that within chapter 4 participants were exercising at a %VC>2peak that 
was greater than that of chapters 3 and 5. The preliminary testing for study 4 was identical to 
that of chapter 3 and 5, yet exercise intensity was -10% above the intended intensity of 70% 
V02peak- This was surprising as in addition to an identical preliminary testing protocol, trial 
running velocity, average VO2, average HR and average peak blood lactate concentrations 
were similar across conditions and chapters (Table 6.2). The unexpected greater %V02peak 
within chapter 4 may be related to the oxygen cell within the metamax-3b system. Within 
chapter 4, after completion of the preliminary testing, the oxygen cell within the Metamax-3b 
was replaced with a fresh cell. Potentially, the cell in place during the preliminary testing 
period was under estimating VO2, relative to the new cell, which resulted in lower maximal 
values, thus explaining the greater %V0 2 peak elicited during the trials when running at a 
velocity of 70% Vmax-
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Based on previous data collected by Rabasa-Lhoret et al. (2001) (e.g. blood glucose changes 
with exercise, Full A-3.36 ± 6.08 and 50% A-2.26 ± 4.32 mmol.l'1) for a statistical power of 
80% 33 subjects would have been required. Unfortunately, this sample size was beyond the 
pool of T1DM individuals available. As a result, data was underpowered with power ranging 
between 45 and 59 % across chapters 3 to 5. Furthermore, for 80% power sample sizes of 33, 
16, and 34 would have been required across chapters 3 to 5. Although lacking statistical 
power, there was sufficient power to detect condition*time interactions, and a lack of 
statistical power does not detract the clinical meaningfulness of these findings.
The findings of this thesis are applicable to an exercise model that falls within the ACSM 
guidelines for T1DM individuals. However, as shown by Rabasa-Lhoret et al. (2001), the 
required insulin reduction varies with intensity and duration of exercise. Therefore, subtle 
alterations to the exercise intensity and duration could result in altered insulin, carbohydrate 
and timing requirements. Moreover, the modality of the exercise also effects blood glucose 
responses (i.e. continuous vs. intermittent; Guelfi et al., 2005b) with differences in gluco- 
regulatory hormonal responses being responsible. Again, these differences in blood glucose 
responses may result in different insulin, carbohydrate and timing requirements.
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6.7 Directions for future research
Future research should aim to address:
• Pre-exercise insulin dose in combination with the glycaemic index and amount of 
carbohydrate (i.e. the glycaemic load) consumed prior to exercise at various 
intensities and duration.
• With modem basal insulin analogues having peakless 24 hour profiles and exercise 
increasing insulin sensitivity, there is a need to examine the efficacy of reducing 
basal insulin dose. Specifically examining the impact of reducing basal insulin dose 
on glycaemia and ketogenesis before, during and for 24 hours after exercise.
• After exercise there is an increased uptake of blood glucose to replenish depleted 
muscle glycogen stores. Moreover, it has been suggested that hepatic glucose output 
is unable to meet the augmented uptake of glucose by the exercised musculature and 
this mismatch in glucose production and uptake contributes to the development of 
late-onset hypoglycaemia. Therefore, methods to preserve/replenish muscle and liver 
glycogen during and after exercise need to be examined.
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Appendix B
Participant response form
Swansea University 
Prifysgol Abertawe
Subject Contact Form
Thank you for showing an interest in this project. We look forward to meeting and working with 
you. Please fill in the details below so that we may contact you to organise the testing schedule.
PLEASE FILL IN BLOCK CAPITALS 
Your Name:
Date o f Birth:_____________  Age: (years)____ (months)
Contactable Address:
Home Phone_________________________________
Work Phone ______________________________
Mobile Phone________________________________
E-mail ______________________________________
What types o f exercise do you typically perform? _
How long do your exercise sessions typically last? _
How long have you been in regular training? ____
What insulins are you using? ___________________
Are you able to jog for 45 minutes?_____________
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Appendix C
AHA/ACSM Health/Fitness Facility Preparticipation Screening Questionnaire.
Name
Address
Phone number home 
Emergency contact name 
Date of birth
work
phone
History Assess your health needs by marking all true statements.
You have had:
Lia heart attack
□ heart surgery
□ cardiac catheterization I f  you marked any o f the statements
□ coronary angioplasty (PTCA) in this section, consult you a health
□ pacemaker/implantable cardiac provider before engaging in exercise.
defibrillator/rhythm disturbance You may need to use a facility with a
□ heart valve disease medically qualified staff.
□ heart failure
□ heart transplantation
□ congenital heart disease
Symptoms and other health issues:
□ You experience chest discomfort with exertion.
□ You experience unreasonable breathlessness.
□ You experience dizziness, fainting, blackouts.
□ You take heart medications.
□ You take prescription medication(s).
□ You have musculoskeletal problems.
f (You have concerns about the safety of exercise.
□ You are pregnant.
Cardiovascular risk factors
□ You are a man older than 45 years.
□ You are a woman older than 55 years or you have had a
hysterectomy or you are postmenopausal.
□ You smoke. I f  you marked two or more
□ Your blood pressure is greater than 140/90. o f the statements in this
□ You don't know your blood pressure. section, you should consult
□ You take blood pressure medication. your healthcare provider
□ Your blood cholesterol level is >240 mg/dL. before engaging in exercise.
□ You don't know your cholesterol level. You might benefit by using a
□ You have a blood relative who had a heart attack faciltiy with professionally
before age 55 (father or brother) or age 65 (mother or sister). qualified exercise staff to
□ You are diabetic or take medicine to control your blood sugar guide your exercise program.
□ You are physically inactive (i.e., you get less than 30 minutes
of physical activity on at least 3 days per week).
□ You are more than 20 pounds overweight.
f None of the above is true.
You should be able to exercise safely without consulting your healthcare provider in
almost any facility that meets your exercise programme needs.
Declaration:
Please sign below to confirm that you have answered questions honestly and to the best of your ability.
Signature   Date
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Appendix D
Informed Consent for venesection
1. EXPLANATION OF VENESECTION BLOOD SAMPLING
Venesection includes the following venous blood sampling techniques: (i) venepuncture and (ii) 
cannulation. Following location of a suitable vein, the puncture site will be cleaned with an alcohol 
pad and allowed to dry. A tourniquet will be applied then the needle is used to enter the vein. 
During venepuncture the blood will be drawn directly into blood containers for future analysis. 
After blood collections have been completed the needle will be taken out of the vein and a dressing 
will be applied. During cannulation a thin flexible plastic tube will be advanced into the vein and 
this remains in the vein during the entire sampling period. Following each blood sample the cannula 
will be ‘flushed’ with saline. Following the period of blood collection the cannula will be removed 
from the vein and a dressing will be applied. After analysis the remaining blood will be disposed as 
clinical waste.
2. RISKS AND DISCOMFORTS
Even though the volume of blood taken is small (less than 30 ml per sample) there exists the 
possibility that during or immediately following this procedure you may feel light headed or faint. 
There is an extremely small risk that this procedure could result in an air or plastic embolism, but 
good practice minimises this risk. In addition, every effort will be made to minimise the risks of 
contaminating the wound by using sterile disposable equipment and standardised procedures for 
collection and disposal of biohazard wastes.
3. RESPONSIBILITIES OF THE PARTICIPANTS
Please advise a member of staff if you have experienced difficulties when blood has been taken in 
the past. You are responsible to fully disclose appropriate information when requested by those 
undertaking the assessment.
4. INQUIRIES
Any questions about the procedures used during the measurement process are encouraged. If you do 
have any questions, please ask for further explanations.
5. FREEDOM OF CONSENT
Your permission to perform this procedure is voluntary. You are free to deny consent or stop the 
assessment at any point.
I have read this form and I understand the procedures that will be perform. I consent to participate in 
this________________________________procedure.
Questions:
Response:
Signature of subject
Signature of witness Date / /
xxx
Appendix E
Chapter 3 informed consent
Swansea University 
Prifysgol Abertawe
Study Number: Patient Identification Number:
CONSENT FORM
Title of Project: ‘The cardiorespiratory and metabolic effects of reductions in insulin dose prior to 
performing an acute bout of aerobic exercise’
Name of Researcher: Dr. Richard Bracken
Please initial box:
1 I confirm that I have read and understand the information sheet
dated............................. for the above study. I have had the opportunity to consider
the information, ask questions and have had these answered satisfactorily.
□
2 I understand that my participation is voluntary and that I am free to withdraw at
□any time, without giving any reason, without my medical care or legal rights 
being affected.
3 I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from Swansea
□University, from regulatory authorities or from the NHS Trust, where it is relevant 
to my taking part in this research. I give permission for these individuals to have 
access to my records.
4 I agree to take part in the above study u
Name of Patient Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
Appendix F
Chapter 4 informed consent
Swansea University 
Prifysgol Abertawe
Study Number: Patient Identification Number:
CONSENT FORM
Title of Project: ‘The cardiorespiratory and metabolic responses to aerobic exercise following 
alterations to the type of pre-exercise carbohydrate food’
Name of Researcher: Dr. Richard Bracken
Please initial box:
1 I confirm that I have read and understand the information sheet
dated............................. for the above study. I have had the opportunity to consider
the information, ask questions and have had these answered satisfactorily. i 
I 
□ 
□
i
2 I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.
3 I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from Swansea 
University, from regulatory authorities or from the NHS Trust, where it is relevant 
to my taking part in this research. I give permission for these individuals to have 
access to my records.
□
4 I agree to take part in the above study
Name of Patient Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
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Appendix G
Chapter 5 informed consent
Swansea University 
Prifysgol Abertawe
Study Number: Patient Identification Number:
CONSENT FORM
Title of Project: ‘The cardiorespiratory and metabolic responses to alterations in the timing of insulin 
administration and carbohydrate feeding on the post-exercise glucose concentrations in type 1 
diabetes patients'
Name of Researcher: Dr. Richard Bracken
Please initial box:
1 I confirm that I have read and understand the information sheet
dated............................. for the above study. I have had the opportunity to consider
the information, ask questions and have had these answered satisfactorily.
□
2 I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.
□
3 I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from Swansea 
University, from regulatory authorities or from the NHS Trust, where it is relevant 
to my taking part in this research. I give permission for these individuals to have 
access to my records.
□
4 I agree to my GP being informed of my participation in the study. u
5 I agree to take part in the above study u
Name of Patient Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
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Appendix H 
Anti-Oxidant
For chapters 3 to 5, 30 ml of anti-oxidant was required for the preservation of plasma 
adrenaline and noradrenaline.
1.83 g of glutathione, 2.28 g of EGTA and 20 ml of distilled water were added to a beaker 
and left to mix on an unheated stirrer (FB70806 Fisherbrand unheated stirrer, Fisher 
Scientific, UK). Once fully dissolved a pH meter (InoLab pH 720, WTW, GmbH, Germany) 
was placed within the beaker and either 0.5 - 1 ml of HC1 or NaCl was added at a time until a 
pH of 7.0 was achieved. Once pH was stable at 7.0, the 30 ml volume was attained through 
the addition of distilled water.
e.g. 1.83 g glutathione + 2.28 g EGTA 
20 ml of distilled H2O 
3 ml NaCl 
0.5 ml HC1 
6.5 ml distilled H2O
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Appendix I
GEM 3000: Overview of Operation
The GEM 3000 central component is a sensor card which provides a low volume, gas tight 
chamber in which the blood sample is presented to the sensors. Sensors specific for the 
analysis of pH, Hct, Glucose and Lactate, in addition to a reference electrode, are key parts of 
the chamber, with chemically sensitive membranes permanently attached to the chamber 
body (Figure below). When the cartridge is installed, the chamber is maintained at 37 ± 0.3 in 
a thermal block, and provides the electrical interface to the sensors.
Calibration and Control Checks
Within the cartridge are two solutions, A and B. These solutions purpose is for calibration 
and/or internal process control checks. The A and B solutions provide high and low 
concentrations for all parameters, except Hct, which calibrates at one level using the B 
solution. Prior to calibration, the A and B solutions are read as unknown solutions, and these 
values are recorded in the instruments database. During calibration, these values are adjusted 
for any slope or drift that may occur over time.
The third solution, C, is used to calibrate the low oxygen level. The C solution is also used 
for conditioning the glucose and lactate sensors, removing micro clots and cleaning the 
sample path (below).
xxxv
Sam ple
Inlet
Solution  C
Distribution Valve 
(Selects Solution  A, B or C)
W aste
Container
. Check
Peristaltic Valve 
Pump
Sensor  
Card
Reference
/S o lu t io n S o lu t io n  A
/ s o l u t i o n  B/ 
Rinse
Figure: Internal com ponents o f the GEM 3000.
Electrochemical sensors: pH
The pH sensors are all based on the principle o f ion-selective electrodes, where an electrical 
potential can be established across a membrane which is selectively permeable to a specific 
ion. The potential is described by the Nem st equation:
E = E ’ + (S x Log C)
E = Electrode potential, E ’ is the standard potential for the membrane, S is the sensitivity
(slope), and C is the ion activity. E ' and S can be determined by the sensor responses to the
calibration solutions, and the equation can be solved for the activity o f  the ion o f interest. For
pH, Log C is replaced by pH. The pH sensors are polyvinyl chloride (PVC) based on ion
selective electrodes, consisting o f an internal silver chloride (AgCl) reference electrode and
an internal salt layer. Their potentials are measured against the card reference electrode.
xxxvi
Appendix J
Calculation of Plasma Volume Shifts
Plasma volume shifts were calculated via the method of Dill and Costill (1974), described 
below.
Where BV = blood volume, CV = cell volume, PV = plasma volume. BVpre = 100
1 )  B V pre =  B V p o s t  X ( H b p o s t  /  H b p0s t)
2) CVpre =  BVpre X(Hctpre)
3) PVpre = BV^-CVpre 
Calculations of % changes in B V, CV and PV.
1) ABV% =100*  (BVpost -  BVpre) / BVpre
2) ACV% = 100 * (CVpost -  CVpre) / CVpre
3) APV% = 100 * (PVpost -  PVpre) / PVpre
Table 2.8: Percentage changes in plasma volume, pre to post-exercise, across chapters 3 to 5.
Chapter 3 Chapter 4 Chapter 5
Trial APV% Trial APV% Trial APV%
Full -6.7 ± 0.9 LGI -8.0 ± 1.4 120min 6.5 ± 1.3
75% -3.8 ± 1.4 HGI -7.6 ± 1.2 90min 6.2 ± 2.2
50% -3.5 ± 1.2 60min 4.0 ± 1.3
25% -2.8 ± 1.0 30min 2.1 ±0.7
Data presented as Mean ± SEM
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Appendix K
I n s u l i n  a n d  E x e r c i s e  R e g i m e n  Q u e s t i o n s
Name: |H j|jjH ^ | Date 07/04/08
Age: |
What insulin(s) are you currently taking?
Brand names
Novorapid
Lantus
What typical doses do you usually administer?
Basal and short/rapid
Basal (before bed): 14 units
Rapid: Breakfast: 10 units 
Lunch: 4-6 units 
Dinner: 4-6 units 
What time o f  day do you usually administer them?
Morning, midday, afternoon, prior to bed 
See above!
How do you take them?
Insulin Pen, Type brand names etc 
Novorapid Flexpen 
Lantus Optiset
How long have you been on this regimen? 8 years
What regimen were you previously on?
Reasons fo r  change
N ovo Nordisk Penmix 30/70 for 9 years. Current regime was a little more flexible for my lifestyle.
How often do you exercise a week? 
6 - 7  times a week for 1 -2 hours
xxxviii
What do you do with regards to insulin & carbohydrate before you exercise?
Food and drink consumed? How much?
I exercise at least 3 hours after last injection o f  rapid insulin (so that circulating insulin levels are 
lower) and prior to a main meal so that I can inject insulin soon after I have finished exercising in 
order to help with muscle glycogen repletion (to hopefully stop later onset hypos).
For prolonged high intensity exercise I usually take about 60g carbs (Lucozade Energy) prior to 
exercise which will last 1 -  1 Vi hours. I sip a sports drink (Lucozade Sport) during exercise giving 
me about another 15g o f  carbs.
For anaerobic exercise (i.e. weight lifting) with only a low intensity aerobic element a sports drink 
(about 30g carbs) will be enough assuming blood sugars are okay to begin with.
For steady state exercise (30-60 min) I usually eat a large portion o f  fruit and some weatabix to give 
me a slower release o f  carbohydrates and so that my sugars don’t get too high,
Have you ever experienced a hypo during or after exercise?
How long after exercise did it occur?
I quite often experience nocturnal hypos which usually occur about 8 hours after high intensity 
exercise.
What did you eat or drink to clear it?
I usually drink lucozade energy -  about 60g carbs.
Do you consume caffeine? E.g. coffee, Red Bull 
How much/often?
I don’t consume caffeine.
How does it affect your blood glucose and insulin regimen? 
vda.
When was the last time your regimen was dramatically upset?
Date, Why?
Last week -  blood sugars very high then very low for 24 hours. Possible over-correction o f  nocturnal 
hypo forcing sugars up in the morning. Extra insulin taken to combat high sugars which, when 
combined with exercise, lowers sugars dramatically etc. Often a weekly occurrence.
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